CA2259573A1 - Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of factor xa and of thrombin - Google Patents

Abstract

The present application describes amidinoindoles, amidinoazoles, and analogs thereof of formula (I): wherein W, W1, W2, and W3 are selected from CH and N, provided that one of W1 and W2 is C(C(=NH)NH2) and at most two of W, W1, W2, and W3 are N and one of Ja and Jb is substituted by -(CH2)n-Z-A-B, which are useful as inhibitors of factor Xa or thrombin.

Description

CA 022~9~73 1999-01-06 TITLE
AMIDINOTNDOLES, AM~D~NOAZOLES, AND ANALOGS T~EREOF AS INHlBllORS OF FACTOR
Xa AND OF THROMBIN
FIELD OF THE INVENTION
This invention relates generally to amidinoindoles, amidinoazoles, and analogs which are inhibitors of trypsin-like serine protease enzymes, especially thrombin and factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.

BACKGROUND OF THE INVENTION
EP 0, 540,051 and JP 06227971 describe a series of 15 compounds useful as factor Xa inhibitors or to treat influenza based on the formula:

NH~ X--(CH2)n--Y

wherein A is an alkylene linker optionally substituted by hydroxyalkyl, carboxyl, alkoxycarbonyl, alkoxycarbonylalkyl, or carboxyalkyl, X is a bond, O, S, or carbonyl, n is 0-4, and Y is an optionally substituted carbocycle or heterocycle. The present invention does not involve compounds containing the above noted combination of A, X, n, and Y.
Tidwell et al, Thrombosis Research 1981, 24, 73-83, describe factor Xa inhibitory activity of a series of aromatic mono- and di-amidines. The amidino aromatic moieties are include indole, indoline, benzofuran and benzimidazole.
Tidwell et al, J. Med. Chem. 1983, 26, 294-298, report a series of amidinoindoles of the formula:

X
wherein one of Rl and R2 is amidine, X may be methyl or ethyl when Y and Z are H, Y may be C(O)CH2CH3 when X and Z are H, and . . .

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 Z may be CHO, COCH3, COCF3, or C(O)Ph when X and Y are H.
Thrombin inhibition constants are given for these compounds.
EP 0,655,439 discuss IIb/IIIa antagonists of the formula:

~X7 X, (La)--A

wherein the core ring is a heterocycle, B is a basic group, A
is an acidic group, Rl is an optional substituent, R2 is an optional substituent, and La and Lb are linkers which may optionally be substituted. The present invention does not contain the La-A group.
Fairley et al, J. Med. Chem. 1993, 36, 1746-1753, illustrate a series of bis(amidinobenzimidazoles) and bis(amidinoindoles) of the formulae:

N N~ Nr N~1 wherein R is an amidine or derivative thereof and X is an alkylene, alkenylene, phenylene or phenylenedimethylene linker. The DNA binding capabilities of these compounds were studied and reported, but inhibition of trypsin-like enzymes was not discussed.
WO 95/08540 depicts bis(amidinobenzimidazolyl)alkanes of the formula:

Z~H N3~ Z
wherein Z is an amidine derivative and R and Rl are selected from a variety of substituents including hydroxyl, amino, and alkoxy. These compounds are said to be useful in the treatment of viruses, specifically HIV. No mention is made of Xa or thrombin inhibition.
Trypsin-like enzymes are a group of proteases which hydrolyzed peptide bonds at basic residues liberating either a C-terminal arginyl or lysyl residue. Among these are enzymes of the blood coagulation and fibrinolytic system required for CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 hemostasis. They are Factors II, X, VII, IX, XII, kallikrein, tissue plasminogen activators, urokinase-like plasminogen activator, and plasmin. Elevated levels of proteolysis by these proteases can result in disease states. For example, consumptive coagulopathy, a condition marked by a decrease in the blood levels of enzymes of both the coagulation system, the fibrinolytic system and accompanying protease inhibitors is often fatal. More specifically, proteolysis by thrombin is required for blood clotting. Inhibition of thrombin results in an effective inhibitor of blood clotting. The importance of an effective inhibitor of thrombin is underscored by the observation that conventional anticoagulants such as heparin (and its complex with the protein inhibitor, antithrombin III) are ineffective in blocking arterial thrombosis associated with myocardial infarctions and other clotting disorders.
However, a low molecular weight thrombin inhibitor, containing a different functionality, was effective in blocking arterial thrombosis (Hanson and Harker, Proc. Natl. Acad. Sci. U.S.A.
85, 3184 (1988).
Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway o blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca2~ and phospholipid). Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin ~Elodi, S., Varadi, K.: Optimization of conditions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation.
Thromb. Res. 1979, 15, 6l7-629~, inhibition of factor Xa may be more ef icient that inactivation of thrombin in interrupting the blood coagulation system.
There-ore, efficacious and specific inhibitors of factor Xa or thrombin are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders. It is CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 thus desirable to discover new thrombin or factor Xa inhibitors.

SUMMARY OF THE INVENTION
Accordingly, one object of the present invention is to provide novel amidinoindoles and analogs thereof which are useful as factor Xa or thrombin inhibitors or pharmaceutically acceptable salts or prodrugs thereof.
It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formula (I):

,W2~ 3 Jb or pharmaceutically acceptable salt or prodrug forms thereof, wherein D, Da, J, Ja, Jb, W, Wl, W2, and W3, are defined below, are effective factor Xa or thrombin inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[l] Thus, in a first embodiment, the present invention provides a novel compound of formula I:

CA 022~9~73 1999-01-06 W O 98/01428 ' PCT~US97/11325 ,W2~ Jb Da W3 I

or stereoisomer or pharmaceutically acceptable salt form thereof wherein:
W and W3 are selected from CH and N;

W1 and w2 are selected from C, CH, and N;

provided that from 0-2 of W, W1, W2, and W3 are N;

one of D and Da is selected from H, C1_4 alkoxy, CN, C ( =NR7 ) NR8R9, NHC ( =NR7 ) NR8R9, NR8CH ( =NR7 ), C ( O ) NR8R9, and (CH2 ) tNR8R9, and the other is absent;

provided that if one of D and Da is H, then at least one of W, wl, w2, and W3 is N;

one Of Ja and Jb is substituted by -(CH2)n-Z-A-B;
J, Ja~ and Jb combine to form an aromatic heterocyclic system containing from 1-2 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R1, provided that Jb can only be C or N;
J, Ja, and Jb can, alternatively, combine to form a heterocyclic ring wherein Jb is N and J and Ja are CH2 substituted with 0-1 Rl;

J, Ja, and Jb can, alternatively, combine to form a heterocyclic ring wherein Jb is CH, J is NR1 and Ja is CH2 substituted with 0-1 Rl;

R1 is selected from H, Cl_4 alkyl, (CH2)roR3~ (CH2)rNR3R3 , - 35 (CH2)rC(=O)R2, (CH2) r (CH=CH)(CH2)rC(=O~R2, (CH2)rNR3C(=o)R2~ (cH2)rso2R4~ (CH2)rNR3So2R4~ and (CH2) r~

CA 022~9~73 1999-01-06 WO98/01428 PCT~S97/1132 5-membered heterocyclic system having 1-4 heteroatoms selected from N, O, and Si R2 is selected from H, oR3 ~ Cl_4 alkyl, NR3R3 , CF3, and C3_10 carbocyclic residue substituted with 0-2 R6;

R3 and R3 are independently selected from H, Cl_4 alkyl, and C3_l0 carbocyclic residue substituted with 0-2 R6;

10 R4 is selected from C1_4 alkyl, NR3R3 , and C3_10 carbocyclic residue substituted with 0-2 R6;

Z is selected from CH=CH, CH~(CH2)mQ(CH2)mR5)~
CH((CH2)mQ(CH2)mR5)C(o)NR3~ CH((CH2)mC(o)(CH2)mR5a), N((cH2)qQ(cH2)mR5)~ N(Q'(CH2)mR5)~
C(o)N((cH2)mQ~(cH2)mR5a)~ C(O)(CH2)r, C(O)O(CH2)r, OC(O) (CH2)r, C(O) (CH2)rNR3(CH2)r, NR3C(o) (CH2)r, oC(o)NR3(cH2)r~ NR3C(o)o(cH2)r~ NR3C(o)NR3(CH2)r, S(O)p(CH2)r, S02CH2, SCH2C(o)NR3, So2NR3(CH2)r, NR3S02(CH2)r, and NR3So2NR3(CH2)r;

Q is selected from a bond, O, NR3, C(O), C(o)NR3, NR3C(o), S02, NR3So2, and S02NR3;

Q' is selected from a bond, C(O), C(O) NR3, S02, and So2NR3;

R5 is selected from H, Cl_4 alkyl, C3_10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system cont~in;ng from 1-3 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R6, provided that when Q is SO2 or NR3So2~ R5 is other than H
and when Q' is S02, R5 is other than H;

RSa is selected from NHR5, oR5, and R5;
A is selected from:
benzyl substituted with 0-2 R6, phenethyl substituted with 0-2 R6, CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 phenyl-CH= substituted with 0-2 R6, C3_l0 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consistin~ of N, O, and S
substituted with 0-2 R6;

B is selected from:
X-Y, C3-6 alkyl, NR3R3 , C(=NR3)NR3R3 , NR3C(=NR3)NR3R3', benzyl substituted with 0-2 R6, C3_10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;
~5 A and B can, alternatively, combine to form a Cg_l0 carbocyclic residue substituted with 0-2 R6 or a 9-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;
X is selected from Cl_4 alkylene, -C(O)-, -C(o)CR3R3 -, -CR3R3 C(O), -S~O)p-, -S(o)pCR3R3 -, -CR3R3'S(o)p-, -S(o)2NR3-, -NR3S(0)2-, -C(o)NR3-, -NR3C(o)-, -NR3-, NR3CR3R3'- -CR3R3'NR3-, O, -CR3R3 O-, and -oCR3R3 -;
Y is selected from:
C3-1o carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

R6 is selected from H, OH, (cH2)noR3~ halo, Cl_4 alkyl, CN, NO2, (CH2)rNR3R3 , (CH2)rC(O)R3, NR3C(O)R3 , NR3C(o)NR3R3', CH(=NH)NH2, NHC(=NH)NH2, So2NR3R3 , CoNHSo2R4, NR3So2NR3R3 , NR3So2-cl-4 alkyl, and (Cl-4 alkyl)-tetrazolyl;

., . ~

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 R7 is selected from H, OH, Ci-6 alkyl, C1 6 alkylcarbonyl, C1_O
alkoxy, Cl_4 alkoxycarbonyl, C6_l0 aryloxy, C6_l0 aryloxycarbonyl, C6_l0 arylmethylcarbonyl, Cl 4 alkylcarbonyloxy Cl_4 alkoxycarbonyl, C6_l0 arylcarbonyloxy Cl_4 alkoxycarbonyl, Cl_6 alkylaminocarbonyl, phenylaminocarbonyl, and phenyl Cl_~
alkoxycarbonyl;

R8 is selected from H, Cl-6 alkyl and (CH2)n-phenyl;
R9 is selected from H, Cl_6 alkyl and (CH2)n-phenyl;

n is selected from 0, l, 2, 3, and 4;

m is selected from 0, l, and 2;

p is selected from 0, l, and 2;

q is selected from l and 2; and, r is selected from 0, l, 2, 3, and 4;

provided that:
(a) Z is other than CH2; and, (b) if Z is CH((cH2)mQ(cH2)mR5) or CH((CH2)mC(o)(cH2)mR5a)~
then B is other than X-Y, a C3 l0 carbocyclic residue or a 5-l0 membered heterocyclic system.

[2] In a preferred embodiment, the present invention provides compounds of formula II:
D_ Wl ~ J~

a_W2 ( ~ z B
n wherein: from 0-l of W, Wl, W2, and W3 are N;

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 Rl is selected from H, Cl 4 alkyl, (CH2)roR3/ (CH2)rNR3R3 , ( CH2 ) rC ( =0 ) R2, ( CH2 ) rNR3C ( =0 ) R2, ( CH2 ) rSo2R4, (CH2)rNR3So2R4~ and (cH2)r-5-membered heterocyclic system having 1-4 heteroatoms selected from N, O, and S;

R2 is selected from H, GR3, Cl~4 alkyl, NR3R3 , and CF3;

R3 and R3 are independently selected from H, Cl 4 alkyl, and phenyl;

R4 is selected from Cl 4 alkyl, phenyl and NR3R3 ;

Z is selected from CH=CH, CH((CH2) mQ (CH2 ) mR5 ), CH((CH2) mQ (CH2 ) mR5 ) C (O) NR3, CH((CH2)mC(o)(cH2)mR5a)~
N((CH2)qQ(CH2)mR5)~ N(Q'(CH2)mR5)~
C(O)N((CH2)mQ'(CH2)mR5a), C(O), C(O)CH2, C(O)O, OC(O), C ( O ) ( CH2 ) rNR3 ( CH2 ) r , NR3C(o), oC(o)NR3, NR3C(o)o, NR3C(o)NR3, S(O)p, SO2CH2~ So2NR3/ NR3So2/ and NR3So2NR3;
B is selected from:
X-Y, C3-6 alkyl, benzyl substituted with 0-2 R6, C3_10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

A and B can, alternatively, combine to form a Cg_lo carbocyclic residue substituted with 0-2 R6 or a 9-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6; and, ~5 R6 is selected from H, OH, (cH2)noR3~ halo, Cl_g alkyl, CN, NO2, (CH2)rNR3R3 , (cH2)rc(o)R3~ NR3C(o)R3 , NR3C(o)NR3R3', So2NR3R3 , CoNHso2R4~ NR3So2NR3R3 , NR3So2-cl-4 alkyl and (Cl_4 alkyl)-tetrazolyl.

.. . .. . .
. .

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 [3] In a more preferred embodiment, the present invention provides compounds of formula II, wherein:
J, Ja, and Jb combine to form an aromatic heterocyclic system containing from 1-2 nitrogen atoms, substituted with 0-l Rl i J, Ja, and Jb can, alternatively, combine to form a heterocyclic ring wherein Jb is N and J and Ja are CH2 substituted with 0-l Rl;

J, Ja, and Jb can, alternatively, combine to form a heterocyclic ring wherein Jb is CH, J is NRl and Ja is CH2 substituted with 0-l ~l;

Rl is selected from H, Cl_4 alkyl, (CH2)roR3t (CH2)rNR3R3 , (CH2)rC(=O)R2, (cH2)rNR3c(=o)R2~ (CH2)rSo2R4~ and (CH2)rNR3So2R4;

Z is selected from CH((CH2) mQ ( CH2 ) mR5 ), CH((CH2)mQ(CH2)mR5)C(O)NR3~ CH((CH2)mC(o)(cH2)mR5a)~
N( (CH2)C~Q(CH2)mRS) ~ N(Q' (CH2)mR5), C(O)N( (CH2)mQ' (CH2)mR5a), C(O), C(O)CH2, C(O) (CH2)rNR3(cH2)r~ NR3C(o), NR3C(o)NR3, S(0)2, S02CH2, So2NR3, NR3So2, and NR3So2NR3;

A is selected from:
benzyl substituted with 0-2 R6, C3_l0 carbocyclic residue substituted with 0-2 R6, and 5-lO membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;
B is selected from:
X-Y, C3-6 alkyl, benzyl substituted with 0-2 R6, CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 C5-6 carbocyclic residue substituted with 0-2 R~, and 5-6 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

X is selected from -C(O)-, -C(O) CR3R3 -, -S(0)2-, -S(o)pCR3R3 -, -S(G)2NR3-, -C(o)NR3-, -NR3-, -NR3CR3R3 -, and O;

Y is selected from:
10Cs_6 carbocyclic residue substituted with 0-2 R6, and 5-6 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

15R6 is selected from H, OH, (cH2)noR3~ halo, Cl_4 alkyl, CN, N02, (CH2)~NR3R3 , (CH2)rC(o)R3~ NR3C(o)R3 , NR3C(o)NR3R3', S02NR3R3 , CoNHso2R4~ NR3So2NR3R3 , NR3So2-cl-4 alkyl and (Cl_4 alkyl)-tetrazolyl;

n is selected from 0, 1, and 2i and, r is selected from 0, 1, and 2.

[4] In an even more preferred embodiment, the present invention provides compounds of formula II:

D ~ J~

Da Jb (\~Z'A'B

III
wherein:

J and Jb combine to form an aromatic heterocyclic system containing from 1-2 nitrogen atoms, substituted with 0-1 Rl;

... . . .

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 J and Jb can, alternatively, form a heterocyclic ring wnerein Jb is N and J is CH2 substituted with 0-1 Rli J and J~ can, alternatively, form a heterocyclic ring wherein Jb is CH and J is NRl;

z is selected from C(o)N(Q'R5a), C(O), C(o)NR3, NR3C(o), and So2NR3;

Q' is selected from C(O) and C(o)NR3;

R5 is selected from H and Cl 4 alkyl;

R5a is selected from NHR5, oR5, and R5;
A is selected from:
benzyl substituted with 0-1 R6, phenyl substituted with 0-1 R6, piperidinyl substituted with 0-1 R6, piperazinyl substituted with 0-1 R6, and pyridyl substituted with 0-1 R6;

B is selected from:
X-Y, benzyl substituted with 0-1 R6, phenyl substituted with 0-2 R6, cyclohexyl substituted with 0-1 R6, and pyridyl substituted with 0-1 R6;

30 X is selected from: -C(O)-, -S(O)2-, SO2CH2~ -S(0)2NR3-, -NR3-and -C(O) NR3-;

Y is selected from:
phenyl substituted with 0-2 R6, and pyridyl substituted with 0-1 R6;

R6 is selected from H, OH, (cH2)noR3~ halo, Cl_4 alkyl, CN, NO2, (CH2)rNR3R3 , (CH2)rC(o)R3~ NR3C(o)R3 , NR3C(o)NR3R3 , CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/1132S
So2NR3R3 , CoNHso2R4~ NR3so2NR3R3 , NR3So2-cl-4 alkyl and (Cl_4 alkyl)-tetrazolyl;

n is selected from 0, l, and 2.

[5] In a further preferred embodiment, the present invention provides compounds of formula IV:

DJ~z,A~B
IV
wherein A, B, D, and Z are as defined above.

[6] In a still further preferred embodiment, the present invention provides compounds selected from:

3-((4-cyclohexyl)phenylaminomethylcarbonyl)methyl-5-amidinoindole 3-(4-p-toluenesulfonyl-piperazinecarbonyl~methyl-5-amidinoindole 3-(4-(2-aminosulfonylphenyl)pyridine-2-aminocarbonyl)methyl-5-amidinoindole;

3-(4-[2-tetrazole]phenyl)phenylaminocarbonyl)methyl-5-amidinoindole;

3-(4-biphenylaminocarbonyl)methyl-5-amidinoindole;

3-(4-(phenylmethylsulfonyl)piperazinecarbonyl)methyl-5-amidinoindole;
-3-(4-cyclohexylphenylaminocarbonyl)methyl-5-amidinoindole;

. . .

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 3-(4-benzylpiperazinecarbonyl)methyl-5-amidinoindole;

3-(3-amidinobenzylamino(methylcarbonylmethoxy)carbonyl)methyl-5-amidinoindole;

3-(4-(2-aminosulfonyl)phenyl)phenylaminocarbonylmethyl-5-amidinoindole;

3~ benzylpiperidine-4-aminocarbonyl)methyl-5-amidinoindole;

3-(4-phenylpiperazinecarbonyl)methyl-5-amidinoindole;

3-(4-benzylpiperidinecarbonyl)methyl-5-amidinoindole;
3-{2-bromo-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyanoindole;

3-{2-methyl-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-methylamino indole;

3-{2-fluoro-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-amidnoindole;

3-~2-chloro-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyanoindole;

3-{2-iodo-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyanoindole;

3-{2-methyl-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-amidinoindole;

CA 022~9~73 1999-01-06 WO98/01428 PCT~S97/11325 3-{2-methyl-4-(2-(t-butylaminosulfonyl))phenylphenylaminocarbonyl)methyl-5-amidinoindole;

3-{4-~2-aminosulfonyl)phenyl)phenylaminocarbonylmethyl-a-(methylcarboxy methyl ether)-5-amidinoindole;

3-{4-(2-aminosulfonyl)phenyl)phenylaminocarbonylmethyl -a-(benzyl)-5-amidinoindole;
3-{4-(2-trifluoromethyl)phenyl)pyrid-2-ylaminocarbonylmethyl 5-amidinoindole;

3-{4-(2-ethylaminosulfonyl)phenyl)phenylaminocarbonylmethyl-5-amidinoindole;

3-{4-(2-propylaminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindole;

20 2-methyl-3-~2-iodo-4-(2-aminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindole;

2-methyl-3-{4-(2-aminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindole;

3-{4-(2-aminosulfonyl)phenyl)phenyl}-N-methylaminocarbonylmethyl-5-amidinoindole;
2-methyl-3-{4-(2-t-butylaminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-methoxyindole; and, ~ 35 3-{4-(2-N-methylaminosulfonyl)phenyl)phenyl}-N-methylaminocarbonylmethyl-5-amidinoindole;

..... ........ . . . .. . ...

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 or a stereoisomer or pharmaceutically acceptable salt form thereof.

[7] In another further preferred embodiment, the present invention provides compounds of formula IVa:

D'~ ~ z~A~s IVa wherein A, B, D, and Z are as defined above.

[8] In another still further preferred embodiment, the present invention provides compounds selected from:
3-{4-(2-(n-butylaminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyanoindoline 3-{4-(2-(n-propylaminosulfonyl)phenylphenylaminocarbonyl)methyl-5-amidinoindoline;

(-)-3-{4-(2-aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindoline;

3-{4-(2-aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindoline;

3-{4-(2-dimethylaminosulfonyl)phenyl)phenylaminocarbonylmethyl-5-amidinoindoline;

(+)-3-{4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindoline;

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 -)-3-{4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindoline;

3-{4-(2-aminosulfonyl)phenyl)pyrid-2-yl)aminocarbonylmethyl-5-aminocarboxyindoline;

3-{4-(2-t-butylaminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindoline; and, 3-{4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-yl}aminocarbonylmethyl-5-amidinoindoline;
~5 or a stereoisomer or pharmaceutically acceptable salt form thereof.

[93 In another further preferred embodiment, the present invention provides compounds of formula IVb:

,A
Z B
IVb wherein A, B, D, and Z are as defined above.

[lO] In another still further preferred embodiment, the present invention provides compounds selected from:
~0 3-{4-(2-aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-6-amidinoindazole;

3-{4-(2-aminosulfonyl)phenyl)phenyl aminocarbonylmethyl-6-amidinoindazole;

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 3-{4-(2-t-butyl aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-6-amidinoindazolei and, 3-{4-(2-t-butylaminosulfonyl)phenyl)phenyl aminocarbonylmethyl-6-amidinoindazole;

or a stereoisomer or pharmaceutically acceptable salt form thereof.

[ll] In another further preferred embodiment, the present invention provides compounds of formula IVc:

D~ ~ (?~ A

IVc wherein D, Da, Z, A, and B are as defined above.

~ 12] In another still further preferred embodiment, the present invention provides compounds selected from:

[4-(phenyl)phenylcarbonyl~methyl-6-amidinobenzimidazole;

[4-(phenyl)phenylcarbonyl]methyl-5-amidinobenzimidazole;
[4-(3-aminophenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;

[4-(3-aminophenyl)phenylcarbonyl]methyl-5-amidinobenzimidazole;

[4-(4-fluorophenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;

,_ . ~.

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 [4-(4-formylphenyl)phenylcarbonyl]methyl-5-amidinobenzimidazole;

[4-(2-aminosulfonylphenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;

[4-(2-tert-butylaminosulfonylphenYl)phenylcarbonyl]methyl-6 amidinobenzimidazole;
~0 {4-[(2-tetrazolyl)phenyl]phenylcarbonyl}methyl-6-amidinobenzimidazole;

[4-(2-aminosulfonylphenyl)phenylaminocarbonyl]methyl-6-amidinobenzimidazole;
[4-(2-aminosulfonylphenyl)phenylaminocarbonyl]methyl-5-amidinobenzimidazole;

1-(4-benzylpiperidinecarbonyl)methyl-6-amidinobenzimidazole;
1-(4-benzylpiperidinecarbonyl)methyl-5-amidinobenzimidazole;
., 1-(4-benzylpiperidinecarbonyl)methyl-6-amidinobenzimidazole;

2-[4-(2-aminosulfonylphenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;

2-[4-(2-tert-butylaminosulfonylphenyl)phenylcarbonyl]methyl-5-azabenzimidazole;
2S-[4-(2-tert-aminosulfonylphenyl)phenylaminocarbonyl]methyl-thio-lH-imidazo(4,5-C) pyridine; and, 2S-[4-(2-aminosulfonylphenyl)phenylaminocarbonyl]methyl-thio-lH-imidazo(4,5-C) pyridine;

or a stereoisomer or pharmaceutically acceptable salt form thereof.

.. . . .. .. . . . . ..

CA 022~9~73 1999-01-06 - WO98/01428 - PCT~S97/11325 [13] In a preferred embodiment, the present invention provides compounds of formula V:

W 'W3 V
wherein one of R and Ra is -(cH2)n-z-A-B and the other H;
~O W, W2, and W3 are selected from CH and N, provided that at most one of W, W2, and W3 can be N;

J is selected from N and C-Rl;

Rl is selected from H, O, (CH2)roR3~ (CH2)rC(=O)R2, (CH=CH)C(=O)R2, (CH2)rNR3C(=o)R2~ (CH2)rSo2R4, (CH2)rNR3So2R4~ and (cH2)r-5-membered heterocyclic system having 1-4 heteroatoms selected from N, O, and Si ~0 R2 is selected from H, oR3, Cl_4 alkyl, NR3R3 , CF3, and C3_l0 carbocyclic residue substituted with 0-2 R6;

R3 and R3 are independently selected from H, Cl_4 alkyl, and C3_l0 carbocyclic residue substituted with 0-2 R6;

R4 is selected from oR3, Cl_4 alkyl, NR3R3 , and C3_l0 carbocyclic residue substituted with 0-Z R6;

Z is selected from CH=CH, CH(CH2) mQ (CH2 ) mR5, CH((CH2)mQ(CH2)mR5)C(o)NR3~ CH(cH2)mc(o)(cH2)mR5 N(CH2)qQ(CH2)mR5~ NQ~(cH2)mRs~ C(o)N((cH2)mQ~(cH2)mR5a)~
C(O), C(O)CH2, C(O)O, OC(O), C(o)NR3(cH2)r~ NR3C(o), oC(o)NR3, NR3C(o)o, NR3C(o)NR3, S(O)p, SO2CH2, S02NR3, NR3So2, and NR3So2NR3;

CA 022j9j73 1999-01-06 PCT~S97/11325 ~ WO98/01428 Q is selected from a bond, O, NR3, C(O), C(o)NR3, NR3C(o), SO2, NR3So2, and So2NR3i Q~ is selected from a bond, C(O), C(o)NR3, SO2, and So2NR3;

R5 is selected from H, C1_4 alkyl, C3-s carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R6, provided that when Q is SO2 or NR3so2~ R5 is other than H
and when Q' is SO2, R5 is other than H;

R5a is selected from NHR5, oR5, and R5;
~5 A is se~ected from:
benzyl substituted with 0-2 R6, C3_10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S~0 substituted with 0-2 R6;

B is selected from:
H, X-Y, NR3R3 , C(=NR3)NR3R3 , NR3C(=NR3)NR3R3 , benzyl su~stituted with 0-2 R6, C3_10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;
~0 X is selected from C1-4 alkylene, -C(O)-, -C(o)CR3R3 -, -CR3R3 C(O), -S(O)p-, -S(o)pCR3R3 -, -CR3R3'S(o)p-, -S(0)2NR3-, -NR3S(o)2-~ -C(o)NR3-, -NR3C(o)-, -NR3-, -NR3CR3R3 -, -CR3R3 NR3-, O, -CR3R3 O-, and -oCR3R3'-;

Y is selected from:
C3_10 carbocyclic residue substituted with 0-2 R6, and . .

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 5-l0 membered heterocyclic system containing from l-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

R6 is selected from H, OH, (CH2)nOR3~ halo, Cl_4 alkyl, CN, NO2, (CH2)rNR3R3 ~(CH2)rC(o)R3~ NR3C(o)R3 , NR3C(o)NR3R3', CH(=NH)NH2, NHC(=NH)NH2, C(=o)R3, S02NR3R3 , NR3So2NR3R3', and NR3So2-Cl_4 alkyl;

n is selected from 0, l, 2, 3, and 4;

m is selected from 0, l, and 2;

p is selected from 0, l, and 2;
q is selected from l and 2; and, r is selected from 0, l, 2, 3, and 4.

[14] In another more preferred embodiment, the present invention provides compounds of formula VI:

~ ~ J

VI
wherein one of R and Ra is ~(CH2)n-Z-A-B and the other H;

W and w2 are selected from CH and N, provided that at most one of W and w2 can be N;
J is selected from N and C-Rl;

Rl is selected from H, (CH2)roR3~ (CH2)rC(=O)R2, (CH2)rNR3C(=o)R2, (CH=CH)C(=O)R2, (CH2)rSo2R4~ and (CH2) rNR3So2R4;

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 R2 is selected from H, oR3, C1_4 alkyl, NR3R3 , and CF3;

R3 and R3 are independently selected from H, C1_4 alkyl, and phenyl;

R4 is selected from oR3, Cl_4 alkyl, NR3R3 , and phenyl;

Z is selected from C(O), C(o)cH2~ C(o)NR3, NR3C(o), S(O)2, S02CH2, S32NR3~ NR3So2~ and NR3So2NR3;

A is selected from:
C3_10 car~ocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

B is selected from:
X-Y, C3_10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

X is selected from -C(O)-, -C(O) CR3R3 -, -CR3R3'C(o), -S(O)p-, -S(o)pCR3R3 -, -CR3R3 S(O)p-, -S(0)2NR3-, -NR3S(0)2-, -C(o)NR3- -NR3-, -NR3CR3R3'-, and -CR3R3 NR3-;

Y is selected from:
C3_10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

35 R6 is selected from H, OH, (cH2)noR3~ halo, C1_4 alkyl, CN, N02, (CH2)rNR3R3 ,(CH2)rC(O)R3, NR3C(O)R3 , NR3C(O)NR3R3 , C(=o)R3, So2NR3R3 , NR3So2NR3R3 , and NR3So2-cl-4 alkyl;

CA 022~9~73 1999-01-06 n is selected from 0, 1, 2, 3, and 4;

p is selected from 0, 1, and 2; and, 5 r is selected from 0, 1, 2, 3, and 4.

[15] In another even more preferred embodiment, the present invention provides compounds of formula VII:

HN w2~ A
~Z \B
VII
wherein, W and w2 are selected from CH and N, provided that at most one of W and w2 can be N;
R 1 i s s elected from H, (CH2)roR3~ (CH2)rC(=O)R2, ( CH2 ) rNR3C ( =0 ) R2, (CH=CH) C ( =0 ) R2, ( CH2 ) rSo2R4, and tCH2) rNR3 SO2 R4;

R2 is selected from H, oR3, Cl_4 alkyl, NR3R3 , and CF3;

R3 and R3 are independently selected from H, C1_4 alkyl, and phenyli R4 is selected from oR3, C1_4 alkyl, NR3R3 , and phenyl;

Z is selected from C(O), C(o)cH2~ C(o)NR3, S(O)2, SO2CH2, So2NR3, and NR3So2NR3;
~0 A is selected from:
C3_10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

. ~

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 B is selected from:
X-Y, C3_l0 carbocyclic residue substituted with 0-2 R6, and 5-l0 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

X is selected from -S(O)p-, -S(O) pCR3R3 -, -CR3R3 S (O) p-, 0 -S (O) 2NR3-, -NR3S (O) 2-, and -C(o)NR3-;

Y is selected from:
C3_l0 carbocyclic residue substituted with 0-2 R6, and 5-l0 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

R6 is selected from H, OH, (cH2)noR3~ halo, Cl_4 alkyl, CN, NO2, (CH2)rNR3R3 ,(CH2)rC(O)R3/ NR3C(o)R3 , NR3C(o)NR3R3 , C (=O) R3, So2NR3R3 , NR3so2NR3R3 , and NR3So2-cl-4 alkyl;

n is selected from 0, l, 2, 3, and 4;

p is selected from 0, l, and 2; and, r is selected from 0, l, 2, 3, and 4.

[16] In another further preferred embodiment, the present invention provides compounds selected from:

l-(4-benzylpiperidinecarbonyl)methyl-5-amidinoindole;

l-(4-benzylpiperidinecarbonyl)ethyl-5-amidinoindole;
l-(4-(3-fluoro)benzylpiperidinecarbonyl)methyl-5-amidinoindole;

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 (4-amidino)benzyl-N-(methylacetate)aminocarbonyl)meth 5-amidinoindole;

methyl l-(4-benzylpiperidinecarbonyl)methyl-5-amidinoindole-3-propanoate;

l-((4-benzylpiperidinecarbonyl)methyl-(3-ethanehydroxyl)-5 amidinoindole;
~O l-(4-benzylpiperidine-l-carbonyl)methyl-3-methylcarboxylic acid-5-amidinoindole;

l-(l-benzylpiperidine-4-aminocarbonyl)methyl-5-amidinoindole;

l-(4-benzoylpiperidinecarbonyl)methyl-5-amidinoindole;

l-(4-(3-fluoro)benzylpiperazinecarbonyl)methyl-5-amidinoindole;

l-(4-phenylbenzylaminocarbonyl)methyl-5-amidinoindole;

methyl l-(4-benzylpiperidinecarbonyl)methyl-5-amidinoindole-3-propenoate; and, ~5 l-(4-(2-fluoro)benzylpiperidinecarbonyl)methyl-5-amidinoindole;

or a stereoisomer or pharmaceutically acceptable salt form thereof.

In a second embodiment, the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug form thereof.

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 In a third embodiment, the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug form thereof.

DEFINITIONS
The compounds herein described may have asymmetric centers. Compounds of the present invention con~i n ing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
When any variable (e.g., R6) occurs more than one time in any constituent or formula for a compound, its definition on each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R6, then said group may optionally be substituted with up to two R6 and R6 at each occurrence is selected independently from the defined list of possible R6.
Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used herein, "Cl_4 alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, CA 022~9~73 1999-0l-06 WO98/01428 PCT~S97/11325 n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, and t-butyl;
~Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.
IlHalo'' or "halogen" as used herein refers to fluoro, chloro, bromo, and iodoi and ~counterion~ is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.
As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to lO-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic.
Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl,; [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).
As used herein, the term "heterocycle~' or "heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to lO-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and from l to 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S
and O atoms in the heterocycle exceeds l, then these heteroatoms are not adjacent to one another.

CA 022~9~73 1999-01-06 WO98/01428 PCT~S97/11325 As used herein, the term "aromatic heterocyclic system~
is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to lO-membered bicyclic heterocyclic ring which consists of carbon atoms and from l to 4 heterotams independently selected from the group consisting of N, O and S. It is preferred that the total number of S and O atoms in the aromatic heterocycle is not more than l.
Examples of heterocycles include, but are not limited to, lH-indazole, 2-pyrrolidonyl, 2H,6H-l,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-l,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, ~-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-l,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxazolidinyl., oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-l,2,5-thiadiazinyl, thianthrenyl, thiazolyl, thienyl, thienothiazole, thienooxazole, thienoimidazole, thiophenyl, triazinyl, xanthenyl. Preferred ~ 35 heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, ~ benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl. Also CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 included are fused ring and spiro compounds containing, for example, the above heterocycles.
When a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
The term "substituted", as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two;
generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
"Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mAmm~lian subject. Prodrugs of a compound of formula (I~ are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mAmm~lian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively.
Examples of prodrugs include, but are not limited to, acetate, ~ 35 formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I), and the - like. Preferred prodrugs are amidine prodrugs wherein either D or Da is C(=NH)N(H)Rl0, and Rl0 is selected from OH, Cl_4 ~ . . ...... . . .

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 alkoxy, C6_l0 aryloxy, Cl_4 alkoxycarbonyl, C6_l0 aryloxycarbonyl, C6_l0 arylmethylcarbonyl, Cl_ 4 alkylcarbonyloxY Cl_~ alkoxycarbonyl, and C6_l0 arylcarbonyloxy Cl_4 alkoxycarbonyl. More preferred prodrugs are where R7 is OH, methoxy, ethoxy, benzyloxycarbonyl, methoxycarbonyl, and methylcarbonyloxymethoxycarbonyl.
I~Stable compound" and "stable structure~ are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

SYNTHESIS
Compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those methods described below. Each of the references cited below are hereby incorporated herein by reference. All the temperatures are reported herein in degrees Celsius.
The compounds of Formula I can be prepared using the reactions and techniques described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups CA 022~9~73 1999-01-06 ~ WO98/01428 - PCT~S97/11325 present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts ( Protective Groups In Organic Synthesis, Wiley and Sons, l99l).
The following descriptions detail general methods of making benzimidazoles, indazoles and indoles through a variety of intermediates. These methods are not intended to represent all of the possible means of making the above compounds, merely a broad representation. One of ordinary skill in the art would readily understand what s~arting groups would be necessary to make all of the present compounds.
Intermediate l which can be formed via acylation of 4-amino-3-nitrobenzonitrile (Aldrich Chemical Co.) with an acyl chloride (RlCHO) or an anhydride ((RlCO)2O) in the presence of a base, followed by hydrogenation is shown below in Scheme l.
Reductive amination of an aldehyde (RCHO) in the presence of l using borane-pyridine in acetic acid can afford N-alkylated product 2. Alkylation of l with a halide (P3X) in the presence of a base, such as Cs2CO3~ can provide compound 3. Compounds 2 and 3 can be subjected to the Pinner reaction to give 6-amidino-benzimidazole derivative 4 and 5-amidino-benzimidazole derivative 5, respectively (see ~h~nn~ et al ~. Org. Chem.
1995, 60, 960).

Scheme l: Amidino-benzlmidazole~ via 4-A~;no-3-n~trn~n7o~itrile ~ ., WO 98/01428 - PCT/US97/1132~i NC~ NH2 o NC~ ~ Rl-- H Rl BH3-Pyr. \ K2CO3 1) HCl (gas), EtOH NC N
2) (NH4)2CO3, EtOH ~ Nl\~ R

H2N ~ N ~ R1 1) HCl (gas), EtOH

2 ) ( NH4 )2C03, EtOH

NH

R= (CH2)n 1-Z-A-B H2N
P3=(CH2)n-Z-A-B N

Scheme 2 shows palladium (0) catalyzed coupling of 3-amino-4-nitrophenyl halides with zinc cyanide in DMF under reflux can provide compound 6 (see Lawton et al J. Org. Chem.
1959, 24, 26). Acylation of 6 with an acyl chloride or anhydride in the presence of base, followed by hydrogenation can form compound 7. Alkylation of 7 with a halide in the presence of a base, such as Cs2CO3~ can provide compound 8.
Reductive amination of an aldehyde with 7 using borane-pyridine in acetic acid can afford N-alkylated product 9.
Compounds 8 and 9 can be converted to either their 6-amidino-benzimidazole or 5-amidino-benzimidazole derivatives, respectively via the Pinner reaction.
~h~ - 2: Amidino-h~n7;mi~7oles via 3-amino-4-nitrophenyl halides WO98/01428 - ~ PCT~S97/1132S
zn(CN)2 X ~ NH2 Pd(0) NC ~ NH2 N02 DMF ~ NO2 reflux 6 X = Br, I
l) RlCOCl or (RlCO) 2~~ NaH
2) H2, 10% Pd/C, p3 ~ MeOH
NC ~ ~ Rl NC ~ N ~ R1 NC ~ N\~ R

N P3X NH2 ~ RCHo ~ N
K2CO3 BH3-Pyr 8 7 9 ~-R

Ullmann reaction of 4-chloro-3-nitrobenzonitrile with an amine (P3NH2) in the presence of a base, such as NaHCO3, can form compound l0 shown in Scheme 3. Hydrogenation of lO, followed by cyclization with an acid, such as formic acid, can give compound 5, which can be converted to its 5-amidino-benzimidazole derivatives as described above. In addition, compound 5 could be derivatized by addition of Br-(CH2)n-Z-A-B
and the resulting mixture subjected to the Pinner reaction and separated by standard techniques.

Scheme 3: Amidino-benzimldazoleg via the Ullmann Reaction 1O NHP3 RlCO2H or 5 RlCOCl 3 As described in Scheme 4, bromination of 4-amino-benzonitrile with NBS, followed by treatment with NaNO2 and Cu2O in conc. HCl can provide compound ll (see Tsuji et al 20 Chem. Pharm. Bull. 1992, 40, 2399). Ullmann reaction of ll with an amine in the presence of a base, such as NaHCO3, can - form compound 12. Hydrogenation of ll, followed by cyclization with formic acid can give compound 8, which can be WO98/01428 - PCT~S97/11325 converted to its 6-amidino-benzimidazole derivative as described above.

Scheme 4: Amidino-benzimidazoles ~ia the Ullmann Reaction NC ~ 1) NBS WC ~ P3-NH2 NH2 2) NaNO2 ~ N02 Cu2~ 11 conc. HCl 1 3 Pl 3 NC " ~ N 1) H2, 10% Pd/C NC NH
2) R1COOH ~ NO2 Scheme 5 details the synthesis of 2-substituted-amidino-benzimidazoles from 3,4-diamino-benzonitrile and 3-amino-4-hydroxybenzonitrile 13 which are obtained by hydrogenation of4-amino-3-nitro-benzonitrile or 4-hydroxy-3-nitrobenzonitrile.
Treatment of 13 with an acyl chloride or an acid in the presence of PPA can form compound 14 (see Walker et al Synthesis 1981, 303). Compound 14 can be converted to its amidino derivative via the Pinner reaction. Alternatively, when Y is NH, alkylation of 14 with a halide in the presence of a base, such as K2CO3, can afford a mixture of two regioisomers 15 and 16, which can, after being separated, be subjected to the Pinner reaction to give 2-substituted-6-amidino-benzimidazoles and 2-substituted-5-amidino-benzimidazole derivatives, respectively.

Scheme 5: 2-Substituted-amidino-benz;~;dazolss CA 022~9~73 l999-0l-06 ~ WO98101428 - PCT~S97/11325 N_ , ~ NH2 ' [ ~ \ ~ P3 JH P3C02H or P3COCl J

/ when J = NH
RlX, K2C03 Rl ~/ Rl / ~ + ~ N

Protection of 6-hydroxy-indazole with pivalic anhydride in the presence of a base, followed by treatment with triflic anhydride can give compound 17 as shown in Scheme 6.
Palladium (0) catalyzed coupling of 17 with zinc cyanide can provide compound 18. Deprotection of compound 18 under acidic conditions, followed by alkylation of with a halide in the presence of a base can yield compound 19, which can be converted to its 6-amidino-indazole derivative via the Pinner reaction.

Scheme 6: Amidino-benz;nA~7~1es ~ia 6-llyd o~y-;n~7ole HO ~ 1) (Boc)2O ~ ~ Zn(cN)2 Pd(0) NC~ ~ N 2) P3X K2CO Nr ~ Boc 1-Substituted-amidino-indoles and -indazoles could be made from 5-cyanoindole as outlined below in Scheme 7.
Intermediate 21 can easily be obtained via alkylation of 20 with Br(CH2)nZ. Peptide coupling with H-A-B using the BOP

CA 02259573 l999-0l-06 WO98/01428 - PCT~S97/11325 reagent or alkylation should afford intermediate 22 which is can then be converted to amidine 23 under Pinner conditions.

Scheme 7: 1-Substituted-P~;dino-indole8 and -;~7Oles from 5-cyanoindole (Ja=CH or N) ~=\ l.NaH, DMF ~ \ Z-H

NC~ Br(CH2) nZ ~N~n f~J\ ~Z--A-B ~=J\ ~A-B
peptide ~N~ n l.HCl , ~N~ n coupling, ~ MeOH

acylation, NC 22 2.(NH4) 2C~3 HN 23 alkylation H-A-B

Scheme 8 shows 3-substituted-amidino-indoles and -indazoles are also derivable from 5-cyanoindole. Compound 26 may be obtained by substitution Of R1 on 24 to form 25 and acylation of 25 in the presence of oxalyl chloride at r.t.
under nitrogen atmosphere. The compound can be subjected to selective ketone reduction with triethylsilane in trifluoroacetic acid for 3h and then coupled with H-A-B.

Scheme 8: 3-Substituted-amidino-indoles and indazoles from 5-cyanoindole (Ja=CH or N) CA 02259573 l999-0l-06 WO98tO1428 - PCT~S97/11325 l.NaH, ~ 1. (COCl)2 ~OMe :~ XRl b~ CH2CL2 ~ ~

CN CN CN

l.TFA ~ ~A-B 1 . HCl, ~A-B
Et3SiH ~ ~ MeOH
2. KOH ~ 2.(NHs)2CO3 ~ , 3. peptide CN ~ ~
coupling HN NH2 The piperazine phenylsulfonamide, 31, and various other sulfonamide analogues can be prepared from commercially available BOC-piperazine via sulfonation with phenylsulfonyl chloride in CH2cl2 and triethylamine as indicated in Scheme 9.

Scheme 9: Phenylsulfonylpiperazines from Boc-piperazine r~ R6-PhS02C1 BoCNAN--\\S~/ r E~ N-- ~, 29 CH2Cl2/Et3N 30 ~ R6 ~

Biphenyl compounds may be prepared by procedures known to those of skill in the art. For example, Scheme 10 shows how to obtain substituted biphenyls via a Suzuki coupling with BOC
protected 4-bromoaniline (or 1-bromo-4-nitrobenzene) to afford compound 35.

Scheme 10: Biphenyls from bromoAn;l;ns B (OH) 2 NHBOC N~2 Oc) 20 ~ ~p6 ~., 3 TFA

Compound 38 can be obtained via deprotection of the t-butyl group when R6=so2NH-t-Bul with TFA followed by alkylation or acylation with R3X as outlined in Scheme 11.

gcheme 11: Preparation of 4~-~;no-biphenyl-2-sulfon~ides TFA ~ R3X
~3,SO2NH-t-Bu ~3,SO2NH2 ~So2NH-R3 Scheme 12 shows how intermediates 43-45 may be obtained via the same intermediate 39. Acylation with oxalyl chloride followed by addition of methanol should yield ketoester 40 and selective reduction with triethyl silane may afford methyl acetate 42. Reduction with sodium borohydride can give the alcohol which then can be converted to 45 with R3X.
Intermediate 43 may be obtained via formylation with POC13 in DMF to yield aldehyde 41 which could then subjected to a Wittig olefination to afford compound 43.

Scheme 12: Addition Of Rl substituent to l-substituted indoles or ; n~ 701es CA 02259573 l999-0l-06 B-A~ B-A~

2 MeOH
3CgN CN 4 0 TFA, DMF, POC13 Et3SiH
B-A~ B~

~H C ~ ,D OMe Ph3P=CH2R2 / l.NaBH4 THF / l.NaBH4 EtOH
~ EtOH 2.XR3, NaH
B-A
z 2.XR3, NaH
B -A~
\~ R2 ~ Z

~/ B~ oR3 43 1 \) oR3 CN
[~ 45 CN

Sulfonyl chloride 49 may be obtained via aldehyde 47.
The aldehyde can be reduced with sodium borohydride, sulfonated with methane sulfonyl chloride, and displaced with sodium sulfite in ethanol. Sulfonyl chloride 49 should then be obtained via chlorination with sulfonyl chloride as detailed in Scheme 13.

, CA 02259573 l999-0l-06 WO98/01428 ~ PCT~S97/11325 Scheme 13: Addition of Rl to l-protQcted indole~ or in~7Oles ; POCl3 ~ ~ NaBH4 ~ _~OH

CN CN CN
~6 47 48 l.NaH, MsCl ~ so2c 2.Na2SO3 3.Socl2 CN

P is a protecting ~roup e.g. MEM-group.

Scheme 14 details how substitution at the 2-position of the indole may be acomplished via lithiation with s-BuLi at -78'C followed by addition of RlX to yield compound 51.
Compound 51 can then converted to compound 52 by the previously mentioned methodology.

Scheme 14: Addition of two R1'B to l-protected indole ~ ~ l.s-BuLi 3~ ~ OH

2 . XR
CN CN CN

In Scheme 15, it is shown how the 5-cyanoindole compound 54 may be prepared via compound 53 by using sodium methoxide in the presence of nitromethane, followed by Zn reduction and condensation.

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 Scheme 15: Formation of indole~

w2~ ~ l.NaOMe NC~ W
w~ No2 CH3NO2 W2~w3 N
53 2. Zn/EtO~ 54 H
TFA
s Groups A and B are available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis. The required reactive functional groups appended to analogs of A and B are also available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis. In the tables that follow the chemistry required to effect the coupling of A to B is outlined.

Table l: Preparation of Amide, Ester, Urea, Sulfon~ide and Sulf~ide l;n~A~es be~.re_" A ~nd B.
then the reactive to give the Rxn. substituent of following product No. if A contains : Y is : A-X-Y :
1 A-NHR3 as a ClC(O)-Y A-NR3-C(o)-Y
substituent 2 a secondary NH ClC(O)-Y A-C(O)-Y
as part of a ring or chain 3 A-OH as a ClC(O)-Y A-O-C(O)-Y
substituent 4 A-NHR3 as a ClC(O)-CR3R3 -Y A-NR3-C(o)-CR3R3 -Y
substituent a secondary NH ClC(O)-CR3R3 -Y A-C(o)-CR3R3 -Y
as part of a ring or chain CA 022~9~73 1999-0l-06 WO9$/01428 PCT~S97/1132 6 A-OH as a ClC(O)-CR3R3 -Y A-o-C(o)-CR3R3 -Y
substituent 7 A-NHR3 as a ClC(O)NR3-Y A-NR3-C(o)NR3-Y
substituent 8 a secondary NH ClC(O)NR3-Y A-C(o)NR3-Y
as part of a ring or chain 9 A-OH as a ClC(O)NR3-Y A-o-C(o)NR3-Y
substituent 10 A-NHR3 as a ClSO2-Y A-NR3-So2-Y
substituent 11 a secondary NH ClS02-Y A-SO2-Y
as part of a ring or chain 12 A-NHR3 as a ClSO2-CR3R3 -Y A-NR3-So2-CR3R3 -Y
substituent 13 a secondary NH ClSO2-CR3R3 -Y A-So2-CR3R3 -Y
as part of a rinq or chain 14 A-NHR3 as a ClSO2-NR3-Y A-NR3-So2-NR3-Y
substituent 15 a secondary NH ClSO2-NR3-Y A-So2-NR3-Y
as part of a ring or chain 16 A-C(O)Cl HO-Y as a A-C(O)-O-Y
substituent 17 A-C(O)Cl NHR3-Y as a A-C(o)-NR3-Y
substituent 18 A-C(O)Cl a secondary NH as A-C(O)-Y
part of a ring or chain 19 A-CR3R3 C(O)Cl HO-Y as a A-CR3R3 C(O)-O-Y
substituent A-CR3R3 C(O)Cl NHR3-Y as a A-CR3R3 C(o)-NR3-Y
substituent .. . . . .. ..

CA 022~9~73 1999-01-06 - WO98/01428 PCT~S97/1132 21 A-CR3R3 C(O)Cl a secondary NH as A-C(R3)2C(O)-Y
part of a ring or chain 22 A-S02Cl NHR3-Y as a A-So2-NR3-Y
substituent 23 A-S02Cl a secondary NH as A-S02-Y
part of a ring or chain 24 A-CR3R3 S02Cl NHR3-Y as a A-CR3R3 So2-NR3-Y
substituent A-CR3R3 S02Cl a secondary NH as A-CR3R3 S02-Y
part of a ring or chain The chemistry of Table 1 can be carried out in aprotic solvents such as a chlorocarbon, pyridine, benzene or toluene, at temperatures ranging from -20 C to the reflux point of the solvent and with or without a trialkylamine base.

T~ble 2: Preparation of ketone linkages between A and B.
then the reactive to give the Rxn. substituent of following product No. if A contains : Y is : A-X-Y :
1 A-C(O)Cl BrMg-Y A-C(O)-Y
2 A-CR3R3 C(O)Cl BrMg-Y A-CR3R3 2C(O)-Y
3 A-C(O)Cl BrM~CR3R3 -Y A-C(o)CR3R3 -Y
4 A-CR3R3 C(O)Cl BrMgCR3R3 -Y A-CR3R3 C(o)CR3R3 -y The coupling chemistry of Table 2 can be carried out by a variety of methods. The Grignard reagent required for Y is prepared from a halogen analog of Y in dry ether, dimethoxyethane or tetrahydrofuran at 0 C to the reflux point of the solvent. This Grignard reagent can be reacted directly under very controlled conditions, that is low temeprature (-20 C or lower) and with a large excess of acid chloride orwith catalytic or stoichiometric copper bromide-dimethyl , , CA 022~9~73 1999-0l-06 ~ WO98/01428 - PCT~S97tll32 sulfide complex in dimethyl sulfide as a solvent or with a variant thereof. Other methods available include transforming the Grignard reagent to the cadmium reagent and coupling according to the procedure of Carson and Prout (Org. Syn. Col.
Vol. 3 (1955) 601) or a coupling mediated by Fe(acac)3 according to Fiandanese et al.(Tetrahedron Lett., (1984) 4805), or a coupling mediated by manganese (II) catalysis (Cahiez and Laboue, Tetrahedron Lett., 33(31), (1992) 4437).

Table 3: Preparation of ether and thioether link~es between A and B
then the reactive to give the Rxn. substituent of following No. if A contains : Y is : product A-X-Y :
1 A-OH Br-Y A-O-Y
2 A-CR3R3 -OH Br-Y A-cR3R3lo-y 3 A-OH Br-cR3R3l-y A-oCR3R3 -Y
4 A-SH Br-Y A-S-Y
A-CR3R3 -SH Br-Y A-CR3R3's_y 6 A-SH Br-CR3R3 -Y A-SCR3R3 -Y

The ether and thioether linkages of Table 3 can be prepared by reacting the two components in a polar aprotic solvent such as acetone, dimethylformamide or dimethylsulfoxide in the presence of a base such as potassium carbonate, sodium hydride or potassium t-butoxide at temperature ranging from ambient temperature to the reflux point of the solvent used.

CA 022~9~73 l999-0l-06 ~ WO98/01428 - PCT~S97/11325 Table 4: Preparation of -SO- and -S02- link~es from thioethers of Table 3.
and it is oxidized and it is oxidized with m-chloroper-with Alumina (wet)/ benzoic acid (Satoh if the Oxone (Greenhalgh, et al., Chem. Lett.
Rxn. starting Synlett,(1992) 235) (1992) 381, the No. material is : the product is : product is :
1 A-S-Y A-S(O)-Y A-SO2-Y
2 A-CR3R3 S-Y A-CR3R3 S(O)-Y A-CR3R3 SO2-Y
3 A-SCR3R3 -Y A-S(o)CR3R3 -Y A-So2CR3R3 -Y

The thioethers of Table 3 serve as a convenient starting material for the preparation of the sulfoxide and sulfone analogs of Table 4. A combination of wet alumina and oxone provides a reliable reagent for the oxidation of the thioether to the sulfoxide while m-chloroperbenzoic acid oxidation will give the sulfone.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration fo the invention and are not intended to be limiting thereof.
ExamPles The synthesis of representative compounds according to the invention is described in further detail below with reference to the following specific, but non-limiting examples.
Abbreviations used in the Examples are defined as follows: "~C" for degrees Celsius, "d" for doublet, "dd" for doublet of doublets, "DAST" for diethylaminosulfur trifluoride, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "mL" for milliliter or milliliters, "H" for hydrogen or hydrogens, "hr"
for hour or hours, "m" for multiplet, "M" for molar, "min" for minute or minutes, "MHz" for megahertz, "MS" for mass spectroscopy, "nmr" or "NMR" for nuclear magnetic resonance WO98/01428 PCT~S97/11325 spectroSCOpy, "t~ for triplet, "TLC" for thin layer chromatography.
Examples 1-15 were prepared by Michael addition of 5-cyano-benzimidazole to the a,~-unsaturated esters by using K2CO3 (2 mmol) as a base in DMF (10 mL) at 90-110~C for 16-24 hours, followed by the Pinner reaction. A mixture of meta-and para-isomers was obtained by purification on TLC plates with 10-20% MeOH in CH2cl2. The pure meta- or para-isomer was separated by HPLC.

5--Cy~nr~hsn 7; ~ ~ 7~1e N C~ MeOH \(~N N C~N?

reflux H

A solution of 4-amino-3-nitrobenzonitrile (20 mmol) in MeOH ~300mL) in the presence of 5% of Pd/C (1 g) was treated with hydrogen at room temperature for 16 hours. The reaction mixture was filtered and concentrated to give 3,4-diaminobenzonitrile (2.4 g, 90% of yield), which was directly treated with formic acid (20 mL) under reflux for 4 hours.
After removal of the excess formic acid, the residue was dissolved in EtOAc, washed with 10% sodium bicarbonate and brine, and dried over MgSO4. Concentration gave 5-cyanobenzimidazole (2.2 g, 85%). lH MMR (CD30D)~8.39 (s, lH), 8.05 (s, lH), 7.76 (d, J = 8.4 Hz, lH), 7.59 (dd, J = 8.4 Hz, J = 1.1 Hz, lH)i MS: 144 (M+H)+.

Preparation of Ethyl 2-~3-cy~norh~nyl)ethacrylate and Ethyl 2-(4-cy~norh~nyl)ethacrylate To a stirred suspension of zinc powder (22 mmol) in THF
(10 mL) was added 1,2-dibromoethylene (0.2 g) at room temperature and the mixture was stirred for 30 minutes. A
solution of 3-cyanobenzylbromide or 4-cyanobenzylbromide (20 mmol) in THF (25 mL) was slowly added at a rate of one drop CA 022~9~73 1999-0l-06 WO98101428 - PCT~S97/11325 per five seconds at 5-10~C. The mixture was stirred for 3 hours, and then transferred into a solution of copper (I) cyanide (20 mmol) and lithium chloride (40 mmol) in THF (20 mL) at -78~C. The resulting mixture was warmed up and stirred at -20~C for 20 minutes, and was then cooled to -78~C. After ethyl 2-(bromomethyl)acrylate (20 mmol) was slowly added, the mixture was stirred at -78~C for 2 hours, and then warmed to room temperature overnight. Ether (100 mL) and aqueous saturated ammonium chloride (50 mL) were added to the mixture and the mixture filtered- The filtrate was washed with water and brine, and dried over MgSO~. Concentration gave a residue, which was purified by column chromatography with gradient solvent system (cH2cl2-EtoAc) to give ethyl 2-(3-cyanophenyl)ethacrylate (1.2 g, 26.2%) and ester ethyl 2-(4-cyanophenyl)ethacrylate (3.6 g, 78.6%).
For ethyl 2-(4-cyanophenyl)ethacrylate: lH NMR (CDCl3)~
7.58 (dd, J = 8.4 Hz, J = 1.8 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 6.17 (d, J = 1.1 Hz, lH), 5.48 (dd, J = 2.6 Hz, J = 1.1 Hz, lH), 4.22 (q, J = 7.3 Hz, 2H), 2.86 (dd, J = 8.6 Hz, J =
7.1 Hz, 2H), 2.61 (dd, J = 8.6 Hz, J = 7.0 Hz, 2H),1.32 (t, J
= 7.0 Hz, 3H); MS: 247 (M+NH4)+.
For ethyl 2-(3-cyanophenyl)ethacrylate: lH NMR (CDC13)~
7.51-7.36 (m, 4H), 6.17 (s, lH), 5.48 (d, J = 1.1 Hz, lH), 4.22 (q, J = 7.3 Hz, 2H), 2.84 (dd, J = 8.4 Hz, J = 7.0 Hz, 2H), 2.61 (dd, J = 8.4 Hz, J = 7.0 Hz, 2H),1.32 (t, J = 7.0 Hz, 3H); 13C MMR (CDC13)~166.80, 142.85, 139.41, 133.14, 132.05, 129.85, 129.17, 118.94, 112.43, 60.79, 34.50, 33.57, 14.22; MS 247 (M+NH4)+.

Preparation of Ethyl t3-(4-cY~norhenyl)-2-bromomethyl~acrylate To a solution of 4-cyanobenzylbromide (40 mmol) in xylene (40 mL) was added triphenylphosphine (40 mmol) and the resulting solution was heated at 110~C for 2 hours. After removal of xylene, a white solid was obtained, which was dissolved in a mixture of THF (40 mL) and EtOH (40 mL), treated with DBU (40 mmol) at room temperature for one hour, and then to it was added ethyl pyruvate (40 mmol). The CA 022~9~73 l999-0l-06 ~ WO98/01428 - PCT~S97/113~5 resulting mixture was stirred at room temperature overnight and filtrated to remove Ph3PO. The filtrate was concentrated, dissolved in EtOAc, washed with lN HCl, water and brine, and dried over MgSO4. Concentration gave a mixture of cis and trans olefins in almost quantitative yield. A solution of the olefins (5 mmol), NBS (5 mmol), and AIBN (0.25 mmol) in CC14 (200 mL) was refluxed under nitrogen for 16 hours, filtered, concentrated and purified by column chromatography with gradient solvent system (cH2cl2-EtoAc) to give the title 10compound (1.25 g, 85 %) as a white solid. lH NMR (CDC13)~7.71 (d, J = 1.4 Hz, lH), 7.68 (d, J = 8-8 Hz, 2H), 7.58 (J = 8.5 Hz, 2H), 4.29 (q, J = 7.3 Hz, 2H), 4.23 (s, 2H), 1.32 (t, J =
7.3 Hz, 3H).

15Prepara~ion of Ethyl 2-(4-benzyloxyphenyl)methacrylate A mixture of 4-bromophenol (40 mmol), benzylbromide (40 mmol) and Na2CO3 in DMF (200 mL) was stirred at room temperature for 24 hours and was then poured into water. A
solid was collected and was further recrystallized from hexane to give 4-benzyloxy~enzene bromide in almost quantitative yield. A solution of the bromide in THF ( 100 mL) was treated with BuLi (44 mmol) at -78~C over 30 minutes and then with a solution of ZnI2 (40 mmol) in THF(40 mL) over 20 minutes.
After the resulting mixture was warmed to room temperature over an hour, it was cooled to -78~C and a solution of copper (I) cyanide (40 mmol) and lithium chloride (80 mmol) in THF
(50 mL) was slowly added. The resulting mixture was warmed and stirred at -20~C for 20 minutes, cooled to -78~C, and to it was added ethyl 2-(bromomethyl)acrylate (40 mmol). The resulting mixture was stirred at -78~C for 2 hours and was then warmed to room temperature overnight. Ether and aqueous saturated ammonium chloride were added and filtered. The filtrate was washed with water and brine, and dried over MgSO4.
Concentration gave a residue, which was purified by column chromatography with gradient solvent system (CH2Cl2-EtOAc) to give the title compound (3.6 g, 30.4%): lH NMR (CDC13) ~7.44-7.26 (m, 5H),7.12 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.4 HZ, CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 2H), 6.20 (s, lH), 5.92 (s, lH), 5.07 (s, 2H), 4.18 (q, J =
7.4 Hz, 2H), 3.57 (s, 2H), 1.27 (t, J = 7.4 Hz, 3H)i MS: 314 (M+NH4)+.

ExamPle 1 Pre~aration of EthYl 2-(3-ar;~; n~h~nYl )ethYl-3-(5-am;~;n~n7;~;dazole)pro~ionate and Ethvl 2-(3-amidino~henYl)ethYl-3-(6-am;~; n~h~n 7 imidazole)DroDionate A mixture of 5-cyanobenzimidazole (2 mmol), ethyl 2-(3-cyanophenyl)ethacrylate (2 mmol) and K2CO3 (2 mmol) in DMF (10 mL) was heated at 90~C under nitrogen for 16 hours. The mixture was diluted with EtOAc (150 mL), washed with lN HCl, water, and brine, and dried over MgSO4. After filtration and concentration, a residue was purified by column chromatography with gradient solvent system (cH2cl2-EtoAc) to give a mixture of ethyl 2-(3-cyanophenyl)ethyl-3-(6-cyanobenzimidazole)propionate and ethyl 2-(3-cyanophenyl)methyl-3-(5-cyanobenzimidazole)propionate (0.57 g, 76.4%) as a colorless oil. lH NMR (CDCl3)~8.13-7.36 (m, 8H), 4.55 (dd, J = 14.3 Hz, J = 9.2 Hz, lH), 4.28 (dd, J = 14.3 Hz, J = 5.5 Hz, lH), 4.07 (q, J = 7.0 Hz, 2H~, 3.00-2.91 (m, lH), 2.80-2.64 (m, 2H), 2.18-2.07 (m, lH), 1.92-1.82 (m, lH), 1.12 (t, J = 7.0, 3H).
ExamPles 2 and 3 PreDaration of EthYl 2-(3-amidinoDhenYl)ethYl-3-(5-am;~;n~h~n~imidazole)~ro~ionate and EthYl 2-(3-Pm;dino~henYl)ethY1-3-(6-ami~i nnh~n7; midazole)Dro~ionate The mixture of esters o~tained in Example 1 was treated with HCl (gas) in anhydrous ethanol (10 mL) for 15 minutes at 0~C and then stirred for 16 hours. After removal of excess HCl (gas) and ethanol, the residue was treated with (NH4)2CO3 (5 equivalents) in anhydrous ethanol (10 mL) at room temperature for 24 hours. Concentration gave a residue, which was purified on TLC plates with 10% MeOH in CH2C12 to give a mixture of the title compounds (400 mg, 65.4%): mp 160-165~C;

CA 02259573 l999-0l-06 ESMS: 204.2 (M+2H)2+ The mixture was further separated by HPLC on chiral OJ column with CO2/MeOH/TEA (80/20/0.1) to give Example 2, ethyl 2-(3-amidinophenyl)ethyl-3-(5-amidinobenzimidazole)propionate~ and Example 3, ethyl 2-(3-amidinophenYl)ethyl-3-(6-amidinobenzimidazole)propionate~

Example 2: 1H NMR (CD30D) ~8.36 (s, lH), 8.17 (s, lH) ,7.75-7.72 (m, 2H), 7.63 (bs, 2H), 7.50-7.48 (m, 2H), .4.66 (dd, J = 9.5 Hz, J = 14-3 Hz, lH), 4.55 (dd, J = 5.5 Hz, J =
1014.2 Hz, lH), 4.02-3-92 (m, 2H), 3 14-3 08 (m, lH), 2.81 (t, J
= 7.0 Hz, 2H), 2.19-1.93 (m, 2H), 1.04 (t, J = 7.0 Hz, 3H);
ESMS: 204.2 (M+2H)2+.

Example 3: lH NMR (CD30D) ~8.37 (s, lH), 8.10 (s, lH) 15,7.84 (d, J = 8.4 Hz, lH), 7.72 (d, J = 8.4 Hz, lH), 7.65-7.62 (m, 2H), 7.55-7.46 (m, 2H), 4.68 (dd, J = 9.5 Hz, J = 14.3 Hz, lH), 4.56 (dd, J = 5.5 Hz, J = 14.2 Hz, ~H), 4.04-3.94 (m, 2H), 3.24-3.18 (m, lH), 2.83 (t, J = 7.0 Hz, 2H), 2.19-1.95 (m, 2H), 1.05 (t, J = 7.0 Hz, 3H); ESMS: 204.2 (M+2H)2+.
ExamDle 4 PreDaration of EthYl 2-(4-amidinoDhenyl)ethyl-3-(5-a~;~;nnh~n7;m;A~ole)~ro~ionate and EthYl 2-(4-amidino~henYl)ethYl-3-(6-am;~; n~h~n 7; ~; ~A 701e)~ro~ionate Example 4 was made using the same method as described for Example 1, except ethyl 2-(4-cyanophenyl)ethacrylate (2 mmol) was used (100 mg, 13~ for two steps): mp 230~C (Dec.); ESMS:
407 (M+H)+; HRMS: 407.2200 (obs.), 407.2195 (calcd.) for 30C22~26N6O2. Example 4 was further separated to gi~e Examples 5 and 6.

Exam~les 5 and 6 Pre~aration of EthYl 2-(4-amidinoPhenyl)ethyl-3-(5_ 35ami~;nnhen7;m;dazole)Propionate and EthYl 2-(4-;no~henyl)ethyl-3-(6-am;~;noh~n7imidazole)Dro~ionate CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 The mixture of compounds obtained in Example 4 were further separated to give Examples 5 and 6.

Example 5, ethyl 2-(4-amidinophenyl)ethyl-3-(5-amidinobenzimidazole)propionate: lH NMR (DMso-d6):~9~43-9.o8 (m, 6H), 7.74-7.65 (m, 2H), 7.40-7.38 (m, 2H), 7.35-7.00 (m, 4H), 4.67-4.55 (m, 2H), 4.06 (bs, 2H), 3.48 (bs, 2H), 3.20 ~bs, lH), 2.70 (bs, 2H), 1.00 (bs, 3H); ESMS: 407 (M+H)+.

Example 6, ethyl 2-(4-amidinophenyl)ethyl-3-(6-amidinobenzimidazole)propionate: lH NMR (DMSO-d6):~9.23-9.12 (m, 6H), 8.41 (s, lH), 8.21 (s, lH), 7.84-7.82 (m, lH), 7.74 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 7.8 Hz, 2H), 7.24 (bs, lH), 4.58-4.56 (m, 2H), 3.95-3.89 (m, 2H), 3.10-3.00 (m, lH), 2.73-2.71 (m, 2H), 1.90-1.88 (m, 2H), 0.98-0.96 (m, 3H); ESMS: 407 (M+H)+.

Exam~le 7 PreDaration of Ethvl [3-(4-am;~;n~Dh~nvl)-2-(5-ami~;nQhqn7imidazole)methYl]acrvlate A mixture of 5-cyanobenzimidazole (2 mmol), ethyl [3-(4-cyanophenyl)-2-bromomethyl]acrylate (2 mmol) and K2CO3 (2 mmol) in DMF (10 mL) was heated at 90~C under nitrogen for 24 hours.
The mixture was diluted with EtOAc (150 mL), washed with lN
HCl, water, and brine, and dried over MgSO4. After filtration and concentration, the residue was purified by column chromatography ~cH2cl2-EtoAc) to give ethyl [3-(4-cyanophenyl)-2-(5-cyanobenzimidazole)methyl]acrylate (0.401 g, 56.3 %) as a colorless oil. lH NMR (CDCl3)~8.10-8.00 (m, 4H), 7.83-7.77 (m,, 2H), 7.52-7.44 (m, 2H), 7.01-6.98 (m, lH), 5.20 (s, 2H), 4.24 (q, J = 7.3 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H); MS: 357 (M+H)+.
The Pinner reaction converted ethyl [3-(4-cyanophenyl)-2-(5-cyanobenzimidazole)methyl]acrylate (0.42 mmol) to the title compound (400 mg, 65.4%): lH NMR (CD30D)~8.19-8.12 (m, 2H), 7.92-7.88 (m, 3H), 7.74-7.69 (m, 4H), 4.22-4.19 (m, 2H), 1.24-CA 022~9~73 1999-0l-06 ~ WO98/01428 PCT~S97/11325 1.20 (m, 3H); ESMS: 196.2 (M+2H)2+; HRMS: 391.1889 (obs.), 391.1882 (calcd.).
Exam~le 8 Pre~aration of EthYl 2-(4~ dino~henvl)methyl-3-(6_ am; ~; n~h~n 7; ~; ~ ~ 7ole)Dro~ionate and Ethvl 2-(4-n~r~h~nYl)methyl-3-(5-am;~;n~h~n7imidazole)~roDionate Ethyl [3-(4-cyanophenyl)-2-(5-cyanobenzimidazole)methYl]aCrYlate was hydrogenated in MeOH in the presence of 10% palladium on active carbon to give ethyl 2-(4-cyanophenyl)methYl-3-(6-cyanobenzimidazole)propionate and ethyl 2-(4-cyanophenyl)methyl-3-(5-cyanobenzimidazole)proPionate: lH NMR (CDC13) ~8.24-8.02 (m, 2H), 7.87-7.50 (m,, 4H), 7.34-7-28 (m, 2H), 4.58-4.55 (m, lH), 4.32-4.27 (m, lH), 4.12-3.93 (m, 2H), 3.20-2.91 (m, 2H), 2.79-2.72 (m, lH), 1.10-0.95 (m, 3H).
The mixture obtained (1.5 mmol) was subjected to the Pinner reaction to obtain the title compound (300 mg, 48%): 1H
NMR (CD30D):~8.63 (bs, lH), 8.27-7.96 (m, 7H), 4.98-4.54 (m, 2H), 3.98-3.80 (m, 2H), 3.53-3.45 (m, lH), 3.37-3.09 (m, 2H), 1.00-0.96 (m, 3H); ESMS: 197 (M+2H)2+.

Examples 51-63 were prepared by Method A, B, or C. All compounds were finally purified by HPLC (CH3CN/H2/0.05% TFA).

Method A: Examples 51-59 were made by Suzuki coupling reactions of [(4-bromophenyl)carbonyl]methyl-6-cyanobenzimidazole or [(4-bromophenyl)carbonyl]methyl-5-cyanobenzimidazole with a variety of boronic acids by using Na2CO3 (2-4 equivalents) and Pd(PPh3)4 (5-10% mmol~1) as catalyst in THF (80% in H2O, 10 mL/mmol), followed by Pinner reactions.
A mixture of [(4-bromophenyl)carbonyl]methyl-6-cyanobenzimidazole and [(4-bromophenyl)carbonyl]methyl-5-cyanobenzimidazole was made in over 90% yield by alkylation of 5-cyano-benzimidazole (36 mmol) with 2, 4'-dibromoacetophenone (36 mmol) by using NaH (48 mmol) as a base in THF (80 mL).

.

CA 022~9~73 199s-0l-06 WO98/01428 - PCT~S97/11325 The mixture were isolated by HPLC on chiralcel OJ column with MeOH/CO2 (20/80) to give pure individual compounds.
[(4-Bromophenyl)carbonyl]methyl-6-cyanobenzimidazole: lH
NMR (CDCl3)~8.35 (s, lH), 8.11 (dd, J = 1.1 Hz, J = 0.7 Hz, lH), 8.08 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.4 Hz, 2H), 7.56 (dd, J = 8.4 Hz, J = 1.8 Hz, lH), 6.16 (s, lH); ESMS:
340/342 (M+H)+.
[(4-Bromophenyl)carbonyl]methyl-5-cyanobenzimidazole: lH
NMR (CDCl3)~8.31 (s, lH), 8.13 (t, J = 0.7 Hz, lH), 8.07 (d, J
= 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.75 (dd, J = 8.4 Hz, J = 0.7 Hz, lH), 7.57 (dd, J = 8.4 Hz, J = 1.1 Hz, lH), 6.15 (s, lH)i ESMS: 340/342 (M+H)+.

ExamDle 51 PreParation of [4-(Phenyl)phenylc~rhonyl]methyl-6 am; ~; n~h9n7i~; dazole MP: 155-157~Ci lH NMR (CD30D)~8.44 (s, lH), 8.23 (d, J =
8.4 Hz, lH), 8.07 (d, J = 1.1 Hz, lH), 7.91 (d, J = 8.8 Hz, lH), 7.88 (dd, J = 8.4, 2H), 7.72 (dd, J = 8.4 Hz, J = 1.1 Hz, 3H), 7.52-7.41 (m, 3H), 6.10 (s, 2H); MS: 355 (M+H)+, HRMS:
3S5.1554 (obs.), 355.1559 (calcd-)i Anal : (C22Hl8N4Ol +
0.9TFA + 1.2HCl + 0.5H20) C, H, N, F, Cl.

ExamDle 52 PreParation of [4-(DhenYl)~henYlcarbonyl]methyl-5 ami~;nohsn7imidazole MP: 260-261~C; lH NMR (CD30D)~8.41 (s, lH), 8.22 (s, lH), 8.20 (d, J = 8.8 Hz, 2H~, 7.87 (d, J = 8.4 Hz, 2H), 7.73-7.70 (m, 4H), 7.51-7.41 (m, 3H), 6.10 (s, 2H); MS: 355.2 (M+H)+; HRMS: 355.1538 (obs.), 355.1559 (calcd.); Anal.:
(C22HlgN~Ol + 1.5TFA + 0.08HCl + lH2O) C, H, N, Cl.

Exa ~ le 53 preDaration of ~4-(3-aminoPhenYl)~henYlc~rho~yl]methyl-6-am;~;nohenzimidazole CA 022~9~73 l999-0l-06 WO98/01428 - PCT~S97/11325 H NMR (DMSO-d6)~9.22 (s, 1.5 H), 9.04 (s, 1.5 H), 8.48 ~s, lH), 8.22 (d, J = 1.4 Hz, lH), 8.18 (d, J = 8.3 Hz, 2H), 7.91 (d, J = 8.5 Hz, lH), 7.84 (d, J = 8.5 Hz, 2H), 7.69 (dd, J = 8.6 Hz, 1.7 Hz, lH), 7.21 (t, J = 1 8 Hz, lH), 7.04 (s, lH), 7.00 (d, J = 8.4 Hz, lH), 6 73 (d, J = 8.1 Hz, lH), 6.14 (s, 2H); 13C NMR (DMso-d6) ~ 192-4, 165.9, 148.6, 147.6, 146.7, 146.2, 139.3, 134-3, 132-9, 129 7, 128.8, 126.8, 121.8, 121.3, 119.7, 115.6, 115.1, 113.0, 111.8, 51.0; MS: 370 (M+H)+; HRMS: 370.1664 (obs.), 370.1668 (calcd.) ExamPle 54 PreParation of ~4-(3-am;noPh~nyl)~henylcarbonyl]methyl-5 ami~in~hsn 7 imidazole lH NMR (CD30D)~8.48 (s, lH), 8.32 (d, J = 8.4 Hz, 2H), 7.87 (d, J = 845 Hz, 2H), 7.74 (s, 2H), 7.62-7.56 (m, 2H), 7.53 (d , J = 8.4 Hz, 2H), 7.25 (d, J = 7.4 Hz, lH), 6.12 (s, 2H); MS: 370 (M+H)+, HRMS: 370.1664 (obs.), 370.1668 (calcd.) ExamDle 55 PreDaration of [4-(4-fluoroDhenyl)Dhenylcarbonyl]methyl-6 am;~;n~henzimidazole MP: 102-105~C; lH NMR (CD30D) ~ 8.54 (bs, lH), 8.23 (d, J
= 8.8 Hz, 2H), 8.10 (bs, lH), 7.92 (bs, lH), 7.86 (d, J = 8.4 Hz, 2H); 19F NMR~-116.3, -77.65 (TFA); 13C NMR (CD30D) ~
192.9, 168.6, 165.0, 163.5, 147.2, 137.1, 134.3, 130.3, 130.2, 130.1, 128.5, 124.7, 123.4, 120.8, 117.1, 116.9, 112.9, 52.5;
MS: 373.2 [(M+H)+; HRMS: 373.1481 (obs.), 373.1465 (calcd.);
Anal.: (C22H17N4OlFl + l.9TFA + O.lHCl + 2H2o) C, H, N, F, Cl.

ExamDle 56 Pre~aration of [4-(4-formYlPhenyl)phenylcar-h~onyl]methyl-6 am;~;n~hsn7imidazole MP: 125-128~C; lH NMR (CD30D) ~10.05 (s, lH), 8.48 (s, lH), 8.27 (d, J = 8.4 Hz, lH), 8.07 (bs, lH), 8.05 (d, J = 8.4 Hz, 2H), 7.97 (d, J = 8.1 Hz, 2H), 7.95 (d, J = 8.1 Hz, 2H), CA 022~9~73 l999-0l-06 7.93 (d, J = 8.4 Hz , 2H), 7.73 (dd, J = 8.4 Hz, J = 1.8 Hz, lH), 6.12 (s, 2H); 13C NMR (CD30D) ~192.99, 168.67, 147.86, 140.90, 140.15, 134.44, 130.10, 128.64, 128.57, 128.09, 124.63, 123.41, 120.75, 112.87, 104.26, 54.45i MS: 192.2 (M+2H)2+iHRMS: 383.1531 (obs.), 383.1508 (calcd.).

Exam~le 57 Pre~aration of [4-(2-al in9~1l1 fonYlDhenY~ henylc~h~rtyl]methyl-6 am~A; nnh9n7imidazole MP: 126-128~C; lH NMR (CD30D) ~ 8.55 (bs, lH), 8.18 (d, J = 8.4 Hz, 2H), 8.13 (dd, J = 7.7 Hz, J = 1.4 Hz, lH), 8.09 (s, lH), 7.94 (d, J = 8.8 Hz, lH), 7.71 (dd, J = 8.4 Hz, J =
151.4 Hz, lH), 7.67 (d, J - 7.8 Hz, lH), 7.65 (d, J = 8.1 Hz, 2H), 7.60 (dd, J = 7.8 Hz, J = 1.4 Hz, lH), 7.36 (dd, J = 7.3 Hz, J = 1.4 Hz, lH), 6.13 (s, 2H); MS: 217.7 (M+2H)2+; HRMS:
434.1303 (obs.), 434.1287 (calcd.) 20ExamDle 58 PreDaration of ~4-(2-tert-butYlaminosulfonYlDhenYl)~henYlC~rh~nYl]methYl-6-a~n; A; n~he~n7imidazole 25MP: 118-120~C; lH NMR (CD30D) ~ 8.60 (bs, lH), 8.19 (d, J = 8.4 Hz, 2H), 8.13 (dd, J = 7.7 Hz, J = 1.4 Hz, lH), 8.09 (s, lH), 7.95 (d, J = 8.8 Hz, lH), 7.76 (dd, J = 8.4 Hz, J =
1.4 Hz, lH), 7.67 (d, J = 8.4 Hz, 2H), 7.63 (dd, J = 7.7 Hz, J
= 1.5 Hz, lH), 7.60 (dd, J = 7.7 Hz, J = 1.4 Hz, lH), 7.34 (dd, J = 7.7 Hz, J = 1.4 Hz, lH), 6.14 (s, 2H), 1.09 (s, 9H) 3C NMR (CD30D) ~ 193.25, 168.78, 149.52, 147.86, 143.50,140.87, 134.76, 133.27, 133.07, 132.83, 131.58, 130.45, 129.77, 129.49, 128.76, 127.34, 124.45, 123.22, 120.99, 112.68, 55.30, 52.38, 30.22; Anal.: (c26H27N5o3sl + l.9TFA +
- 35 lH2O) C, H, N, F, S, Cl.

, CA 022~9~73 l999-0l-06 ~ WO98/01428 - PCT~S97/1132 ExamDle 59 Pre~aration of {4-~(2-tetrazolYl)Dhenyl]~henylcarbonyl}meth 6-am;~;n~h~n7lmldazole MP: 144-145~Ci lH NMR (CD30D)~ 8.56 (bs, lH), 8.11-8.09 ( m, 3H), 7.93 (d, J = 8.5 Hz, lH), 7.76 (dd, J = 8.5 Hz, J =
1.7 Hz, lH), 7.73 (d, J = 7.3 Hz, 2H), 7.67-7.62 (m, 2H), 7.38 (d, J = 8.8 Hz, 2H), 6.09 (s, 2H); 13C NMR (CD30D) ~ 192.97, 168.66, 156.91,149.40, 147.07, 146.51,142.32, 135.60, 134.66, 132.64, 131.79, 131.71, 130.90, 129.88, 129.47, 124.56, 123.43, 120.75, 112.87, 52.45i MS: 212.2 (M+2H)2+; HRMS:
423.1686 (obs.), 423.1682(calcd.)i Anal.: (c23HlgNgol+ 1.9TFA
+ 1 HCl +0.5H20) C, H, N, F, S, Cl.

Method B: Examples 60, 61 and 62 were made by alkylation of 5-cyanobenzimidazole with ~4-(2-tert-butylaminosulfonylphenyl)phenylaminocarbonyl]methylene chloride, or (4-benzylpiperidinecarbonyl)methylene chloride, followed by Pinner reactions.
Exam~les 60 and 61 PreDaration of r4-(2-aminosulfonYl~henYl1Dhem~laminocarbonyl]methYl-6-am;~;n~h~n7;m;~7ole (ExamDle 60) and ~4-(2-aminosulfon~l~hen~l)DhenYlam;n~bonYl]methYl-5-am;~;noh~n~;m; ~A701 e (Exam~le 61) [4-(2-tert-Butylaminosulfonylphenyl)phenyl-aminocarbonyl]methylene chloride was prepared by acylation of 4-[(o-SO2NHtBu)phenyl]aniline (3 mmol) with a-chloroacetyl chloride (4 mmol) in CH3CN (100 mL) and K2CO3 (4 mmol).
Alkylation of 5-cyanobenzimidazole (2 mmol) with [4-(2-tert-butylaminosulfonylphenyl)phenyl-aminocarbonyl]methylene chloride (2 mmol) in DMF (10 mL) and K2CO3 (4 mmol) at r.t.
over 16 hours, followed by purification on thin layer TLC
plates, and further isolation by HPLC gave [4-(2-tert-butylaminosulfonylphenyl)phenylaminocarbonyl]methyl-6-cyanobenzimidazole (240 mg, 56%) and [4-(2-tert-CA 022~9~73 l999-0l-06 WO98/01428 ~ PCT~S97/11325 butylaminosulfonylphenyl)phenylaminocarbonyl]methyl-5-cyanobenzimidazole (160 mg, 37%).
[4-(2-tert-Butylaminosulfonylphenyl)phenyl-aminocarbonyl]methyl-6-cYanobenzimidazole was converted to Example 60 via ~he Pinner reaction and purified by HPLC: MP:
134-136~C; lH NMR (CD30D)~ 8.73 (bs, lH), 8.15 (s, lH), 8.10 (dd, J = 8.6 Hz, J = 1.2 Hz, lH), 7.93 (d, J = 8.3 Hz, lH), 7.75 (d, J = 7.4 Hz, lH), 7.64 (d, J = 8.4 Hz, 2H), 7.60 (dd, J = 7.6 Hz, J = 1.2 Hz, lH), 7.52 (td, J = 7.6, J = 1.4 Hz, lH), 7.40 (d, J = 8.8 Hz, 2H), 7.32 (dd, J = 7.6 Hz, J = 1.2 Hz, lH), 5.36 (s, 2H); 13C NMR (CD30D) ~168.79, 166.75, 143.05, 141.48, 138.93, 137.50, 133.63, 132.92, 131.28, 128.75, 128.59, 124.63, 123.35, 120.96, 120.53, 112.80, 47.51;
MS: 449.3 (M+H)+; HRMS: 449.1401 (obs.), 449.1396 (Calcd.);
Anal.: (C22H20N6o3sl+ 1.8TFA + 0.25 HCl +lH2O) C, H, N, F, S, Cl.
[4-(2-tert-Butylaminosulfonylphenyl)phenyl-aminocarbonyl]methyl-5-cyanobenzimidazole was converted to Example 61 via the Pinner reaction and purified by HPLC: MP:
254~C (Dec.); lH NMR (CD30D) ~8.55 (s, lH), 8.22 (s, lH), 8.08 (d, J = 6.6 Hz, lH), 7.83-7.75 (m, 2H), 7.62 (d, J = 8.8, 2H), 7.59-7.52 (m, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.31 (d, J =
7.4 Hz, lH), 5.33 (s, 2H); 13C NMR (DMSO-d6) ~165.73, 164.97, 147.72, 142.58, 142.19, 139.43, 138.17, 137.63, 135.23, 132.31, 131.35, 129.69, 127.39, 127.23, 122.20, 121.03, 120.96, 120.17, 118.21, 118.12, 111.24, 47.51; MS:
449.3 (M+H)+; HRMS: 449.1414 (obs.), 449.1396 (calcd.);
Anal.: (C22H20N6o3sl+ 2TFA + 0.15 HCl +l.5H2o) C, H, N, F, S, Cl.
ExamPle 62 Pre~aration of 1-(4-benzYlDiPer;~;nec~ho~yl)methyl-6 am;~;n~h~n7Lmidazole and 1-(4-benzYl~iDer;~;ne~honyl)meth 5-a~;~;n~hAn7imidazole (4-Benzylpiperidinecarbonyl)methylene chloride was prepared by acylation of 4-benzylpiperidine (100 mmol) with a-chloroacetyl chloride (100 mmol) in THF (250 mL) and K2CO3 (100 CA 022~9~73 1999-0l-06 mL. Alkylation of 5-cyanobenzimidazole (2 mmol) with (4-benzylpiperidinecarbOnyl)methylene chloride (2 mmol) in DMF (5 mL) in the presence of NaH (3 I~unol) at from 0~C to room temperature over 16 hours, followed by purification on TLC
5 plates gave 1-(4-benzylpiperidinecarbonyl)methyl-6-cyanobenzimidazole and 1-(4-benzylpiperidinecarbonyl)methyl-5 cyanobenzimidazole (0.4 g, 56% of yield) This mixture (1.11 mmol) was then carried through the Pinner reaction, followed by purification on TLC plates with 10% MeOH in CH2Cl2, and 10 further purification by HPLC to give the title compounds: MP:
54-56~C; MS: 376.4 (M+H)+; HRMS:376.2118 (obs.), 376.2137 (calcd.); Anal.: (c22H2sNsol+ 1.8TFA + 0.1 HCl).

Method C: Example 63 was made by Ulmann coupling 15 reaction of 4-chloro-3-nitrobenzenitrile with (4-benzylpiperidinecarbonYl)methylamine~ followed by reduction of 4-[(4-benzylpiperidinecarbonyl)methylJamino-3-nitrobenzonitrile, cyclization with formic acid, and finally the Pinner reaction.
Exa~le 63 PreParation of 1-(4-benz~,rlPiDer;~;n~c~ nYl)methyl-6-ami ~ i n-~hqn ~ imidazole (4-BenzylpiperidineCarbonyl)methylamine was made by treatment of (4-benzylpiperidinecarbonyl)methylene chloride with NaN3 in aqueous acetone, followed by hydrogenation with 5%
Pd/C. Reaction of (4-benzylpiperidinecarbonyl)methylamine (8.6 mmol) with 4-chloro-3-nitro-benzonitrile ~10 mmol) in DMF
(10 mL) in the presence of NaHCO3 (10 mmol) at 100~C for 16 hours gave 4-[(4-benzylpiperidinecarbonyl)methyl]amino-3-nitrobenzonitrile (1.6 g, 49.2% of yield), which was then hydrogenated in MeOH in the presence of 5% of Pd/C (10% w/w) to produce 1-(4-benzylpiperidinecarbonyl)methyl-6-cyanobenzimidazole (1.3 g, 90% of yield). 1-(4-BenzylpiperidinecarbOnYl)methyl-6-cyanobenzimidazole (0.57 mmol) was then carried through the Pinner reaction, followed by purification on TLC plates with 10% MeOH in CH2Cl2, and CA 022~9~73 1999-01-06 ~ WO98/01428 - PCT~S97/11325 further purification by HPLC to give the title compound: mp:
68-70~Ci lH NMR (CD3OD)~ 8.52 (s, lH), 8.20 (s, lH), 7.75 (s, 2H), 7.29-7.24 (m, 2H), 7.18-7.16 (m, 3H), 5.43 (dd, J = 17.2 Hz, J = 24.5 Hz, 2H), 4.40 (d, J = 12.8 Hz, lH), 4.00 (d, J =
12.8 Hz, lH), 3.18 (t, J = 12.8 Hz, lH), 2.68 (t, J = 12.8 Hz, lH), 2.59 (d, J = 7.00 Hz, 2H), 1-87-1 78 (m, 2H), 1.72-1.68 (m, lH, 1.42-1.35 (m, lH), 1-22-1-15 (m, lH); 13C NMR (CD30D) 168.76, 166.06, 148.73, 141.23, 139.50, 130.17, 129.45, 129.33, 127.35, 127.11, 124.04, 120.40, 113.19, 47.38, 46.36, 43.93, 43.73, 39.15, 33.35, 32.73i MS: 188.8 (M+2H)2+;
HRMS:376.2130 (obs.), 376.2137 (calcd ); Anal.: (C22H2sNsOl+
1.85TFA + 0.18HCl+ 0.5H20).

ExamDle 64 PreDaration of 2- r4- (2-~;no~ulfonvlDhenYl)PhenYlcarbonyl]methyl-6 am; ~i nl~h~n7; i ~5~ 701e N-ethylmalonyl-4'-amin~h;~l ~yl-2-tert-butyl~ulfonamide. To a solution of 1.01 g of 4'-aminobiphenyl-2-tert-butylsulfonamide in 30 mL anhydrous methylene chloride and 0.93 mL
triethylamine was added 0.43 mL of ethylmalonyl chloride by dropwise addition. Let reaction mixture stir overnight at ambient temperature. Concentrated in vaCuo to give a residue which was taked up in 50mL ethyl acetate. The organics were washed 3x20 mL water. The resulting organics were dried over magnesium sulfate and concentrated under reduced pressure to give the crude product. The crude product was purified via st~n~rd chromatographic technique to give 0.70 g of N-ethylmalonyl-4'-aminobiphenyl-2-tert-butylsulfonamide.
LRMS(NH3-CI): 436(M+NH4). H NMR(CDC13, 300MHz): ~ 9.42 (s, lH), 8.18 (d, lH), 7.79 ~d, 2H), 7.52 (m, 3H), 7.49 (d, lH), 7.30 (d, lH), 4.30 (q, 2H), 3.60 (s, lH), 3.50 (s, 2H), 1.35 (t, 3H), 1.0 (s, 9H).
2-~4-(2-aminosulfonylphenyl)phenylc~rhonyl]methyl-6-cy~noben7im;~7ole. A mixture of 0.32 g of 3,4-diaminobenzonitrile and 0.70 g of N-ethylmalonyl-4~-CA 022~9~73 1999-0l-06 W098/01428 - PCT~S97/11325 aminobiphenyl-2-tert-butylsulfonamide was heated to 180~C for 2Oh. Let mixture cool to ambient temperature. Concentration and high vacuum gave 0.09 g of crude 2-[4-(2-aminosulfonylphenyl)phenylcarbonyl]methyl-6-cyanobenzimidazole. The crude material was carried through tothe next reaction sequence. LRMS(ES+): 431(M+H).

2-t4-(2-aminosulfonylPh~nyl)phenyl~Arhonyl~methyl-6-am;~;n~h~n7imidazole. A solution of the crude 2-[4-(2-aminosulfonylphenyl) phenylcarbonyl]methyl-6-cyanobenzimidazole in 10 mL 1:1 anhydrous chloroform to anhydrous ethanol was stirred in an ice bath. Hydrogen choride gas was bubbled into the reaction vessel for 20 minutes. Then the reaction mixture was allowed to warm to ambient temperature over l5h. Concentrated the reaction mixture under reduced pressure and placed the crude product on high vacuum. The resultant ethylimidate was treated directly with 0.30 g of ammonium carbonate in anhydrous ethanol. The reaction mixture was stirred at ambient temperature for 24h.
Concentrated reaction mixture under reduced pressure and purified crude product via standard HPLC technique to give purified 2-[4-(2-aminosulfonylphenyl)phenylcarbonyl]methyl-6-amidinobenzimid-azole. LRMS(ES+): 449(m+H). HRMS(FAB): calcd 449.139586 mass 449.139273. H NMR (DMSO,d6,300MHz~: ~ 10.50 (s, lH), 9.20 (bs, 2H), 8.67 (bs, 2H), 7.79 (d, 2H), 7.55 (m, 4H), 7.25 (m, 4H), 4.05 (s, 2H).

ExamDle 65 Pre~aration of 2-~4-(2-tert-butYl_minoQulfonYl~hen~l)~henYlcA~h~Yl~methYl-5-A 7:~h~n 7im:Ldazole N-ethylmalonyl-4'-am; n~h~ ph~nyl - 2-tort-hutylsulf onA~; ~9 . To a solution of 1.01 g of 4'-aminobiphenyl-2-tert-butylsùlfonamide in 30 mL anhydrous THF and 0.93 mL of triethylamine was added 0.43 mL of ethylmalonyl chloride by dropwise addition. Let reaction mixture stir for 24h. Concentrated in vacuo to give a residue which was taked up in 50mL ethyl acetate. The CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/1132 organics were washed 3x20mL water. The resultant organics were dried over magnesium sulfate and concentrated under reduced pressure. The crude product was purified via standard chromatographic technique to give 0.63g of N-ethylmalonyl-4/-aminobiphenyl-2-tert-butylsulfonamide. LRMS(NH3-CI):
436(M+NH4). H NMR(CDC13, 300MHz): ~ 9.42 (s,lH), 8.18 (d,lH), 7.79 (d,2H), 7.52 (m,3H), 7.49 (d,lH), 7.30 (d,lH).

2-~4-(2-t~rt-butYlam; n~ l fonylphenyl)phenylc~h~nyl]methyl-5-0 A~ h~n7Lmidazole. A mixture of 0.026 g of 3,4-diaminopyridine and 0.10 g of N-ethylmalonyl-4~-aminobiphenyl-2-tert-butylsulfonamide was heated to 165 C for 20h. Let mixture cool to ambient temperature. Purified crude material by standard chromatographic technique to give the 2-[4-(2-tert-butylaminosulfonylphenyl)phenylcarbonyl]methyl-6-azabenzimid-azole. LRMS(ES+): 464(M+H). HRMS(NH4-CI): Mass 464.175637 Calcd 464.175630. H NMR(CDC13,300MHz): ~ 9.49 (s,lH), 8.40 (s,lH), 8.15 (d,lH), 7.98 (s,lH), 7.47 (m,3H), 7.31 (d,2H), 7.25 (d,2H), 4.30 (s,2H), 1.0 (s,9H).
Exam~le 66 preDaration of 2S- [4- (2-tert-am; n~ fonvlDhen~l)phenylam;n~c~he~l]methyl-thio-lH
i~idazo( 4, 5 -C ) PYridine To a solution of lH-imidazo(4,5-C) pyridine-2-thiol (37 mg, 0.245 mmol) in DMF (2.5 mL) was added 4-(2-tert-butylaminosulfonylphenyl)phenylaminocarbonyl]methyl chloride (75 mg, 0.197 mmol) and then K2CO3 (58 mg, 0.42 mmol), and the resulting mixture was heated at 120~C for 1 hour. To the mixture at room temperature was added HCl (lN in Et2O, 1 mL) and then MeOH (6 mL), a clear solution was obtained. To it was then slowly added Et2O (200 ml), and a white suspension was observed, which was filtered and a white solid (120 mg) was collected. The solid was soluble in DMSO (8 mL), and the resulting solution was purified by HPLC with H2O-CH3CN-TFA to give the title compound (60 mg). HRMS (M+H)+ calc. m/z:
496.1477, obs: 496.1492.

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 ExamDle 67 PreParation of 2S- [4- (2-aminosulfonYlDhenYl)DhenYlaminOCarbOnvl]meth~ -thio-lH
5imidazo(4,5-C) DYridine A solution of Example 66 (26 mg) in TFA (0.5 mL) was heated for 16 hours. Removed all of the solvent and purified by HPLC with H2o-cH3cN-TFA to give the title compound (13 mg).
HRMS (M+H)+ calc. m/z : 440.0851, obs : 440.0831.

ExamDle Pre~aration of 1-(4-benz~lPiDeri~inecA-bonyl)meth~l-5 amidinoindole 5-Cyanoindole-1-methylaCetate. To a stirred solution of 5-cyanoindole (5.0 g, 35.2 mmol) in 10 mL of dry DMF at O C
under N2 atmosphere was added NaH (l.lg, 42.2mmol). The reaction was stirred for 30 min. and then ~-bromomethyl-acetate (5.4g, 35.2mmol) was added and stirred at roomtemperature for 2h. It was then quenched with H2O, extracted with ethyl acetate ~3x), dried with Na2SO4, filtered and concentrated in vacuo to afford a light yellow solid (7.5g, 35.2 mmol). lH NMR (CDC13) ~ppm 3.2 (s, 2H), 3.8 (s, 3H), 7.03 (s, lH), 7.32 (d, lH, J= 7.5Hz), 7.41 (d, lH, ~=7.5Hz), 7.61 (s, lH), 7.81 (s, lH). LRMS NH3-CI m/z (M+H)+ 229, (M+NH4)+ 246.

3-(5-Cyanoindole) acetic acid. Methyl-5-cyanoindole-1-acetate was saponified in MeOH, KOH (3.3eq) at rt for 18h. The mixture was concentrated in vacuo, dissolved in water, extracted with diethylether (2x) and the acidic aqueous layer was acidified with 2N HCl. The resulting white solid was filtered and dried in a vacuum oven to afford 6.2 g of the title compound. LRMS ESI (M+H)+ 201.

1-(4-Benzylpiper;~; n9rA ~bonyl)methyl-5-cyano; nAol e. To a stirred complex of 3-acetic acid-5-cyanoindole (2.0g, CA 022~9~73 1999-0l-06 ~ WO98/01428 - PCT~S9711132 0.1mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC) in dry CH2cl2 was added 4-benzylpiperidine (1.8g, 0.01mmol). The mixture was stirred under N2 atmosphere for 18h, then concentrated in vacuo, dissolved in ethyl acetate, washed with lN HCl (3x), NaHCO3 (3x), brine (2x), dried with Na2SO4, filtered and concentrated in vacuo to afford a white solid (2.8g). HRMS for C23H24N3o (M+H)+ calc.
358.191938, found 358.193278.

1-(4-Benzylpiper;~;n9cA~ho~yl)methyl-5-amidinoindole. N-l-Acetyl-l-N'-PiPeridinYl-4-benZyl-5-cyanoindole (500mg), was dissolved in dry MeOH (30 mL) cooled to O C and saturated with HCl(g). The resulting solution was allowed to warm up to rt over 18h. The mixture was concentrated in vacuo, re-dissolved in dry MeOH and (NH4)2co3 (672.0 mg) was added, flask sealed and stirred for 18 at rt. The resulting suspension was filtered through Celite~, rinsed with dry MeOH, concentrated in vacuo to afford 997mg of product (89~ by HPLC); 100 mg of which was further purified via prep HPLC to afford 29 mg (100%
purity by HPLC). M.p. 214-21S C HRMS (NH3-CI) for C23H26N40 (M+H)+ calc. 375.217601, found 375.218487. lH NMR (CD30D) ~
ppm 1.05 (qd, lH, J= 7.5 Hz, J= 2.5 Hz), 1.25 (qd, lH, J=7.5, J=2.5 Hz), 1.65 (bd, lH, J=7.5 Hz), 1.76 (bd, lH, J=7.5 Hz), 1.83 (m, lH), 2.58 (d, 2H, J=6.0 Hz0, 2.63 (t, lH, J= 75 Hz), 3.07 (t, lH, J=7.5 Hz), 4.03 (bd, lH, J=7.5 Hz), 4.2 (bd, lH, J=7.5 Hz), 5.21 (qd, 2H, J= 7.5 Hz), 6.63 (s, lH), 7.18 (m, 3H), 7.23 (m, 2H), 7.38 (s, lH), 7.51 (d, lH, J= 5.0 Hz), 7.58 (d, lH, J=5.0 Hz), 8.05 (s, lH).

ExamDle 102 PreParation of 1-(4-benzYl~i~er;~; ne~A~ho~l )eth~1-5-amidinoindole Methyl-5-cyAnn;n~ole-3-ProPionate. To a stirred solution of 5-cyanoindole (1.0g, 7.Ommol), K2CO3 (0.966 g, 7.Ommol) in acetonitrile was added 3-bromomethylpropionate (1.17 g, 7.Ommol). The mixture was stirred at reflux for 18h under a nitrogen atmosphere, cooled, diluted with H2O, extracted with CA 022~9~73 1999-0l-06 W098/01428 - PCT~S97/11325 ethyl acetate, dried with Na2so4~ filtered and concentrated in vacuo to afford 1.59 g of product. lH NMR (CD30D) ~ppm 2.85 (t, 2H, J= 6.6 Hz), 3.61 (s, 3H), 4.58 (t, 2H, J= 6.6 Hz), 6.61 (s, lH), 7.42, (m, 3H), 7-62 (d, lH, J= 8.4 Hz), 7.99 (s, lH).

5-cYanoinaole-3-propionic acid. Methy-5-cyanoindole-3-propionate (200 mg) was saponified in MeOH (lOmL)/KOH (150 mg, 0.88mmol) at rt for 18h. The solution was concentrated in vacuo, dissolved in water and washed with chloroform. The acidic layer was acidified and extracted with ethyl acetate, dried with Na2so4~ filtered and concentrated in vacuo to afford 188 mg of product. lH NMR (CD30D) ~ppm 2.83 (t, 2H, J=6.6Hz), 4.43 (t, 2H, J=6.6 Hz), 6.6 (nd,lH, J3.2 Hz), 7.42 (d, 2H, J= 7.3 Hz), 7.43 (s, lH), 7.61 (d, lH, J=7.3 Hz), 7.99 (s, lH); LRMS ESI (M+H)+ 215.

1-(4-Benzylpiperi~; n9C~ ~hQnyl )ethyl-5-~;dinoindole.
Preparation follows the same last two steps of example 101.
Afforded 156 mg of the TFA salt lH NMR (DMSO-d6) ~ppm 2.42 (m, 4H), 2.89 (m, 4H), 3.21 (d, 2H, J= 5.0 Hz), 3.72 (bd, lH, J=10.0 Hz), 4.12 (m,lH), 4.38 (bd, lH, J= 10 Hz), 4.51 (m, 2H), 6.62 ~s, lH), 7.1-7.31 (m, 5H), 7.62 (m,2H), 7.72 (d, lH, J=6.0 Hz), 8.21 (bs, lH); HRMS (M+H)+ for C24H2gN40 calc.
389.234137, found 389.231258.

Exam~le 103 Pre~aration of 1-(4-(3-fluoro)benzYlDi~er;~;n~c~bonYl)methyl-5-amidinoindole 4-(3-F1UG o~e"zyl)piperidine. To a stirred solution of 1-benzylpiperidin-4-one (O.99mL, 5.34mmol) in THF was added Ph3P=CH-(3-fluoro)phenyl (2.4lg, 5.34mmol) at O C under a nitrogen atmosphere. After stirring for 4h at rt, the reaction was quenched with H20, concentrated in vacuo and the residue was chromatographed on silica gel using 1:1 hexanes:ethyl acetate as the eluant to afford 313mg of product. LRMS NH3-CI (M+H)+ 282. The product (330 mg) was CA 02259573 l999-0l-06 WO98/01428 - PCT~S97/11325 hydrogenated in MeOH, 10% Pd/C (300mg) and conc. HCl (5mL) in a parr shaker at 50psi for 18h. The reaction was filtered through Celite~ and the filtrate was concentrated in vacuo to afford 250 mg of the title compound. LRMS NH3-CI (M+H)+ 194.

1-(4-(3-Fluoro)benzyl~ep;~;~;n~hQnyl)methyl-5-cyanoindole.
Prepared as in example 101. LRMS ESI (M+H)+ 376.

1-(4-(3-Fluoro)benzylpepirill;nocA~hQnyl)methyl-5-a~;~; n~ n~l e. Example 103 was prepared via the same method as example 101. HRMS FAB glycerol matrix for C23H26N4FO
(M+H)+ calc. 393.209065, found 393.208858.

Exam~le 104 Pre~aration of 1-(1-(4-a~;~;n~)benzYl-N-(methYlacetate)a~in~c~r~onyl)methyl-5-amidinoindole (4-Cyano)benzyl-N-(methylacetate)amine. ~-Bromo-tolunitrile (2.0g, 10.5mmol) was dissolved in CHC13 and glycine methyl ester (2.64g, 21.0mmol) and triethyl amine (2.92mL, 10.5mmol) was added. The mixture was stirred for 18h under nitrogen atmosphere, concentrated in vacuo and purified via silica gel column using 1:1 hexanes:ethyl acetate as the eluant to afford 1.07g of the title compound (5.25mmol). LRMS ESI (M+H)+ 205.
lH NMR (C~Cl3) ~ppm 3.42 (s, 2H), 3.78 (s, 3H), 3.91 (s, 2H), 7.42 (d, 2H, J=8.0 Hz), 7.62 (d, 2H, J=8.0 Hz).

1-(l-(4-cyano)benzyl-N-(methylacetate)am;no~a~hQ~yl)methyl-5 cyAno;n~sle. Compound was prepared using the same coupling procedure as in example 101. HRMS NH3-CI for C23H20N4o3 (M+H)+ calc. 401.161366, found 401.159527.

1-(l-(4-Amidino)benzyl-N-(methylacetate)am;no~A~bonyl)meth 5-amidinoindole. Prepared by the same Pinner conditions as example 101. LRMS ESI (M+2H)+2 218.

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 ExamDle 105 Pre~aration of Methvl 1-(4-benzYl~iDeridino-~-carbonyl)meth~
5-a~;~;noindole-3-~ro~anoate Methyl 1-(4-~enzylpiperidine-1-C~hQ~yl)methyl-5-cyanoindole-3-prspAn~te. 1-( 4-Benzylpiperidine-1-carbonyl)-5-cyanoindole (l.Og, 2.8mmol) was dissolved in 2OmL of dry CH2cl2~ cooled to O C and oxalyl chloride (1.07g, 8.4 mmol) was added. The reaction stirred for 3h at rt- It was then concentrated in vacuo and dissolved in dry MeOH (20mL) and stirred for 18h.
The resulting yellow solution was concentrated in vacuo and l.Og (2.3mmol) was taken up in TFA (20mL) at O C and triethylsilane (535 mg, 4.6mmol) was slowly added. The reaction stirred at O C for 3h and then it was concentrated in vacuo, dissolved in CH2cl2 and washed with sat. NaHC03, dried with sodium sulfate, filtered and concentrated. The resulting residue was chromatographed via silica gel using 7% MeOH/CHCl3 as the eluant to afford 840 mg of the title compound. LRMS ESI
(M+H)+ 430.
1-(4-Benzylpiperidine-1-~A ~hQnyl)methyl-3-methylacetate-5-A~; dinoindole. The amidine was prepared as in example 101.
HRMS NH3-CI for C26H34N4o3 (M+H)+ calc. 447.239616, found 447.241907.
Exam~le 106 Pre~aration of 1-((4-benzvl~i~er;~ine~arbonYl)meth~1-(3-ethAnel-Y~o~1)-5-amidinoindole 1-(~-Benzylpiperidine-l-cA~ho~yl)methyl-3-e~h~n~hydroxyl-5-cy~ne~n~ole. Methyl 1-acetyl-(4-benzylpiperidin-1-yl)-3-acetate-5-cyanoindole (lOOmg, 0.233 mmol) was dissolved in ethanol and sodium borohydride (20mg, 0.51mmol) was added and the solution stirred at rt for 18h. The reaction was concentrated in vacuo diluted with water and extracted with methylene chloride (3x), dried over sodium sulfate, filtered and concentrated in vacuo to afford 93.0 mg of the title compound. LRMS DCI-NH3 (M+NH4)+ 419.

CA 02259573 l999-0l-06 ~ WO98/01428 PCT~S97/11325 1-(4-Benzylpiperidine-l-r~ho~yl)methyl-3-e~h~n~hydroxyl_5_ ami~inoindole. The amidine was prepared as in example 101.
HRMS NH3-CI for C25H3lN4o2 (M+H)+ calc. 419.244702, found 419.245383.

Exam~le 107 PreDaratiOn of 1-(4-benzYl~iDeridine-1-c~honyl)methyl-3-methY~ hnYYlic acid-5-amidinoindole Methyl 1-acetyl-(4-benzylpiperidin-1-yl)-3-acetate-5-amidinoindole was hydrolyzed in TFA/H2O for 18h. Purified via prep HPLC to afford the title compound. LRMS (M+H)+ 433.

ExamPle 108 PreParation of 1-~1-8enzYl~iDeridine-4-r ino~rbonYl)meth~1-5-amidinoindole 1-(l-Benzylpiperidine-g-am;noç~bonyl)methyl-5-cyanoindole.
To a stirred complex of N-1-methylenecarbohydroxy-5-cyanoindole (300mg, 1.5mmol) and DEC was added 4-amino-1 benzylpiperidine and triethylamine (0.209 mL, 1.5mmol). The reaction was stirred at rt for 18h. The volatiles were removed in vacuo and the residue was purified via silica gel using 1%MeOH/CH2C12 as the eluant to afford 160 mg of product.
HRMS NH3-CI for C23H24N4o (M+H) + calc 373.204.204739, found 373.202837.

l-(l-Benzylpiperidine-4-am;nnrA~hnnYl)methYl-5-amidinoindole.
The amidine was prepared as in example 101 to afford 96mg of the title compound. HRMS NH3-CI calc. 390.229386, found 390.229386.

ExamDle 109 PreParation of 1-(4-benzoYlDiDer;~;ne~arbonyl)methyl-5 amidinoindole CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 1-(4-Benzoylpiper;~in0~A~ho~yl)methyl-5-cyanoindole. Prepared as in example 108 except using 4-benzoylpiperidine. HRMS NH3-CI ~M+H)+ for C23H2lN3o2 calc.372.171702, found 372.171620.

1-(4-Benzoylpiper;~;ne~A~bonyl)methyl-5-~mi~;no;n~QlQ, The amidine was prepared using the same method as in example 101.
HRMS ~M+H)+ for C23H24N4o3 calc. 389-197751, found 389.198109.

Exam~le 110 Pre~aration of 1-(4-(3-fluoro)benzyl~i~erA7;
5-A~;dinoindole 1-(4-(3-Fluoro)benzylPiPerA 7; necA ~ho~yl )methyl-5-cyanoindole.
To a stirred solution of l-acetyl-(l-piperazine)-5-cyanoindole (400mg, 1.31mmol), triethylamine (0Ø36 mL, 2.62mmol) in diethyl ether was added 3-fluorobenzyl bromide (0.161 mL, 1.31 mmol) and stirred at room temperature under N2 atmosphere for 18h. The reaction quenced with water, extracted with ethyl acetate, dried with sodium sulfate, filtered and concentrated in vacuo to afford 438mg product. LRMS ~M+H)+ 377.

l-(4-(3-Fluoro)benzylpiperA7;ne~A-honyl)methyl-5-amidinoindole. Prepared as in example 101. HRMS (M+H)+ for C22H24NsOF calc. 394.204314, found 394.204917.
ExamDle 111 Pre~aration of 1-(4-~henYlbenzYlam;ne~hQ~Yl)meth~l-5 am; ~; n-~; n~ole 1-~-Phenylbenzylam;no~A~hQ~yl)methyl-5-cyAnoindole. To a stirred complex of l-acetic acid 5-cyanoindole (250mg, 1.25mmol) and DEC (239mg,1.25mmol) in methylene chloride was added 4-phenybenzylamine (228mg,1.25mmol). After stirring at rt for 18h under a nitrogen atmosphere, the reaction was concentrated in vacuo, dissolved in ethyl acetate, washed with lN HCl, sodium bicarbonate, and brine, dried with sodium sulfate, filtered and concentrated in vacuo to afford 215mg of product. HRMS (M+H)+ calc. 366.260637, found 366.160323.

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 1-(4-Phenylbenzyl_m;nO~A~honYl)methyl-5-amidinoindole.
Prepared as in example 101- HRMS calc. 383.187187 found 383.189667.

ExamDle 112 Pre~artion of methYl 1-(4-benzvl~i~eri~; neCA rho~yl ) methYl-5-a~;~;noindole-3-~L~v6,,oate Methyl 1-(4-benzylpiper;~;necArh~nyl)methyl-5-cyanoindole-3-prop~noAte. To a stirred solution of DMF (15mL) and POCl3 (256mg 1 7mmol) at O C was added 1-(4-benzylpiperidine-carbonyl)methyl-5-cyanoindole (199mg, 0.56mmol). After stirring 3h, the reaction was quenched with 2N sodium hydroxide and stirred for 30 min. It was then extracted with chloroform, dried with sodium sulfate, filtered and concentrated in vacuo to afford product. LRMS (M+H)+ 386. The product was then refluxed in the presence of triphenyl phosphonium~methylenecarbomethoxy)ylide in THF under a nitrogen atmosphere for 18h. The reaction was concentrated in vacuo and the residue purified via silica gel chromatography using 7% MeOH/CHCl3 as the eluant to afford 140mg of product.

Methyl 1-(4-benzylpiper;~;nec~rbonYl)methyl-5-amidinoindole-3-~ v~ oAte. Prepared as in example 101. LRMS (M+H)+ 459.

ExamDle 113 Pre~aration of 1-(4-(2-fluoro)benzYl~i~er;~nec~honYl)meth 5-Amidinoindole 4-(2-Fluoro)benzylpiperidine. To a stirred solution of triphenylphosphonium-2-fluorobenzylbromide in dry THF at -78 C
was added n-buLi (2.5M, 2.13mL) and stirred for 30 min. To it was then added 1-benzyl-4-piperidinene (0.99mL) and the mixture stirred at rt for 4h- The reaction was quenched with water and concentrated in vacuo. The resulting residue was purified via silica gel chromatrography using 1:1 hexanes:ethyl acetate as the eluant to afford 313mg. LRMS

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 (M+~)+ 282. The product was hydrogenated in a parr shaker at 50psi in MeOH (lOmL), 5-OmL conc. HCl and 10%Pd/C (300mg~ for 18h. The mixture was filterd through celite~ and concentrated in vacuo to afford 250mg of product. LRMS (M+H)+ 194.

1-(4-(2-Fluoro)benzylpiper;~i~er~bonyl)methyl-5 Prepared by coupling 3-acetic acid-5-cyanoindole with 4-(2-fluoro)benzylpiperidine using the method described in example 101. LRMS ~M+H)+ 376.
1-(4-(2-Fluoro)benzylpiper;~;nec~bonyl)methyl-5-a~;~ooindole. Prepared as in example 101. HRMS (M+H)+
calc. 393.209065, found 393.208858.

ExamDle 201 Pre~aration of 3-((g-cYclohexvl)~henYlaminomethY1carbOnyl)methyl-5-amidinoindole Methyl 5-cy~n~;n~ole-3-acetate. To a stirred solution of 5-cyanoindole (10.0g) in dry methylene chloride was added (3.0eq, 61.43mL) of oxalyl chloride. After stirring for lh under a nitrogen atmosphere at rt, the resulting precipitate was filtered and rinsed with diethyl ether. The solids were then taken up in dry MeOH and stirred for lh. At this time the solids were filtered and rinsed with MeOH and diethyl ether to afford 5.93g of methyl a-ketoacetate 5-cyanoindole.
LRMS (M+H)+ 229. Methyl a-ketoacetate (4.90g) was dissolved in 50 mL trifluoro acetic acid at O~C and triethyl silane (5.0g) was slowly added via a drop funnel (20 min.) . It was then stirred at O~C for 3h. The resulting yellow solution was concentrated in vacuo, neutralized with sodium bicarbonate, extracted with diethyl acetate, dried with magnesium sulfate filtered and concentrated in vacuo. Purification was accomplished via silica gel chromatography using 1%
MeOH/CH2C12 as the eluant to afford 2.48g of product. LRMS
(M+H)+ 232.

CA 02259573 l999-0l-06 WO98/01428 - ~ PCT/US97/11325 3-(5-Cy~no~n~o1e) acetic acid. The above ester was saponified in KOH/MeOH at rt for 18h. The solution 3 was then concentrated in vacuo, dissolved in water, extracted with ethylacetate and the acidic layer was then acidified with lN
HCl at O~C. The resulting white solids were filtered and further dried under high vacuum to afford the product. M.p.
196.5-198.5; Calc. C66.00 H4.04 N13.99, found C65.71 H4.24 N13.94. lH NMR (CD30D) ~ ppm 3-78 (s, 2H), 7.28 (s, lH), 7.38 (d, lH, J= 8.6 Hz), 7.45 (d, lH, J= 8.6 Hz), 7.89 (s, lH);
LRMS (M+)~ 199.

3-(4-CyclohexylphenYlaminomethYlCarbOnyl)methyl-5-cy~noin~Qle.
To a stirred complex of the 5-cyanoindole acetic acid (312mg, 1.5mmol) and BOP reagent (1.03g) in DMF was added 4-cyclohexylphenylaminomethyl. After heating at 50 C under anitrogen atmosphere for 18h, the reaction was cooled to rt diluted with water and extracted with ethyl acetate, washed with lN HCl, sat. sodium bicarbonate, and brine, dried with sodium sulfate, filtered and concentrated in vacuo. The residue was purified via chromatography using 100% ethyl acetate as the eluant to afford 210mg of product. LRMS (M+H)+
372.

3-((4-Cyclohexyl)phenYlaminomethylcarbonyl)methyl-5-amidinoindole. Prepared as in example 101. HRMS (M+H)+ for C24H2gN4O calc. 389.234137, found 389.232086.

ExamDle 202 PreDaration of 3-(4-D-toluenesulfonyl-Di~er~7;~ec~rho~Yl)meth~1-5-am;~;nQindole 3-(4-Paratol~e~c~lfonylpiper~ 7; n9C~ ~ho~yl )methyl-5-cyanoindole. To a stirred solution of 3-(piperazinecarbonyl)methyl-5-cyanoindole hydrochloride (20Omg, 0.66mmol) and triethylamine (134mg, 185~L) in chloroform was added toluenesulfonylchloride (126mg, 0.66mmol). After stirring for 18h at rt under a nitrogen atmosphere, the reaction was quenched with water, extracted with chloroform, CA 022~9~73 1999-0l-06 W098/01428 PCT~S97/11325 washed with lN HCl, sat sodium bicarbonate, and brine, dried with sodium sulfate, filtered and concentrated in vacuo to afford 237mg of product. LRMS (M+H)+ 423.

3-(4-Paratol~sna~llfOnylpip~7;n9C~h~nyl)methyl-5-amidinoindole. Prepared as in example 101. HRMS (M+H)+ for C22H26N503S, calc. 440.174611, found 440.175637.

Exam~le 203 Pre~aration of 3-(4-(2-aminosulfonvlDhenYl)~yridine-2-am;nocA~bonYl~methYl-5-amidinoindole 3-(4-(2-Aminosulfonylphenyl)pyridine-2-am;no~rhonyl)methyl-5-cyanoindole. To a stirred solution of 5-cyano-3-acetic acid 15indole (400mg, 2.0mmol), BOP (884mg, 3.0mmol) in DMF (15mL) was added 4-(2-aminosulfonyl)phenyl-2-aminopyridine (912mg, 3.0mmol) and heated at 50 C for 3h. The reaction was diluted with water, extracted with ethyl acetate, washed with 10% HCl, sodium bicarbonate, brine, and water, dried with magnesium sulfate, filtered and concentrated in vacuo to afford 420mg of product. LRMS 488. The t-butyl group was removed in TFA
reflux for lh and the product purified via silica gel using 100% ethyl acetate as the eluant to afford 101 mg of product.
LRMS 432.
3-(4-(2-Aminosulfonylphenyl)pyridine-2-aminocar~onyl)methyl-5-~dinoindole. Prepared as in example 101. HRMS (M+H)+ for C22H22NsO3S calc. 449.139586, found 449.139058.

30ExamDle 204 PreParation of 3-(4-~2-tetrazole]~henYl)~henvlam;nec~ho~Yl)methYl-5-amidinoindole 3-(4-~2-Tetrazole]phenyl)phenylam;noc~honyl)methyl-5-cyanoindole. 5-cyanoindole-3-acetic acid was dissolved in DMF/CH2C12, DEC (382mg), and DMAP (lOmg) and the reaction mixture stirred for 15 min. 4-((2-Tetrazole)phenyl)aniline was added and the reactin mixture stirred for 2h. The . .

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/1132 reaction was concentra~ed in vacuo, dissolved in ethylacetate and washed with water and brine, dried with magnesium sulfate, filtered and concentrated in vacuo. Purification was done via silical gel using 1:1 hexanes:ethylacetate to afford 660mg of product. The trityl group was cleaved in THF (30mL) and 4M
HCl dioxane (0.988mL) at rt for 18h. It was then basified with NaOH to pH 11, washed with ether, acidified to pH 3 with 10% HCl and the precipitate was collected and dried under high vacuum to afford 250mg of product. LRMS (M+H)+ 420.
3-~4-[2-Tetrazole]phenyl)phenylam;noc~hsnyl)methyl-5-amidinoindole. Prepared as in example 101. HRMS for C23H20N8o (M+H)+ calc. 437.183833, ~ound 437.186710.

15ExamDle 205 PreDaration of 3-(4-biDhenYlam;n~c~bonyl)methyl-5-am; ~ i nn; n~ole The title compound was prepared as in example 101. HRMS
20(M+H)+ for C23H20N4o calc. 369.172173, found 369.171537.

ExamDle 206 PreDaration of 3-(4-(PhenYlmethYlsulfonYl~DiPeraZ;nscA~bonyl)methYl-5-25amidinoindole The title compound was prepared as in example 101. HRMS
(M+H)+ C22H2sNsO3S calc. 440.176204, found 440.175637.

30ExamDle 207 Pre~aration of 3-(4-cYclohexYlDhenYlam;n~c~bonyl)methyl-5 amidinoindole The title compound was prepared as in example 101. HRMS
35(M+H)+ C23H26N4O calc. 375.218732. found 375.218487.

CA 02259573 l999-0l-06 WO98/01428 - ~ PCT~S97111325 Exam~le 208 Pre~aration of 3-(4-benzYlDi~eraz;ne~A~bonyl)methyl-5-amidinoindole The title compound was prepared as in example 101. HRMS
(M+H~+ for C22H25N5o calc. 376-213722, found 376.213736.

Exam~le 209 Pre~aration of 3-(3-10a~;~;nohen7ylp~;no(methylcarbonylmethoxy)carbonyl)methyl-5 am; dinoindole The title compound was prepared as in example 101. HRMS cal.
435.214464, found 435.216822.
ExamDle 210 Pre~aration of l-methYl-3-(4-ami~inob~n7Ylamino(methylcarbonylmethoxy)carbonyl)methyl-5 ~;dinoindole The title compound was prepared as in example 101. HRMS
calc.435.214464, found 435.213247.

ExamDle 211 25Pre~aration of 1-methYl-3-(4-~2-aminosulfonYl]~henYlbenzYlamin~c~bonyl)methyl-5-ami~;nQindole The title compound was prepared as in example 201. LRMS 476, m.p. 231-C.
ExamDle 212 Pre~aration of l-methYl-3-(4-~henYlbenzylam;no~ho~yl)meth 5-amidinoindole The title compound was prepared as in example 201. HRMS calc.
397.202837, found 397.204520.

CA 02259573 l999-0l-06 WO98/01428 PCT~S97/11325 ExamPle 213 PreDaration of 1-methYl-3-(4-PhenYlPiperazinec~honyl)meth 5- d dinoindole The title compound was prepared as in example 201. HRMS calc.
389.234137, found 389.234635.

ExamDle 214 PreParation of 3-(4-12-aminosulfonyl)DhenylDhenylam; noc~ ~bonyl)methyl-5-amidinoindole The title compound was prepared as in example 203. HRMS
calc.448.144337 found 448.143656.

15Exam~le 215 PreDaration of 3-(1-benzYlPiPeridine-4-aminoc~bonyl)methyl-5-amidinoindole The title compound was prepared as in example 201. HRMS calc.
20390.229386, found 390.230305.

ExamDle 216 PreParation of 3-(4-DhenYlPiPeraz; n~ho~Yl )methYl-5-~m; dinoindole The title compound was prepared as in example 201. HRMS calc.
362.198086, found 362.197315.

ExamPle 217 30PreParation of 3-(4-benzYlDiPer;~;nec~ho~Yl)methyl-5 amidinoindole The title compound was prepared as in example 201. HRMS calc.
374.210662 found 374.210386.
ExamDle 2 18 PreParation of 1-methYl-3-(5-(2-aminosulfonYl)~henylpyridine-2-aminocs~bonYl)methYl-5-amidinoindole CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/1132~

The title compound was prepared as in example 201. HRMS calc.
463.155236, found 463.155236.

Exam~le 219 Preparation of 3-{2-bromo-4-(2-~m; nogulfonyl)phenylphenylam;no~Arbonyl~methyl-5-cyanoindole A solution of 3-{2-bromo-4-(2-10 aminosulfonyl)phenylphenylaminocarbonYl)methyl-5-cyanoindoline (1.2378 mmol, 0.7 g) in anhydrous methyl acetate (15 mL) and anhydrous methanol (0.5 mL, 10.0 eq) was saturated with dry hydrogen chloride gas at -20 C for 20 min. The reaction mixture was stoppered tightly and left at ambient temperature for 18 h. This reaction mixture was evaporated and pumped on for several hours to remove any residual HCl. To this imidate in anhydrous methanol (15 mL) was added ammonium carbonate (1.189 g, 10.0 e~.). This reaction mixture was allowed to stir at ambient temperature for 24 h. This final reaction mixture was evaporated and purified by HPLC on a C-18 column eluted with solvent mixture A (water:TFA 99.95:0.05) and solvent mixture B (acetonitrile:TFA 99.95:0.05) using a gradient starting with A at 80 % and changing to B at 100 %
over 60 min. After lyophylization, 0.122 g of pure product (15%) was obtained; HRMS (M+H) calc. 526.054848, found 526.053791 for o-Br compound.

ExamDle 220 Preparation of 3-~2-methyl-4-(2-~;nosulfonyl)phenylphenylam;nocArh~nyl)methyl-5-methylamino indole To the solution of 3-{2-methyl-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyano indole (0.5992 mmol, 0.3 g) in absolute ethanol:TFA 4:6 was added palladium hydroxide on carbon (0.06 g, 20 % weight equivalent of starting material used). This reaction mixture was stirred under house ~acuum for 10 minutes at ambient temperature to CA 022~9~73 1999-0l-06 WO98/01428 PCT~S97/11325 remove oxygen. Then subjected to 1 atm H2 via balloon method for 3 h. The reaction mixture was filtered through celite to remove catalyst and washed with ethanol (20 mL). The filtrate was evaporated to give the desired product with t-butyl sulfonamide. This product was treated with trifluoroacetic acid at 55~C for 2 h for deprotection of sulfonamide. The reaction mixture was evaporated and purified by HPLC on a C-18 column eluted with solvent mixture A (water:TFA 99.95:0.05) and solvent mixture B (acetonitrile:TFA 99.95:0.05) using a gradient starting with A at 80 % and changing to B at 100 %
over 60 min. to give 10.0 mg of pure product (3 %, poor yield due to poor solubility); HRMS ~M+H) calc. 449.164738, found 449.165207.

ExamPle 221 Preparation of 3-{2-fluoro-4-(2-aminosulfonyl)phenYlphenylam;norA~bonyl)methyl-5-~;dinoindole The titled compound was prepared as in Example 203. HRMS
(NH3-CI/DEP) (M+H)+ for C23H2lNsso3F calculated 466.134915;
found 466.133832.

Exam~le 222 Preparation of 3-{2-chloro-4-(2-aminosulfonyl)phenylPhenylam;nocA~bonyl)methyl-5-cyanoindole The titled compound was prepared as in Example 203. HRMS for C2sH21NsSO3Cl (M+H)+ calc. 482.105364; found 482.103835.

ExamDle 223 Preparation of 3-{2-iodo-4-(2-aminosulfonyl)phenylphenYlam;nocA~bonyl)methyl-5-cy-noindole The titled compound was prepared as in Example 203. HRMS for C23H21INsO3S (M+H)+ calc. 574.040989; found 574.042800.

CA 02259573 l999-0l-06 WO98/01428 PCT~S97/11325 Examole 224 Preparation of 3-{2-methyl-4-~2-ar-; no~-l 1 fonyl)phenylphenYlam;~o~bonyl)methyl-5-amidinoindole The titled compound was prepared as in Examp~e 203. HRMS for C24H24NsO3S (M+H)+ calc. 462.159987; found 462.158553.

Exam~le 225 Preparation of 3-{2-methyl-4-(2-(t-10butylaminosulfonYl))phenylphenylam;n~c~honyl)methyl-5 amidinoindole The titled compound was prepared as in Example 203. HRMS for C2gH32NsO3S ~M+H)+ calc.518.222587; found 518.221998.
Exam~le 226 Preparation of 3-{4-(2-Am;nosulfonyl)phenyl)phenylam;n~r~-honylmeth (methylc~hQYy methyl ether)-5-amidinoindole The titled compound (racemic) was prepared as in Example 203.
HRMS for C26H2sNsOsS (M+H)+ calc 520.166599; found 520.165466.

ExamDle 227 25Preparation of 3-{4-(2-aminosulfonyl)phenyl)phenylaminocarbonYlmethyl-a-(benzyl) am;~;n~;nAole The titled compound (racemic) was prepared as in Example 203.
30HRMS for C3oH29N5o3s ~M+H) + calc. 538.191287; found 538.191263.

Exam~le 228 Preparation of 3-~4-(2-trifluoromethyl)phenyl)pyrid-2-ylar;nnc~honylmethyl-5-P~;dinoindole The titled compound was prepared as in Example 203. HRMS for C23H20N5olF3 (M+H)+ 438.154170; found 438.152166.

CA 022~9~73 l999-0l-06 WO98/01428 PCT~S97/1132S
ExamDle 229 Preparation of 3-{4-(2-ethylaminosulfonYl)phenyl)phenylamin~c~honylmethyl-5 amidinoindole The tltled compound was prepared as in Example 203. HRMS for C26H27NsO3S1 (M+H)+ calc. 476.175637; found 476.175892.

ExamDle 230 10 Preparation of 3-{4-(2-propylam;no~ fonyl)phenyl)phenyl~am;nor~bonylmethyl-5-amidinoindole The titled compound was prepared as in Example 203. HRMS for 15C26H27NsO3S (M+H)+ calc. 490.191287; found 490.190996.

ExamDle 231 Preparation of 2-methyl-3-{2-iodo-4-(2-am; n~--l 1 fonyl)phenyl)phenyl~ami noe~ ~honylmethyl ~ 5 -20~;dinoindole The titled compound was prepared as in Example 203. HRMS for C24H23INsO3S1 (M+H)+ calc. 558.056639; found 558.057057.

25Exam~le 232 Preparation of 2-methyl-3-{4-(2-am;~q~lfonyl)phenyl)phenyl~am~noe~ho~ylmethyl- 5 -am;~;no;n~ole The titled compound was prepared as in Example 203. LRMS for C24H23NsO3S1 (M+H)+ 462.

ExamDle 233 Preparation of 3-{4-(2-am;n~ fonyl)phenyl)phenyl~-N
35methylam;noc~honylmethyl-5-~;dinoindole The titled compound was prepared as in Example 203. LRMS for C24H24NsO3S1 (M+H)+ 462.

CA 022~9~73 1999-0l-06 ExamDle 234 Preparation of 2-methyl-3-{4-(2-t-butylaminosulfonyl)phenyl)phenyl}am;n~r~rbonylmethyl-5 methoxyindole The titled compound was prepared as in Example 203. LRMS for C2gH3lN3O4S1 (M+H)+ 506.

Exam~le 235 Preparation of 3-~4-(2-N-methylam;n~ fonyl)phenyl)phenyl}-N
methylam;no~-A~h~rylmethyl-5 -~m; dino, n~

The titled compound was prepared as in Example 203. HRMS for C2~H23NsO3S (M+H)+ cacl. 462.159987i found 462.159054.

ExamDle 236 Preparation of 3-{4-(2-(n-butylaminosulfonyl)phenylPhenylam;n~rA~ yl)methyl-5 cyAn~;n~line To a solution of 3-acetic acid indoline (0.001 mol, 0.2 g) [or indoline acid (0.001 mol, 0.202 g)] in anhydrous acetonitrile (10 mL) was added thionyl chloride (0.3 mL, 4.0 eq.) [for indoline, 1.0 M HCl in ethyl ether (0.05 mL, 1.0 eq.) was added before thionyl chloride]. This reaction mixture was warmed up at 50~C for 10 min. then allowed to cool to ambient temperature and stirred for 2 h. The solvent and extra thionyl chloride were removed in vacuo and the residue was pumped on for several hours for further dry. To this dried residue was added a mixture of A-B (0.338 g, 1.0 e~.~ and triethyl amine (0.14 mL, 1.0 eq.; 2.0 eq. for HCl salt) in anhydrous methylene chloride (10 mL). This reaction mixture was allowed to stir at ambient temperature for 2 h. The reaction mixture was evaporated and purified by flash chromatography on a silica gel column (50 g) eluted with 3:1 hexane:ethyl acetate to give 0.4 g of pure product with n-butyl sulfonamide (51 %).

CA 02259573 l999-0l-06 WO98/01428 - PCT~S97/11325 Exam~le 237 Preparation of 3-{4-(2-(n-propylam;n~ fonyl)phenylphenylam;n~ bonyl)methyl-5-amidinoindoline The titled compound was prepared as in Example 203. HRMS for C26H30N5S03 (M+H~ + calc. 492.206937; found 492.207667.

ExamDle 238 Preparation of (-)-3-{4-(2-aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmQthyl-5-amidinoindoline The titled compound was prepared as in Example 203. HRMS for 15 C22H24N603Sl (M+H) + calc.451.155236; found 451.154317.

Exa~ le 239 Preparation of 3-{4-(2-aminosulfonyl)phenyl)pyrid-2-yl; ;n~c~hQnylmethyl-5-P~;dinoindoline The titled compound (racemic) was prepared as in Example 203.
HRMS for C22H24N603Sl (M+H)+ calc. 451.155236; found 451.lS4317.

25ExamDle 240 Preparation of 3-{4-(2-dimethylaminosulfonyl)phenyl)phenylam;no~hQnylmethyl-5-am;~;n~indoline The titled compound (racemic) was prepared as in Example 203.
HRMS for C25H26N503Sl (M+H) + calc. 450.159987; found 450.159435.

ExamDle 241 Preparation of (+)-3-t4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-ylam;n~h~nylmethyl-5-ami~;no;n~line CA 02259573 l999-0l-06 WO98/01428 PCT~S97/11325 The titled compound was prepared as in Example 203. HRMS for C26H30N6o3sl (M+H)+ calc- 507.217836; found 507.217901. 98%ee;
rotation (+) 19.23.

5ExamDle 242 Preparation of (-)-3-{4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-ylam;nocArbony~methyl-5-amidinoindoline The titled compound was prepared as in Example 203. HRMS for 10C26H30N603Sl (M+H)+ calc 507-217836; found 507.217678. 98%ee;
rotaion -16.28.

ExamPle 243 Preparation of 3-{4-(2-aminosulfonyl)phenyl)pyrid-2-15yl)am; no~ rbonylmethyl-5- Am; no~arboxyindoline The titled compound (racemic) was prepared as in Example 203.
HRMS for C22H23N603Sl (M+H) + calc. 451.1552036; found 451.154691.
ExamDle 244 Preparation of 3-{4-(2-t-butylaminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindoline The titled compound was prepared as in Example 203. LRMS for C27H31N503Sl (M+H) + calc.506.3; found 506.4.

Exam~l30 Preparation of 3-{4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-yl}am;no~Arbonylmethyl-5-amidinoindoline The titled compound (racemic) was prepared as in Example 203.
LRMS for C26H30N6o3sl (M+H) + calc.507.3; found 507.4.
ExamDle 246 Preparation of 3-{4-(2-aminosulfonyl)phenyl)pyrid-2-yl r ; nr ~arhonylmethyl-6--amidino; n~lA701e CA 02259573 l999-0l-06 W098/01428 - PCT~S97/11325 The titled compound was prepared as in Example 203. HRMS for C21H21N703Sl (M+H)+ calc. 450.134835; found 450.134725.

ExamDle 247 Preparation of 3-{4-(2-aminosulfonyl)phenyl)phenyl am;no~:A~bonylmethyl-6-amidino;nAA7Ole The titled compound was prepared as in Example 203. HRMS for C22H22N603Sl (M+H)+ calc. 449.139586; found 449.138515.

ExamDle 248 Preparation of 3-{4-(2-t-butyl Am;nosulfonyl)phenyl)pyrid-2-ylam;no~A~hor~ylmethyl-6-~n;dino;nAA7ole The titled compound was prepared as in Example 203. HRMS for C25H29N703Sl (M+H)+ calc.450.134835; 450.134725 ExamD20 Preparation of 3-~4-(2-t-butylaminosulfonyl)phenyl)phenyl am;no~A~hnnylmethyl-6-a~;A;noindazole The titled compound was prepared as in Example 203. HRMS for C26H30N6o3sl (M+H)+ calc.505.202186; found 505.202631.

_ WO98/01428 - PCT~S97/11325 Table 5 o OEt ~ A-B

2 b N

Ex A~. A B MS (100%) or Pos. HRMS
1 a+b phenethyl 3-amidino 204 (M+2H)2+
2 b phenethyl 3-amidino 204.2 (M+2H)2+
3 a phenethyl 3-amidino 204.2 (M+2H)2+
4 a+b phenethyl 4-amidino 407.2200 b phenethyl 4-amidino 204 (M+2H)2+
6 a phenethyl 4-amidino 204 (M+2H)2+
7 a+b phenyl-CH= 4-amidino 196.2 (M+2H)2+
8 a+b phenyl 4-amidino 197 (M+2H)2+

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 Table 6a ~Z_A-B
HN a ~ N

EX Am. Z A B MS (100%) pO5 or HRMS
51 a C(O) phenyl 4-phenyl 355.1554 52 b C(O) phenyl 4-phenyl 355.1559 53 a C(O) phenyl 4-(3-NH2)phenyl 370 (M+H~+
54 b C(O) phenyl 4-(3-NH2)phenyl 370 (M+H)+
a C(O) phenyl 4-(4-F)phenyl 373.1481 56 a C(O) phenyl 4-(4-CHO)phenyl 383.1531 57 a C(O) phenyl 4-(2-NH2SO2)phenyl 434.1303 58 a C(O) phenyl 4-(2-tBuNHSO2) phenyl 59 a C(O) phenyl 4-(2-tetrazolyl) 423.1686 phenyl a C(O)NH phenyl 4-(2-NH2SO2)phenyl 449.1414 61 b C(O)NH phenyl 4-(2-NH2SO2)phenyl 449.1401 62 a+b C(O) l-piperidine 4-benzyl 376.2118 63 b C(O) l-piperidine 4-benzyl 376.2130 64 a C(O) phenyl 4-(2-NH2SO2)phenyl 449.1393 65* 6- C(O) phenyl 4-(2-tBuNHs02) 436 aza phenyl Ex. 65 contains the CH2-z-A-B group at the 2-position.

WO98/01428 - PCT~S97/11325 Table 6b H

N ~ '~ A

Ex Z' A B ~RMS
65* CH2C(O) phenyl 4-(2-tBuNHSO2)phenyl 464.1756 66 SCH2C(~)NH phenyl 4-(2-tBuNHS02)phenyl 496.1477 67 ScH2c(o)NH phenyl 4-(2-NH2SO2)phenyl 440.0831 Table 7 ~\ Z '--A- B
~/
H2 ~J
HN

E~ Rl Z ' A B MS or ~MS
101 H C(O) l-piperidine 4-benzyl 375.218 102 H CH2C (O) l-piperidine 4-benzyl 389.231 103 H C (O) l-piperidine4-(3-F)benzyl 393.209 104 HC ( O ) N ( CH2benzyl 4-amidino 218 C02CH3 ) 105 CH2- C(O) l-piperidine 4-benzyl 447.242 C02Me 106 CH2- C(O) l-piperidine 4-benzyl 419.245 107 CH2- C(O) l-piperidine 4-benzyl 433 108 HC ( O ) NH 4-piperidine l-benzyl 390.229 109 H C (O) l-piperidine 4-benzoyl 389.198 110 H C(O) l-piperazinyl 4-(3-F)benzyl 394.205 111 H C (O) NH benzyl 4-phenyl 383.190 112CH=CH- C(O) piperidine 4-benzyl 459 C02Me 113 H C ( O ) p iperidine 4-(2-F)benzyl 393.209 WO98/01428 PCT~S97/11325 Table 8a*

D Z-A-B

Ex D Rl Z A B NS or HRMS
201 Am H C(O)- phenyl 4-cyclohexyl 389.232 202 Am H C(O) 1- 4-p- 440.176 piperazinyl toluenesulfonyl 203 Am H C(O)NH2-pyridyl 4-(2- 449.139 aminosulfonyl) phenyl 204 Am H C(O)NH l-phenyl 4-(2-tetrazol-5- 437.187 yl)phenyl 205 Am H C(O)NH l-phenyl 4-phenyl 369.171 206 Am H C(O) 1- 4-phenyl- 440.176 piperazinyl methylsulfonyl 207 Am H C~O)NH l-phenyl 4-cyclohexyl 375.218 208 Am H C(O) 1- 4-benzyl 376.214 piperazinyl 209 Am Me C(O)N- benzyl 3-amidino 435.217 ( CH2C02 CH3) 210 Am MeC(O) N-benzyl 4-amidino 435,213 (CH2C02 CH3) 211 Am MeC(O)NHbenzyl 4- (2- 476 aminosulfonyl) phenyl 212 Am MeC(O) NHbenzyl 4-phenyl 397.205 213 Am MeC(O)CH2 1- 4-benzyl 389.235 piperazinyl CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 214Am HC(O)NH phenyl 4-(2- 448.144 aminosulfonyl) phenyl 215Am HC(O) 4- 1-benzyl 390.230 piperidinyl 216Am HC (0) 1- 4-phenyl 362.197 - piperazinyl 217Am HC~O) 1- 4-benzyl 374.210 piperidinyl 218Am MeC(O) NH2-pyridyl 5-(2- 463.155 aminosulfonyl) phenyl 219CN HC(O)NH 2-Br-phenyl 4-(2- 526.054 aminosulfonyl) phenyl 220CH3- HC (O)NH2-Me-phenyl 4-(2- 449.164 NH aminosulfonyl) phenyl 221Am HC (O)NH2-F-phenyl 4-(2- 466.134 aminosulfonyl) phenyl 222CN HC(O)NH 2-Cl-phenyl 4-(2- 482.104 aminosulfonyl) phenyl 223CN HC (0) NH2-I-phenyl 4-(2- 574.043 aminosulfonyl) phenyl 224Am HC(O)NH 2-Me-phenyl 4-(2- 462.156 aminosulfonyl) phenyl 225Am HC (0) NH2-Me-phenyl 4-(2-t-Bu- 518.222 aminosulfonyl) phenyl 226Am H(CH30- phenyl 4-(2- 520.165 C(O)- aminosulfonyl) CH2 ) CH phenyl CA 02259573 l999-0l-06 PCT~S97/11325 ~ WO98/0142X

227Am H(phenylphenyl 4-(2- 538.191 -CH2)CH aminosulfonyl) phenyl 228Am HC(O)NH2-pyridyl4-(2-CF3-phenyl) 43~3.152 229Am HC(O)NHphenyl 4-(2- 476.176 ethylaminosulfon yl)phenyl 230Am HC(O)NHphenyl 4-(2- 490.191 propylamino-sulfonyl)phenyl 231Am HC(O)NH2-I-phenyl 4-(2- 558.057 (R1=2- aminosulfonyl) methyl) phenyl 232Am HC(O)NHphenyl 4-(2- 462 (Rl=2- aminosulfonyl) methyl) phenyl 233Am HC(0)- phenyl 4-(2- 462 NCH3 aminosulfonyl) phenyl 234CH30 HC(O)NHphenyl 4-(2-t-Bu- 506 (R1=2_ aminosulfonyl) methyl) phenyl 235Am HC(0)- phenyl 4-~2- 462.160 NCH3 methylamino-sulfonyl)phenyl *For all Examples, but 226 and 277, n=1. For Examples 226 and 227, n=0.

CA 022~9~73 l999-0l-06 WO98101428 - PCT~S97/11325 Table 8b D Z-A-~

Ex D Rl z A B MS or HRMS
236 CN H C(O)NH phenyl 4-(2-n-Bu-aminosulfonyl) phenyl 237 Am H C(O)NH phenyl4-(2-propylamino- 492.208 sulfonyl)phenyl 238 Am H C(O)NH 2-pyridyl 4-(2-aminosulfonyl)451.154 (_) phenyl 239 Am H C(O)NH 2-pyridyl 4-(2-aminosulfonyl)451.155 phenyl 240 Am H C(O)NH phenyl 4-(2-N,N- 450.160 dimethylamino-sulfonyl)phenyl 241 Am H C(O)NH 2-pyridyl4-(2-t-Bu-amino- 507.218 (+) sulfonyl)phenyl 242 Am H C(O)NH 2-pyridyl4-(2-t-Bu-amino- 507.218 (_) sulfonyl)phenyl 243 NH2- H C(O)NH 2-pyridyl 4-(2-aminosulfonyl) 451.154 C(O) phenyl 244 Am H C(O)NH phenyl4-(2-t-Bu-amino- 506.4 sulfonyl)phenyl 245 Am H C(O)NH 2-pyridyl4-(2-t-Bu-amino- 507.4 sulfonyl)phenyl CA 022~9~73 1999-01-06 Tab~e 8c ~N- N Z-A-B

D/~/

E:x D Rl Z A B MS or HRMS
246 Am H C(O)NH 2-pyridyl4-(2- 450.135 aminosulfonyl) phenyl 247 Am H C (O)NH phenyl 4-(Z- 449.139 aminosulfonyl) phenyl 248 Am H C(O)NH 2-pyridyl 4-(2-t-Bu-amino- 450.135 sulfonyl)phenyl 249 Am H C(O)NH phenyl 4-(2-t-Bu-amino- 505.203 sulfonyl)phenyl CA 022~9~73 1999-0l-06 WO98/01428 PCT~S97/11325 Table 9 HN~ ~

H2N (\-~ Z_A_B

Ex n Z A-B
301 1 C(O) 4-(2-aminosulfonylphenyl)phenyl 302 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 303 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 304 1 C(O)4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 305 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 306 1 C(O)3-aminosulfonyl-4-t-butyl-2-pyridyl 307 1 C(O)2-(5-indazol-5-yl)furanyl 308 1 C(O)2-(5-indazol-6-yl)thienyl 309 1 C(O)4-(2-tetrazolylphenyl)phenyl 310 1 C(O)NH 4-(2-aminosulfonylphenyl)phenyl 311 1 C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 312 1 C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 313 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 314 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 315 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 316 1 C(O)NH2-(5-indazol-5-yl)furanyl 317 1 C(O)NH2-(5-indazol-6-vl~thienyl CA 022~9~73 1999-01-06 PCT~S97/11325 W098tO1428 318 1 C(O)NH4-(2-tetrazolylphenyl)phenyl 319 1 NHC(O) 4-(2-aminosulfonylphenyl)phenyl 320 1 NHC(O) 4-(2~aminosulfonylphenyl)-2-pyridyl 321 1 NHC(O) 4-(2-methylaminosulfonyl-phenyl)phenyl 322 1 NHC(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 323 1 NHC(O) 2-aminosulfonyl-4-cyclohexylphenyl 324 1 NHC(O) 3-aminosulfonyl-4-t-butyl-2-pyridyl 325 1 NHC(O) 2-(5-indazol-5-yl)furanyl 326 1 NHC(O) 2-(5-indazol-6-yl)thienyl 327 1 NHC(O)4- (2-tetrazolylphenyl)phenyl 328 1 SO2NH 4-(2-aminosulfonylphenyl)phenyl 329 1 SO2NH 4-(2-aminosulfonylphenyl)-2-pyridyl 330 ; SO2NH 4-(2-methylaminosulfonyl-phenyl)phenyl 331 1 SO2NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 332 1 S02NH 2-aminosulfonyl-4-cyclohexylphenyl 333 1 SO2NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 334 1 S02NH 2-(5-indazol-5-yl)furanyl 335 1 S02NH 2-(5-indazol-6-yl)thienyl 336 1 SO2NH4-(2-tetrazolylphenyl)phenyl 337 0CH(CH2CH20H)C(O)NH 4-(2-aminosulfonylphenyl)phenyl 338 0CH(CH2CH2OH)C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl CA 022~9~73 l999-0l-06 WO98/01428 ~ PCT~S97/11325 339 oCH(CH2CH2OH)C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 340 0CH(CH2CH2OH)C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 341 0CH(CH2CH2OH)C(O)NH2-aminosulfonyl-4-cyclohexylphenyl 342 0CH(CH2CH2OH)C(O) NH3-aminosulfonyl-4-t-butyl-2-pyridyl 343 CCH(CH2CH2OH)C(O)NH2-(5-indazol-5-yl)furanyl 344 oCH(CH2CH20H)C(O)NH2-(5-indazol-6-yl)thienyl 345 oCH(CH2CH2OH)C(O) NH4-(2-tetrazoly~phenyl)phenyl 346 0 CH(CH2- 4-(2-tetrazolyl)C(O) NHaminosulfonylphenyl)phenyl 347 0 CH(CH2- 4-(2-aminosulfonylphenyl)-2-tetrazolyl)C(O) NH pyridyl 348 0 CH(CH2- 4-(2-methylaminosulfonyl-tetrazolyl)C(O)NH phenyl)phenyl 349 o CH(CH2- 4-(2-ethylaminosulfonyl-tetrazolyl)C(O)NH phenyl)-2-pyridyl 350 0 CH(CH2- 2-aminosulfonyl-4-tetrazolyl)C(O) NHcyclohexylphenyl 351 0 CH(CH2- 3-aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O) NH pyridyl 352 0 CH(CH2- 2-(5-indazol-5-yl)furanyl tetrazolyl)C(O) NH
353 0 CH(CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C(O)NH
354 0 CH(CH2- 4-(2-tetrazolylphenyl)phenyl tetrazolyl)C(O) NH

CA 022~9~73 1999-0l-06 WO98/01428 pcT~ss7lll32s Table 10 HN~

H2N (\~ Z--A--B

EX n Z A-B
401 1 C(O) 4-(2-aminosulfonylphenyl)phenyl 402 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 403 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 404 1 C(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 405 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 406 1 C~O)3-aminosulfonyl-4-t-butyl-2-pyridyl 407 1 C(O) 2-(5-indazol-5-yl)furanyl 408 1 C(O) 2-(5-indazol-6-yl)thienyl 409 1 C(O)4-(2-tetrazolylphenyl)phenyl 410 1 C(O)NH 4-(2-aminosulfonylphenyl)phenyl 411 1 C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 412 1 C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 413 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 414 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 415 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 416 1 C(O)NH2-(5-indazol-5-yl)furanyl 417 1 C(O)NH2-(5-indazol-6-yl)thienyl CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 418 1 C(O) NH 4-(2-tetrazolvlphenyl)phenyl 419 1 NHC(O) 4-(2-aminosulfonylphenyl)phenyl 420 1 NHC(O) 4-(2-aminosulfonylphenyl)-2-pyridyl 421 1 NHC(O) 4-(2-methylaminosulfonyl-phenyl)phenyl 422 1 NHC(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 423 1 NHC(O) 2-aminosulfonyl-4-cyclohexylphenyl 424 1 NHC(O) 3-aminosulfonyl-4-t-butyl-2-pyridyl 425 1 NHC(O) 2-(5-indazol-5-yl)furanyl 426 1 NHC(O) 2-(5-indazol-6-yl)thienyl 427 1 NHC(O) 4-(2-tetrazolylphenyl)phenyl 428 1 SO2NH 4-(2-aminosulfonylphenyl)phenyl 429 1 SO2NH 4-(2-aminosulfonylphenyl)-2-pyridyl 430 1 SO2NH 4-(2-methylaminosulfonyl-phenyl)phenyl 431 1 S02NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 432 1 S02NH 2-aminosulfonyl-4-cyclohexylphenyl 433 1 SO2NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 434 1 SO2NH 2-(5-indazol-5-yl)furanyl 435 1 SO2NH 2-(5-indazol-6-yl)thienyl 436 1 SO2NH 4-(2-tetrazolylphenyl)phenyl 437 0CH(CH2CH2OH)C(O)NH 4-(2-aminosulfonylphenyl)phenyl 438 0CH(CH2CH2OH)C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 439 o CH(CH2CH2OH)C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 440 0 CH(CH2CH2OH)C(O) NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 441 0 CH(CH2CH2OH)C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 442 0 CH(CH2CH2OH)C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 443 0 CH(CH2CH2OH)C(O) NH2-(5-indazol-5-yl)furanyl 444 o CH(CH2CH2OH)C(O) NH2-(5-indazol-6-yl)thienyl 445 o CH(CH2CH2OH)C(O)NH4-(2-tetrazolylphenyl)phenyl 446 0 CH(CH2- 4-(2-tetrazolyl)C(O) NHaminosulfonylphenyl)phenyl 447 0 CH(CH2- 4-(2-aminosulfonylphenyl)-2-tetrazolyl)C(O)NH pyridyl 448 0 CH(CH2- 4-(2-methylaminosulfonyl-tetrazolyl)C(O) NH phenyl)phenyl 449 0 CH (CH2- 4-(2-ethylaminosulfonyl-tetrazolyl)C(O) NH phenyl)-2-pyridyl 450 0 CH (CH2- 2-aminosulfonyl-4-tetrazolyl)C(O) NH cyc lohexylphenyl 451 0 CH(CH2- 3-aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O) NH pyridyl 452 0 CH(CH2- 2-(5-indazol-5-yl)furanyl tetrazolyl)C(O) NH
453 0 CH(CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C(O) NH
454 0 CH(CH2- 4-(2-tetrazolylphenyl)phenyl tetrazolyl)C(O) NH

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 Table 11 HN~ ,~N>

H2N (~Z--A--B

Ex n Z A-B
501 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 502 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 503 1 C(O)4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 504 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 505 1 C(O)3-aminosulfonyl-4-t-butyl-2-pyridyl 506 1 C(O)2-(5-indazol-5-yl)furanyl 507 1 C(O)2-(5-indazol-6-yl)thienyl 508 1 C(O)4-(2-tetrazolylphenyl)phenyl 509 1 C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 510 1 C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 511 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 512 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 513 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 514 1 C(O)NH2-(5-indazol-5-yl)furanyl 515 1 C(O)NH2-(5-indazol-6-yl)thienyl 516 1 C(O)NH4-(2-tetrazolylphenyl)phenyl 517 1 NHC(O) 4-(2-aminosulfonylphenyl)phenyl CA 022~9~73 1999-01-06 518 1 NHC ( O ) 4 - ( 2-aminosulfonylphenyl)-2-pyridyl 519 1 NHC(O) 4-(2-methylaminosulfonyl-phenyl)phenyl 520 1 NHC(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 521 1 NHC(O) 2-aminosulfonyl-4-cyclohexylphenyl 522 1 NHC (O) 3-aminosulfonyl-4-t-butyl-2-pyridyl 523 1 NHC (O) 2-(5-indazol-5-yl)furanyl 524 1 NHC(O) 2-(5-indazol-6-yl)thienyl 525 1 NHC(O) 4-(2-tetrazolylphenyl)phenyl 526 1 S02NH 4-(2-aminosulfonylphenyl)phenyl 527 1 SO2NH 4-(2-aminosulfonylphenyl)-2-pyridyl 528 1 S02NH 4-(2-methylaminosulfonyl-phenyl)phenyl 529 1 SO2NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 530 1 S02NH 2-aminosulfonyl-4-cyclohexylphenyl 531 1 SO2NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 532 1 SO2NH 2-(5-indazol-5-yl)furanyl 533 1 S02NH 2-(5-indazol-6-yl)thienyl 534 1 S02NH 4-(2-tetrazolylphenyl)phenyl 535 0CH(CH2CH2OH)C(O) NH 4-(2-aminosulfonylphenyl)phenyl 536 0CH(CH2CH2OH)C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 537 0CH(CH2CH2OH)C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 538 0CH(CH2CH2OH)C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl CA 022~9~73 1999-01-06 539 oCH(CH2CH2OH)C(O)NH2-aminosulfonyl-4-cyclohexylphenyl 540 0CH(CH2CH2OH)C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 541 0CH(CH2CH~OH)C(O)NH2-(5-indazol-5-yl)furanyl 542 0CH(CH2CH2OH)C(O)NH2-(5-indazol-6-yl)thienyl - 543 oCH(CH2CH2OH)C(O)NH4-(2-tetrazolylphenyl)phenyl 544 0CH(CH2- 4-(2-tetrazolyl)C(O)NHaminosulfonylphenyl)phenyl 545 0CH(CH2- 4-(2-aminosulfonylphenyl)-2-tetrazolyl)C(O)NHpyridyl 546 0CH(CH2- 4-(2-methylaminosulfonyl-tetrazolyl)C(O)NHphenyl)phenyl 547 0CH(CH2- 4-(2-ethylaminosulfonyl-tetrazolyl)C(O)NHphenyl)-2-pyridyl 548 0CH(CH2- 2-aminosulfonyl-4-tetrazolyl)C(O)NHcyclohexylphenyl 549 0CH(CH2- 3-aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O)NHpyridyl 550 0CH(CH2- 2-(5-indazol-5-yl)furanyl tetrazolyl)C(O)NH
551 0CH(CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C(O)NH
552 0CH(CH2-4-(2-tetrazolylphenyl)phenyl tetrazolyl)C(O)NH

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 Table 12 HN~ ~N

H2N (\'~ Z_A_B

EX n Z A-B
601 1 C(O) 4-(2-aminosulfonylphenyl)phenyl 602 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 603 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 604 1 C(O)4-(2-ethylaminosulfonyl-phenyl~-2-pyridyl 605 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 606 1 C(O)3-aminosulfonyl-4-t-butyl-2-pyridyl 607 1 C(O)2-(5-indazol-5-yl)furanyl 608 1 C(O)2-(5-indazol-6-yl)thienyl 609 1 C(O)4-(2-tetrazolylphenyl)phenyl 610 1 C(O)NH 4-(2-aminosulfonylphenyl)phenyl 611 1 C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 612 1 C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 613 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 614 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 615 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 616 1 C(O)NH2-(5-indazol-5-yl)furanyl 617 1 C(O)NH2-(5-indazol-6-yl)thienyl CA 022~9~73 1999-01-06 618 1 C~O)NH4-(2-tetrazolylphenyl)phenyl 619 1 NHC(O) 4-(2-aminosulfonylphenyl)phenyl 620 1 NHC(O) 4-(2-aminosulfonylphenyl)-2-pyridyl 621 1 NHC(O) 4-(2-methylaminosulfonyl-phenyl)phenyl 622 1 NHC(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 623 1 NHC(O) 2-aminosulfonyl-4-cyclohexylphenyl 624 1 NHC(O) 3-aminosulfonyl-4-t-butyl-2-pyridyl 625 1 NHC(O) 2-(5-indazol-5-yl)furanyl 626 1 NHC(O) 2-(5-indazol-6-yl)thienyl 627 1 NHC(O)4-(2-tetrazolylphenyl)phenyl 628 1 SO2NH 4-(2-aminosulfonylphenyl)phenyl 629 1 SO2NH 4-(2-aminosulfonylphenyl)-2-pyridyl 630 1 SO2NH 4-(2-methylaminosulfonyl-phenyl)phenyl 631 1 SO2NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 632 1 SO2NH 2-aminosulfonyl-4-cyclohexylphenyl 633 1 SO2NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 634 1 SO2NH 2-(5-indazol-5-yl)furanyl 635 1 SO2NH 2-(5-indazol-6-yl~thienyl 636 1 SO2NH4-(2-tetrazolylphenyl~phenyl 637 0CH(CH2CH2OH)C(O)NH 4-(2-aminosulfonylphenyl)phenyl 638 0CH(CH2CH2OH)C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl -CA 022~9~73 1999-01-06 WO98/01428 PCT~S97/11325 639 0CH(CH2CH2OH)C(O)NH 4-(2-methylaminosulfonyl-phenyl)phenyl 640 0CH(CH2CH2OH)C(O)NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 641 0CH(CH2CH2OH)C(O) NH 2-aminosulfonyl-4-cyclohexylphenyl 642 0CH(CH2CH2OH)C(O)NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 643 0CH(CH2CH2OH)C(O)NH 2-(5-indazol-5-yl)furanyl 644 0CH(CH2CH2OH)C(O) NH 2-(5-indazol-6-yl)thienyl 645 0CH(CH2CH2OH)C(O)NH 4-(2-tetrazolylphenyl)phenyl 646 0CH(CH2- 4-(2-tetrazolyl)C(O) NH aminosulfonylphenyl)phenyl 647 0CH(CH2- 4-(2-aminosulfonylphenyl)-2-tetrazolyl)C(O) NH pyridyl 648 0CH(CH2- 4-(2-methylaminosulfonyl-tetrazolyl)C(O) NH phenyl)phenyl 649 0CH(CH2- 4-(2-ethylaminosulfonyl-tetrazolyl)C(O) NH phenyl)-2-pyridyl 650 0CH (CH2- 2-aminosulfonyl-4-tetrazolyl)C(O) NH cyclohexylphenyl 651 0CH (CH2- 3-aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O) NH pyridyl 652 0CH( CH2- 2-(5-indazol-5-yl)furanyl tetrazolyl)C(O) NH
653 0CH(CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C(O) NH
654 0CH(CH2- 4-(2-tetrazolylphenyl)phenyl tetrazolyl)C(O) NH

.. . . .

CA 022~9~73 1999-0l-06 WO98/01428 PCT~S97/1132S
Table 13 HN ~

H2N (\'t Z_A_B

EX n Z A-B
701 1 C(O) 4-(2-aminosulfonylphenyl)phenyl 702 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 703 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 704 1 C(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 705 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 706 1 C(O)3-aminosulfonyl-4-t-butyl-2-pyridyl 707 1 C(O) 2-(5-indazol-5-yl)furanyl 708 1 C(O) 2-(5-indazol-6-yl)thienyl 709 1 C(O)4-(2-tetrazolylphenyl)phenyl 710 1 C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 711 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 712 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 713 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 714 1 C(O)NH2-(5-indazol-5-yl)furanyl 715 1 C(O)NH2-(5-indazol-6-yl)thienyl 716 1 C(O)NH4-(2-tetrazolylphenyl)phenyl 717 1 NHC(O) 4-(2-aminosulfonylphenyl)phenyl CA 022~9~73 1999-01-06 718 1 NHC(O~ 4-(2-aminosulfonylphenyl~-2-pyridyl 719 1 NHC(O~ 4-(2-methylaminosulfonyl-phenyl~phenyl 720 1 NHC(O~ 4-(2-ethylaminosulfonyl-phenyl~-2-pyridyl 721 1 NHCtO~ 2-aminosulfonyl-4-cyclohexylphenyl 722 1 NHC(O~ 3-aminosulfonyl-4-t-butyl-2-pyridyl 723 1 NHC(O) 2-(5-indazol-5-yl~furanyl 724 1 NHC(O~ 2-(5-indazol-6-yl)thienyl 725 1 NHC(O)4-(2-tetrazolylphenyl~phenyl 726 1 SO2NH 4-(2-aminosulfonylphenyl~phenyl 727 1 SO2NH 4-(2-aminosulfonylphenyl~-2-pyridyl 728 1 SO2NH 4-(2-me~hylaminosulfonyl-phenyl)phenyl 729 1 S02NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 730 1 S02NH 2-aminosulfonyl-4-cyclohexylphenyl 731 1 S02NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 732 1 SO2NH 2-(5-indazol-S-yl)furanyl 733 1 SO2NH 2-(5-indazol-6-yl)thienyl 734 1 S02NH4-(2-tetrazolylphenyl)phenyl 735 0CH(CH2CH2OH)C(O)NH 4-(2-aminosulfonylphenyl)phenyl 736 0CH(CH2CH2OH)C(O~NH4-(2-aminosulfonylphenyl~-2-pyridyl 737 0CH(CH2CH2OH~C(O)NH4-(2-methylaminosulfonyl-phenyl~phenyl 738 0CH(CH2CH20H)C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl CA 022~9~73 1999-0l-06 WO98/01428 PCT~S97/11325 739 oCH(CH2CH2OH)C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 740 0CH(CH2CH2OH)C(O)NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 741 0CH(CH2CH2OH)C(O)NH 2-(5-indazol-5-yl)furanyl 742 0CH(CH2CH2OH)C(O)NH 2-(5-indazol-6-yl)thienyl 743 oCH(CH2CH2OH)C(O)NH 4-(2-tetrazolylphenyl)phenyl 744 0CH(CH2- 4-(2-tetrazolyl)C(O)NH aminosulfonylphenyl)phenyl 745 0CH(CH2- 4-(2-aminosulfonylphenyl)-2-tetrazolyl)C(O)NH pyridyl 746 0CH(CH2- 4-(2-methylaminosulfonyl-tetrazolyl)C(O)NH phenyl)phenyl 747 0CH(CH2- 4-(2-ethylaminosulfonyl-tetrazolyl)C(O)NH phenyl)-2-pyridyl 748 0CH(CH2- 2-aminosulfonyl-4-tetrazolyl)C(O)NH cyclohexylphenyl 749 0CH(CH2- 3-aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O)NH pyridyl 750 0CH~CH2- 2-(5-indazol-5-yl)furanyl tetrazolyl)C(O)NH
751 0CH(CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C(O)NH
752 0CH(CH2- 4-(2-tetrazolylphenyl)phenyl tetrazolyl)C(O)NH

. .

CA 022~9~73 1999-0l-06 W098/01428 - PCT~S97/11325 Table 14 HN ~
H2N (~ Z_A_B

Ex n Z A-B
801 1 C(O) 4-(2-aminosulfonylphenyl)phenyl 802 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 803 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 804 1 C(O)4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 805 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 806 1 C(O)3-aminosulfonyl-4-t-butyl-2-pyridyl 807 1 C(O)2-(5-indazol-5-yl)furanyl 808 1 C(O)2-(5-indazol-6-yl)thienyl 809 1 C(O)4-(2-tetrazolylphenyl)phenyl 810 1 C(O)NH 4-(2-aminosulfonylphenyl)phenyl 811 1 C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 812 1 C(O~NH4-(2-methylaminosulfonyl-phenyl~phenyl 813 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 814 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 815 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 816 1 C(O)NH2-(5-indazol-5-yl)furanyl 817 1 C(O)NH2-(5-indazol-6-yl)thienyl CA 022~9~73 1999-0l-06 WO98/01428 PCT~S97/1l325 818 1 C(O)NH 4-(2-tetrazolylphenyl)phenyl 819 1 NHC(O) 4- (2-aminosulfonylphenyl)phenyl 820 1 NHC(O) 4-(2-aminosulfonylphenyl)-2-pyridyl 821 1 NHC(O) 4-(2-methylaminosulfonyl-phenyl)phenyl 822 1 NHC(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 823 1 NHC(O) 2-aminosulfonyl-4-cyclohexylphenyl 824 1 NHC(O) 3-aminosulfonyl-4-t-butyl-2-pyridyl 825 1 NHC(O) 2-(5-indazol-5-yl)furanyl 826 1 NHC(O) 2-(5-indazol-6-yl)thienyl 827 1 NHC(O) 4-(2-tetrazolylphenyl)phenyl 828 1 SO2NH 4-(2-aminosulfonylphenyl)phenyl 829 1 SO2NH 4-(2-aminosulfonylphenyl)-2-pyridyl 830 1 SO2NH 4-(2-methylaminosulfonyl-phenyl)phenyl 831 1 SO2NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 832 1 S02NH 2-aminosulfonyl-4-cyclohexylphenyl 833 1 S02NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 834 1 SO2NH 2-(5-indazol-5-yl)furanyl 835 1 SO2NH 2-(5-indazol-6-yl)thienyl 836 1 SO2NH 4-(2-tetrazolylphenyl)phenyl 837 0CH(CH2CH2OH)C(O)NH 4-(2-aminosulfonylphenyl)phenyl 838 0CH(CH2CH2OH)C(O)NH4-(2- aminosulfonylphenyl)-2-pyridyl CA 022~9~73 1999-0l-06 W098/01428 - PCT~S97/11325 839 0 CH(CH2CH2OH)C~O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 840 0 CH(CH2CH2OH)C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 841 0 CH(CH2CH2OH)C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 842 0 CH(CH2CH2OH)C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 843 0 CH(CH2CH2OH)C(O)NH2-(5-indazol-5-yl)furanyl 844 0 CH(CH2CH~OH)C(O)NH2-(5-indazol-6-yl)thienyl 845 0 CH(CH2CH20H)C(O)NH4-(2-tetrazolylphenyl)phenyl 846 0 CH(CH2- 4-(2-tetrazolyl)C(O)NHaminosulfonylphenyl)phenyl 847 0 CH(CH2- 4-(2-aminosulfonylphenyl)-2-tetrazolyl)C(O)NH pyridyl 848 0 CH(CH2- 4-(2-methylaminosulfonyl-tetrazolyl)C(O)NH phenyl)phenyl 849 0 CH(CH2- 4-(2-ethylaminosulfonyl-tetrazolyl)C(O)NH phenyl)-2-pyridyl 850 0 CH(CH2- 2-aminosulfonyl-4-tetrazolyl)C(O)NHcyclohexylphenyl 851 0 CH(CH2- 3-aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O)NH pyridyl 852 0 CH(CH2- 2-(5-indazol-5-yl)furanyl tetrazolyl)C(O)NH
853 0 CH(CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C(O)NH
854 0 CH(CH2- 4-(2-tetrazolylphenyl)phenyl tetrazolyl)C(O)NH

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 Table 15 HN~

H2N (\~ Z--A--B

Ex n Z A-s 901 1 C(O) 4-(2-aminosulfonylphenyl)phenyl 902 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 903 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 904 1 C(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 905 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 906 1 C(O)3-aminosulfonyl-4-t-butyl-2-pyridyl 907 1 C(O) 2-(5-indazol-5-yl)furanyl 908 1 C(O) 2-(5-indazol-6-yl)thienyl 909 1 C(O)4-(2-tetrazolylphenyl)phenyl 910 1 C(O)NH 4-(2-aminosulfonylphenyl)phenyl 911 1 C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 912 1 C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 913 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 914 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 915 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 916 1 C(O)NH2-(5-indazol-5-yl)furanyl 917 1 C(O)NH2-(5-indazol-6-yl)thienyl CA 022~9~73 1999-01-06 W O 98/01428 - PCT~US97/11325 918 1 C(O)NH 4-(2-tetrazolylphenyl)phenyl 919 1 NHC(O) 4-(2-aminosulfonylphenyl)phenyl 920 1 NHC(O) 4-( 2-aminosulfonylphenyl)-2-pyridyl 921 1 NHC~O~ 4-(2-methylaminosulfonyl-phenyl)phenyl 922 1 NHC(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 923 1 NHC(O) 2-aminosulfonyl-4-cyclohexylphenyl 924 1 NHC(O) 3-aminosulfonyl-4-t-butyl-2-pyridyl 925 1 NHC(O) 2-(5-indazol-5-yl)furanyl 926 1 NHC(O) 2-(5-indazol-6-yl)thienyl 927 1 NHC(O) 4-(2-tetrazolylphenyl)phenyl 928 1 SO2NH 4-(2-aminosulfonylphenyl)phenyl 929 1 S02NH 4-(2-aminosulfonylphenyl)-2-pyridyl 930 1 SO2NH 4-(2-methylaminosulfonyl-phenyl)phenyl 931 1 SO2NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 932 1 SO2NH 2-aminosulfonyl-4-cyclohexylphenyl 933 1 SO2NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 934 1 S02NH 2-(5-indazol-5-yl)furanyl 935 1 SO2NH 2-(5-indazol-6-yl)thienyl 936 1 SO2NH 4-(2-tetrazolylphenyl)phenyl 937 3 CH(CH2CH20H)C(O)NH 4-(2-aminosulfonylphenyl)phenyl 938 0 CH(CH2CH20H)C(O)NH 4-(2-aminosulfonylphenyl)-2-pyridyl CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 939 0 CH(CH2CH2OH)C(O~NH4-( 2-methylaminosulfonyl-phenyl)phenyl 940 0 CH(CH2CH20H)C(O~NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 941 0 CH(CH2CH2OH)C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 942 0 CH(CH2CH20H)C(O) NH3 -aminosulfonyl-4-t-butyl-2-pyridyl 943 o CH(CH2CH2OH)C(O)NH2-(5-indazol-5-yl)furanyl 944 o CH(CH2CH2OH)C(O~NH2-(5-indazol-6-yl)thienyl 945 o CH(CH2CH20H)C(O)NH4-(2-tetrazolylphenyl)phenyl 946 0 CH(CH2- 4-(2-tetrazolyl)C(O) NHaminosulfonylphenyl)phenyl 947 0 CH (CH2- 4-(2-aminosulfonylphenyl)-2-tetrazolyl)C(O)NH pyridyl 948 0 CH(CH2- 4-(2-methylaminosulfonyl-tetrazolyl)C(O) NH phenyl)phenyl 949 0 CH(CH2- 4-(2-ethylaminosulfonyl-tetrazolyl)C(O)NH phenyl)-2-pyridyl 950 0 CH (CH2- 2-aminosulfonyl-4-tetrazolyl)C(O) NH cyclohexylphenyl 951 0 CH(CH2- 3 -aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O) NH pyridyl 952 0 CH(CH2- 2-(5-indazol-5-yl)furanyl tetrazolyl)C(O) NH
95 3 0 CH(CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C(O) NH
954 0 CH(CH2- 4-(2-tetrazolylphenyl)phenyl tetrazolyl)C(O) NH

CA 022~9~73 1999-0l-06 PCT~S97/1132 ~able 16 HN~_~

H2N (~'~Z--A--B

Ex n Z A-B
1001 1 C(O) 4-(2-aminosulfonylphenyl)phenyl 1002 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 1003 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 1004 1 C(O)4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1005 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 1006 1 C(O)3-aminosulfonyl-4-t-butyl-2-pyridyl 1007 1 C(O)2-(5-indazol-5-yl)furanyl 1008 1 C(O)2-(5-indazol-6-yl)thienyl 1009 1 C(O)4-(2-tetrazolylphenyl)phenyl 1010 1 C(O)NH 4-(2-aminosulfonylphenyl)phenyl 1011 1 C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 1012 1 C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 1013 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1014 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 1015 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 1016 1 C(O)NH2-(5-indazol-5-yl)furanyl 1017 1 C(O)NH2-(5-indazol-6-yl)thienyl CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 1018 1 C(O)NH4-(2-tetrazolylphenyl)phenyl 1019 1 NHC(O) 4-(2-aminosulfonylphenyl)phenyl 1020 1 NHC(O) 4-(2-aminosulfonylphenyl)-2-pyridyl 1021 1 NHC(O) 4-(2-methylaminosulfonyl-phenyl)phenyl 1022 1 NHC~O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1023 1 NHC(O) 2-aminosulfonyl-4-cyclohexylphenyl 1024 1 NHC(O) 3-aminosulfonyl-4-t-butyl-2-pyridyl 1025 1 NHC(O) 2-(5-indazol-5-yl)furanyl 1026 1 NHC(O) 2-(5-indazol-6-yl)thienyl 1027 1 NHC(O)4-(2-tetrazolylphenyl)phenyl 1028 1 SO2NH 4-(2-aminosulfonylphenyl)phenyl 1029 1 SO2NH 4-(2-aminosulfonylphenyl)-2-pyridyl 1030 1 SO2NH 4-(2-methylaminosulfonyl-phenyl)phenyl 1031 1 SO2NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1032 1 SO2NH 2-aminosulfonyl-4-cyclohexylphenyl 1033 1 SO2NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 1034 1 SO2NH 2-(5-indazol-5-yl)furanyl 1035 1 SO2NH 2-(5-indazol-6-yl)thienyl 1036 1 SO2NH4-(2-tetrazolylphenyl)phenyl 1037 0 CH(CH2CH2OH)C(O)NH 4-(2-aminosulfonylphenyl)phenyl 1038 0 CH(CH2CH2OH)C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl . ..

CA 022~9~73 1999-01-06 1039 0CH(CH2CH20H)C~O)NH4-(2-methylaminosulfonyl-~henyl)phenyl 1040 0CH~CH2CH2OH) C~O)NH4-~2-ethylaminosulfonyl-phenyl~-2-pyridyl 1041 0CH~CH2CH2OH)C(O)NH2-aminosulfonyl-4-cyclohexylphenyl 1042 0CH(CH2CH2OH)C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 1043 0CH(CH2CH2OH)C(O)NH2-(5-indazol-5-yl~furanyl 1044 0CH(CH2CH2OH)C(O)NH2-(5-indazol-6-yl~thienyl 1045 0CH(CH2CH2OH)C(O)NH4-(2-tetrazolylphenyl~phenyl 1046 0CH~CH2- 4-~2-tetrazolyl)C~O) NHaminosulfonylphenyl)phenyl 1047 oCH~CH2- 4-~2-aminosulfonylphenyl)-2-tetrazolyl)C~O) NH pyridyl 1048 0CH~CH2- 4-~2-methylaminosulfonyl-tetrazolyl)C~O~ NHphenyl)phenyl 1049 0CH~CH2- 4-~2-ethylaminosulfonyl-tetrazolyl)C~O) NHphenyl)-2-pyridyl 1050 0CH(CH2- 2-aminosulfonyl-4-tetrazolyl)C(O)NHcyclohexylphenyl 1051 0CH(CH2- 3-aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O) NH pyridyl 1052 0CH(CH2- 2-~ 5- indazol-5-yl)furanyl tetrazolyl)C~O)NH
1053 0CH~CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C~O) NH
1054 0CH~CH2- 4-(2-tetrazolylphenyl)phenyl tetrazolyl)C~O) NH

CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 Table 17 HN~

(\~ Z_A_B

EX n Z Rl A-B
1101 1 C(O) H3-acetyl-4-benzylpiperidine 1102 1 C(O) H4-(4-fluorobenzyl)piperidine 1103 1 C (O) H4-(2,3-difluorobenzyl) piperidine 1104 1 C(O) H4-(2-chloro-4-fluorobenzyl) piperidine 1105 1 C(O)CH2CH2OH3-acetyl-4-benzylpiperidine 110 6 1 C ( O )CH2CH2OH4-~3-fluorobenzyl)piperidine 110 7 1 C ( O )CH2CH2 OH4-(4-fluorobenzyl)piperidine 1108 1 C(O)CH2CH2OH4-(2,3-difluorobenzyl) piperidine 1109 1 C(O)CH2CH2OH4-(2-chloro-4-fluorobenzyl) piperidine 1110 1 C(O) CH2OCH34-benzylpiperidine 1111 1 C(O) CH2OCH33-acetyl-4-benzylpiperidine 1112 1 C(O) CH2OCH34-(3-fluorobenzyl)piperidine 1113 1 C(O) CH2OCH34-(4-fluorobenzyl)piperidine 1114 1 C(O) CH2OCH34-(2,3-difluorobenzyl) piperidine 1115 1 C(O) CH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1116 1 C (O)CH2CH2-4-benzylpiperidine tetrazolyl 1117 1 C (O)CH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl 1118 1 C (O)CH2CH2-4-(3-fluorobenzyl)piperidine tetrazolyl CA 022~9~73 1999-0l-06 WO98/01428 - PCT/US97tll325 1119 1 C(O) CH2CH2-4-(4-fluorobenzyl)piperidine tetrazolyl 1120 1 C(O) CH2CH2-4-(2,3-difluorobenzyl) tetrazolylpiperidine 1121 1 C(O) CH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolylpiperidine 1122 1C(O)NH H3-acetyl-4-benzylpiperidine 1123 1C(O)NH H4-(3-fluorobenzyl)piperidine 1124 1C(O)NH H4-(4-fluorobenzyl)piperidine 1125 1C(O)NH H4-(2,3-difluorobenzyl) piperidine 1126 1C(O)NH H4-(2-chloro-4-fluorobenzyl) piperidine 1127 1C(O)NHCH2CH2OH4-benzylpiperidine 1128 1C(O)NHCH2CH2OH3-acetyl-4-benzylpiperidine 1129 1C(O)NHCH2CH2OH4-(3-fluorobenzyl)piperidine 1130 1C(O)NHCH2CH2OH4-(4-fluorobenzyl)piperidine 1131 1C(O)NHCH2CH2OH4-(2,3-difluorobenzyl) piperidine 1132 1C(O)NHCH2CH2OH4-(2-chloro-4-fluorobenzyl) piperidine 1133 1C(O)NH CH2OCH34-benzylpiperidine 1134 1C(O)NH CH2OCH33-acetyl-4-benzylpiperidine 1135 1C(O)NH CH2OCH34-(3-fluorobenzyl)piperidine 1136 1C(O)NH CH2OCH34-(4-fluorobenz~l)piperidine 1137 1C(O)NH CH2OCH34-(2,3-difluorobenzyl) piperidine 1138 1C(O)NH CH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1139 1C(O)NH CH2CH2-4-benzylpiperidine tetrazolyl 1140 1C(O)NH CH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl 1141 1C(O)NH CH2CH2-4-(3-fluorobenzyl)piperidine tetrazolyl CA 022~9~73 l999-0l-06 1142 1C(O)NHCH2CH2-4-(4-fluorobenzyl~piperidine tetrazolyl 1143 1C(O)NHCH2CH2-4-(2,3-difluorobenzyl) tetrazolylpiperidine 1144 1C(O)NHCH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolylpiperidine 1145 1 SO2NH H 4-benzylpiperidine 1146 1 SO2NH H3-acetyl-4-benzylpiperidine 1147 1 SO2NH H4-(3-fluorobenzyl)piperidine 1148 1 SO2NH H4-(4-fluorobenzyl)piperidine 1149 1 SO2NH H4-(2,3-difluorobenzyl) piperidine 1150 1 SO2NH H4-(2-chloro-4-fluorobenzyl) piperidine 1151 1 SO2NHCH2CH2OH4-benzylpiperidine 1152 1 SO2NHCH2CH2OH3-acetyl-4-benzylpiperidine 1153 1 SO2NHCH2CH2OH4-(3-fluorobenzyl)piperidine 1154 1 SO2NHCH2CH2OH4-(4-fluorobenzyl)piperidine 1155 1 SO2NHCH2CH2OH4-(2,3-difluorobenzyl) piperidine 1156 1 SO2NHCH2CH2OH4-(2-chloro-4-fluorobenzyl) piperidine 1157 1 S02NHCH20CH34-benzylpiperidine 1158 1 S02NHCH20CH33-acetyl-4-benzylpiperidine 1159 1 SO2NHCH2OCH34-(3-fluorobenzyl)piperidine 1160 1 SO2NHCH2OCH34-(4-fluorobenzyl)piperidine 1161 1 S02NHCH20CH34-(2,3-difluorobenzyl) piperidine 1162 1 SO2NHCH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1163 1 S02NHCH2CH2-4-benzylpiperidine tetrazolyl 1164 1 S02NHCH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl 1165 1 SO2NHCH2CH2-4-(3-fluorobenzyl)piperidine tetrazolyl CA 02259573 l999-0l-06 ~ WO98/01428 - PCT~S97/11325 1166 1 S02NH CH2CH2-4-(4-fluorobenzyl)piperidine tetrazolyl 1167 1 SO2NH CH2CH2-4-(2,3-difluorobenzyl) tetrazolyl piperidine 1168 1 S02NH CH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolyl piperidine CA 022~9~73 1999-0l-06 PCT~S97/11325 Table 18 H ~N~ ~

(\~ Z_A_B

Ex n Z Rl A-B
1201 1 C(O) H 4-benzylpiperidine 1202 1 C(O) H3-acetyl-4-benzylpiperidine 1203 1 C(O) H4-(3-fluorobenzyl)piperidine 1204 1 C(O) H4-(4-fluorobenzyl)piperidine 1205 1 C(O) H4-(2,3-difluorobenzyl) piperidine 1206 1 C(O) H4-(2-chloro-4-fluorobenzyl) piperidine 1207 1 C(O)CH2CH2OH4-benzylpiperidine 1208 1 C(O)CH2CH2OH3-acetyl-4-benzylpiperidine 1209 1 C(O)CH2CH2OH4-(3-fluorobenzyl)piperidine 1210 1 C(O)CH2CH2OH4-(4-fluorobenzyl)piperidine 1211 1 C(O)CH2CH2OH4-(2,3-difluorobenzyl) piperidine 1212 1 C(O)CH2CH2OH4-(2-chloro-4-fluorobenzyl) piperidine 1213 1 C(O) CH2OCH34-benzylpiperidine 1214 1 C(O) CH2OCH33-acetyl-4-benzylpiperidine 1215 1 C(O) CH2OCH34-(3-fluorobenzyl)piperidine 1216 1 C(O) CH2OCH34-(4-fluorobenzyl)piperidine 1217 1 C(O) CH2OCH34-(2,3-difluorobenzyl) piperidine 1218 1 C(O) CH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1219 1 C(O) CH2CH2-4-benzylpiperidine tetrazolyl 1220 1 C(O) CH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl CA 022~9~73 1999-0l-06 ~ PCT~S97/11325 1221 1 C(O) CH2CH2-4-(3-fluorobenzyl)piperidine tetrazolyl 1222 1 C(O) CH2CH2-4-(4-fluorobenzyl)piperidine tetrazolyl 1223 1 C(O) CH2CH2-4-(2,3-difluorobenzyl) tetrazolylpiperidine 1224 1 C(O) CH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolylpiperidine 1225 1 C(O)NH H 4-benzylpiperidine 1226 1 C(O)NH H3-acetyl-4-benzylpiperidine 1227 1 C(O)NH H4-(3-fluorobenzyl)piperidine 1228 1 C(O)NH H4-(4-fluorobenzyl)piperidine 1229 1 C(O)NH H4-(2,3-difluorobenzyl) piperidine 1230 1 C(O)NH H4-(2-chloro-4-fluorobenzyl) piperidine 1231 1 C(O)NH CH2CH2OH4-benzylpiperidine 1232 1 C(O)NH CH2CH20H3-acetyl-4-benzylpiperidine 1233 1 C(O)NH CH2CH2OH4-(3-fluorobenzyl)piperidine 1234 1 C(O)NH CH2CH2OH4-(4-fluorobenzyl)piperidine 1235 1 C(O)NH CH2CH2OH4-(2,3-difluorobenzyl~
piperidine 1236 1 C(O)NH CH2CH2OH4-(2-chloro-4-fluorobenzyl) piperidine 1237 1 C(O)NH CH2OCH34-benzylpiperidine 1238 1 C(O)NH CH2OCH33-acetyl-4-benzylpiperidine 1239 1 C(O)NH CH2OCH34-(3-fluorobenzyl)piperidine 1240 1 C(O)NH CH2OCH34-(4-fluorobenzyl)piperidine 1241 1 C(O)NH CH2OCH34-(2,3-difluorobenzyl) piperidine 1242 1 C(O)NH CH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1243 1 C(O)NH CH2CH2-4-benzylpiperidine tetrazolyl 1244 1 C(O)NH CH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl . , . ~ , ~

CA 022~9~73 1999-0l-06 ~ WO98/01428 - PCT~S97/11325 1245 1C(O)NH CH2CH2-4-(3-fluorobenzyl)piperidine tetrazolyl 1246 1C(O) NH CH2CH2-4-(4-fluorobenzyl)piperidine tetrazolyl 1247 1C(O)NH CH2CH2-4-(2,3-difluorobenzyl) tetrazolyl piperidine 1248 1C(O)NH CH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolyl piperidine 1249 1SO2NH H 4-benzylpiperidine 1250 1SO2NH H3-acetyl-4-benzylpiperidine 1251 1S02NH H4-(3-fluorobenzyl)piperidine 1252 1SO2NH H4-(4-fluorobenzy~)piperidine 1253 1S02NH H4-(2,3-difluorobenzyl) piperidine 1254 1S02NH H4-(2-chloro-4-fluorobenzyl) piperidine 1255 1SO2NH CH2CH2OH4-benzylpiperidine 1256 1SO2NH CH2CH2OH3-acetyl-4-benzylpiperidine 1257 1SO2NH CH2CH2OH4-(3-fluorobenzyl)piperidine 1258 1SO2NH CH2CH2OH4-(4-fluorobenzyl)piperidine 1259 1SO2NH CH2CH2OH4-(2,3-difluorobenzyl) piperidine 1260 1SO2NH CH2CH2OH4-(2-chloro-4-fluorobenzyl) piperidine 1261 1S02NH CH20CH34-benzylpiperidine 1262 1SO2NH CH2OCH33-acetyl-4-benzylpiperidine 1263 1SO2NH CH2OCH34-(3-fluorobenzyl)piperidine 1264 1SO2NH CH2OCH34-(4-fluorobenzyl)piperidine 1265 1SO2NH CH2OCH34-(2,3-difluorobenzyl) piperidine 1266 1SO2NH CH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1267 1S02NH CH2CH2-4-benzylpiperidine tetrazolyl 1268 1SO2NH CH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl , 1269 1 S02NHCH2cH2-4-(3-fluorobenzyl)piperidine tetrazolyl 1270 1 S02~HCH2CH2-4-(4-fluorobenzyl)piperidine tetrazolyl 1271 1 S02NHCH2CH2-4-(2,3-difluorobenzyl) tetrazolyl piperidine 1272 1 S02NHCH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolyl piperidine CA 022~9~73 1999-01-06 Table 19 H2N~l~N

(\'t Z_A_B

EX n Z R1 A-B
1301 1 C(O) H 4-benzylpiperidine 1302 1 C(O) H3-acetyl-4-benzylpiperidine 1303 1 C(O) H4-(3-fluorobenzyl)piperidine 1304 1 C(O) H4-(4-fluorobenzyl)piperidine 1305 1 C(O) H4-(2,3-difluorobenzyl) piperidine 1306 1 C(O) H4-(2-chloro-4-fluorobenzyl piperidine 1307 1 C(O)CH2CH2OH4-benzylpiperidine 1308 1 C(O)CH2CH2OH3-acetyl-4-benzylpiperidine 1309 1 C(O)CH2CH2OH4-(3-fluorobenzyl)piperidine 1310 1 C(O)CH2CH2OH4-(4-fluorobenzyl)piperidine 1311 1 C(O)CH2CH2OH4-(2,3-difluorobenzyl) piperidine 1312 1 C(O)CH2CH2OH4-(2-chloro-4-fluorobenzyl) piperidine 1313 1 C(O) CH~OCH34-benzylpiperidine 1314 1 C(O) CH2OCH33-acetyl-4-benzylpiperidine 1315 1 C(O) CH2OCH34-(3-fluorobenzyl)piperidine 1316 1 C(O) CH2OCH34-(4-fluorobenzyl)piperidine 1317 1 C(O) CH2OCH34-(2,3-difluorobenzyl) piperidine 1318 1 C(O) CH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1319 1 C(O) CH2CH2-4-benzylpiperidine tetrazolyl 1320 1 C(O) CH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl CA 022~9~73 1999-0l-06 WO98/01428 PCT~S97/11325 1321 1 C(O) CH2CH2-4-~3-fluorobenzyl)piperidine tetrazolyl 1322 1 C(O) CH2CH2-4-(4-fluorobenzyl)piperidine tetrazolyl 1323 1 C(O) CH2CH2-4-(2,3-difluorobenzyl) tetrazolylpiperidine 1324 1 C(O) CH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolylpiperidine 1325 1 C(O)NH H 4-benzylpiperidine 1326 1 C(O)NH H3-acetyl-4-benzylpiperidine 1327 1 C(O)NH H4-(3-fluorobenzyl)piperidine 1328 1 C(O)NH H4-(4-fluorobenzyl)piperidine 1329 1 C(O)NH H4-(2,3-difluorobenzyl) piperidine 1330 1 C(O)NH H4-(2-chloro-4-fluorobenzyl) piperidine 1331 1 C(O)NH CH2CH2OH4-benzylpiperidine 1332 1 C(O)NH CH2CH2OH3-acetyl-4-benzylpiperidine 1333 1 C(O)NH CH2CH2OH4-(3-fluorobenzyl)piperidine 1334 1 C(O)NH CH2CH2OH4-(4-fluorobenzyl)piperidine 1335 1 C(O)NH CH2CH2OH4-(2,3-difluorobenzyl) piperidine 1336 1 C(O)NH CH2CH2OH4-(2-chloro-4-fluorobenzyl) piperidine 1337 1 C(O)NH CH2OCH34-benzylpiperidine 1338 1 C(O)NH CH2OCH33-acetyl-4-benzylpiperidine 1339 1 C(O)NH CH2OCH34-(3-fluorobenzyl)piperidine 1340 1 C(O)NH CH2OCH34-(4-fluorobenzyl)piperidine 1341 1 C(O)NH CH2OCH34-(2,3-difluorobenzyl) piperidine 1342 1 C(O)NH CH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1343 1 C(O)NH CH2CH2-4-benzylpiperidine tetrazolyl 1344 1 C(O)NH CH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl CA 022~9~73 1999-0l-06 PCT~S97/11325 1345 1C(O)NH CH2CH2-4-(3-fluorobenzyl)piperidine tetrazolyl 1346 1C(O) NHCH2CH2 -4-(4-fluorobenzyl)piperidine tetrazolyl 1347 1C(O)NH CH2CH2-4-~2,3-difluorobenzyl) tetrazolylpiperidine 1348 1C(O)NH CH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolylpiperidine 1349 1 SO2NH H 4-benzylpiperidine 1350 1 SO2NH H3-acetyl-4-benzylpiperidine 1351 1 SO2NH H4-(3-fluorobenzyl)piperidine 1352 1 SO2NH H4-(4-fluorobenzyl)piperidine 1353 1 SO2NH H4-(2,3-difluorobenzyl) piperidine 1354 1 S02NH H4-(2-chloro-4-fluorobenzyl) piperidine 1355 1 S02NHCH2CH20H4-benzylpiperidine 1356 1 S02NHCH2CH20H3-acetyl-4-benzylpiperidine 1357 1 SO2NHCH2CH2OH4-(3-fluorobenzyl)piperidine 1358 1 SO2NHCH2CH2OH4-(4-fluorobenzyl)piperidine 1359 1 S02NHCH2CH20H4-(2,3-difluorobenzyl) piperidine 1360 1 S02NHCH2CH20H4-(2-chloro-4-fluorobenzyl) piperidine 1361 1 SO2NH CH2OCH34-benzylpiperidine 1362 1 SO2NH CH2OCH33-acetyl-4-benzylpiperidine 1363 1 S02NH CH20CH34-(3-fluorobenzyl)piperidine 1364 1 SO2NH CH2OCH34-(4-fluorobenzyl)piperidine 1365 1 S02NH CH20CH34-(2,3-difluorobenzyl) piperidine 1366 1 SO2NH CH2OCH34-(2-chloro-4-fluorobenzyl) piperidine 1367 1 SO2NH CH2CH2-4-benzylpiperidine tetrazolyl 1368 1 SO2NH CH2CH2-3-acetyl-4-benzylpiperidine tetrazolyl CA 02259573 l999-0l-06 PCT~S97/11325 1369 1 S02NHCH2CH2-4-(3-fluorobenzyl)piperidine tetrazolyl 1370 1 S02NHCH2CH2-4-(4-fluorobenzyl)piperidine tetrazolyl 1371 1 SO2NHCH2CH2-4-(2,3-difluorobenzyl) tetrazolyl piperidine 1372 1 SO2NHCH2CH2-4-(2-chloro-4-fluorobenzyl) tetrazolyl piperidine CA 022~9~73 1999-0l-06 WO98101428 - PCT~S97/11325 Table 20 HN~ ~
H2N (~Z--A--B

Ex n Z A-B
1401 1 C(O) 4-(2-aminosulfonylphenyl)phenyl 1402 1 C(O)4-(2-aminosulfonylphenyl)-2-pyridyl 1403 1 C(O)4-(2-methylaminosulfonyl-phenyl)phenyl 1404 1 C(O)4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1405 1 C(O) 2-aminosulfonyl-4-cyclohexylphenyl 1406 1 C(O)3-aminosulfonyl-4-t-butyl-2-pyridyl 1407 1 C~O)2-(5-indazol-5-yl)furanyl 1408 1 C(O)2-(5-indazol-6-yl)thienyl 1409 1 C(O)4-(2-tetrazolylphenyl)phenyl 1410 1 C(O)NH 4-(2-aminosulfonylphenyl)phenyl 1411 1 C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 1412 1 C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 1413 1 C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1414 1 C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 1415 1 C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 1416 1 C(O)NH2-(5-indazol-5-yl)furanyl 1417 1 C(O)NH2-(5-indazol-6-yl)thienyl CA 022~9~73 1999-0l-06 WO98/01428 - PCT~S97/11325 1418 1 C(O)NH 4-(2-tetrazolylphenyl)phenyl 1419 1 NHC(O) 4-(2-aminosulfonylphenyl)phenyl 1420 1 NHC(O) 4-(2-aminosulfonylphenyl)-2-pyridyl 1421 1 NHC(O) 4-(2-methylaminosulfonyl-phenyl)phenyl 1422 1 NHC(O) 4-(2-ethylaminosulfonyl-phenyl)-2-pyridy~
1423 1 NHC(O) 2-aminosulfonyl-4-cyclohexylphenyl 1424 1 NHC(O) 3-aminosulfonyl-4-t-butyl-2-pyridyl 1425 1 NHC(O) 2-(5-indazol-5-yl)furanyl 1426 1 NHC(O) 2-(5-indazol-6-yl)thienyl 1427 1 NHC(O) 4-(2-tetrazolylphenyl)phenyl 1428 1 S02NH 4-(2-aminosulfonylphenyl)phenyl 1429 1 S02NH 4-(2-aminosulfonylphenyl)-2-pyridyl 1430 1 S02NH 4-(2-methylaminosulfonyl-phenyl)phenyl 1431 1 SO2NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1432 1 SO2NH 2-aminosulfonyl-4-cyclohexylphenyl 1433 1 SO2NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 1434 1 S02NH 2-(5-indazol-5-yl)furanyl 1435 1 SO2NH 2-(5-indazol-6-yl)thienyl 1436 1 SO2NH 4-(2-tetrazolylphenyl)phenyl 1437 0 CH(CH2CH2OH)C(O)NH 4-(2-aminosulfonylphenyl)phenyl 1438 0 CH(CH2CH2OH)C(O)NH4-(2-aminosulfonylphenyl) -2-pyridyl CA 022~9~73 1999-01-06 WO98/01428 PCT~S97/11325 1439 0CH(CH2CH2OH)C(O)NH 4-(2-methylaminosulfonyl-phenyl)phenyl 1440 0CH(CH2CH2OH)C(O)NH 4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1441 0CH~CH2CH2OH)C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 1442 0CH(CH2CH2OH)C(O)NH 3-aminosulfonyl-4-t-butyl-2-pyridyl 1443 0CH(CH2CH2OH)C(O)NH 2-(5-indazol-5-yl)furanyl 1444 0CH(CH2CH2OH)C(O)NH 2-(5-indazol-6-yl)thienyl 1445 0CH(CH2CH2OH)C(O)NH 4-(2-tetrazolylphenyl)phenyl 1446 0CH(CH2- 4-~2-tetrazolyl)C(O)NH aminosulfonylphenyl)phenyl 1447 0CH(CH2- 4-(2-aminosulfonylphenyl)-2-tetrazolyl)C(O)NH pyridyl 1448 0CH(CH2- 4-(2-methylaminosulfonyl-tetrazolyl)C(O)NH phenyl)phenyl 1449 0CH(CH2- 4-(2-ethylaminosulfonyl-tetrazolyl)C(O)NH phenyl)-2-pyridyl 1450 0CH(CH2- 2-aminosulfonyl-4-tetrazolyl)C(O)NH cyclohexylphenyl 1451 0CH(CH2- 3-aminosulfonyl-4-t-butyl-2-tetrazolyl)C(O)NH pyridyl 1452 0CH(CH2- 2-(5-indazol-5-yl)furanyl tetrazolyl)C(O)NH
1453 0CH(CH2- 2-(5-indazol-6-yl)thienyl tetrazolyl)C(O)NH
1454 0CH(CH2- 4-(2-tetrazolylphenyl)phenyl tetrazolyl)C(O)NH

CA 022~9~73 1999-0l-06 PCT~S97/1132S

~able 21 N ~ '~ A

Ex Z' A-B
1501CH2C(O)NH 4-(2- -aminosulfonylphenyl)phenyl 1502CH2C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 1503CH2C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 1504CH2C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1505CH2C(O)NH 2-aminosulfonyl-4-cyclohexylphenyl 1506CH2C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 1507CH2C(O)NH2-(5-indazol-5-yl)furanyl 1508CH2C(O)NH2-(5-indazol-6-yl)thienyl 1509CH2C(O)NH4-(2-tetrazolylphenyl)phenyl 1510CH2CH2C(O)NH 4-(2-aminosulfonylphenyl)phenyl 1511CH2CH2C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 1512CH2CH2C(O)NH4-~2-tert-butylaminosulfonyl-phenyl)phenyl 1513CH2CH2C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1514CH2CH2C(O)NH2-aminosulfonyl-4-cyclohexylphenyl 1515CH2CH2C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 1516CH2CH2C(O)NH2-(5-indazol-5-yl)furanyl 1517CH2CH2C(O)NH2-(5-indazol-6-yl)thienyl 1518CH2CH2C(O)NH4-(2-tetrazolylphenyl)phenyl CA 022~9~73 l999-0l-06 ~ PCT~S97/11325 1519 SCH2C(O)NH 4-(2-aminosulfonylphenyl)phenyl 1520 SCH2C(O)NH4-(2-aminosulfonylphenyl)-2-pyridyl 1521 SCH2C(O)NH4-(2-methylaminosulfonyl-phenyl)phenyl 1522 SCH2C(O)NH4-(2-ethylaminosulfonyl-phenyl)-2-pyridyl 1523 SCH2C(O)NH2-aminosulfonyl-4-cyclohexylphenyl 1524 SCH2C(O)NH3-aminosulfonyl-4-t-butyl-2-pyridyl 1525 SCH2C(O)NH2-(5-indazol-5-yl)furanyl 1526 SCH2C(O)NH2-(5-indazol-6-yl)thienyl 1527 SCH2C(O)NH4-(2-tetrazolylphenyl)phenyl CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 UtilitY
The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin.
The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometricallY by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, Ki-Factor Xa determinations were made in 0.l0 M sodiumphosphate buffer, pH 7.5, containing 0.20 M NaCl, and 0.5 %
PEG 8000. The Michaelis constant, Km, for substrate hydrolysis was determined at 25~C using the method of Lineweaver and Burk. Values o~ Ki were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 mM-l mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate Ki values:
(vO-vs)/vs = I/(Ki (l + S/Km)) .... .. . . _ CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 where:
vO is the velocity of the control in the absence of inhibitori VS is the velocity in the presence of inhibitor;
I is the concentration of inhibitor;
Ki is the dissociation constant of the enzyme:inhibitor complex;
S is the concentration of substrate;
Km is the Michaelis constant.
Using the methodology described above, a number of compounds of the present invention were found to exhibit a Ki of <5 ~m, thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors.
The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous tAV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (lO mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae. The AV shunt device consists of a piece of 6-cm tygon tubing which contains a piece of silk thread. Blood will flow from the femoral artery via the AV-shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c., or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group.
The ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by linear regression.
The compounds of formula (I) are also considered to be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes.
Some compounds of the present invention were shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. In vitro inhibition constants were determined by the method described by Kettner et al- in J- Biol- Chem. 265, 18289-182g7 (l990), herein incorporated by re~erence. In these assays, thrombin-mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX) was monitored spectrophotometrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of throm~bin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in O.lO M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% PEG 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the st~n~rd method of Lineweaver and Burk. Using the methodology described above, some compounds of this invention were evaluated and found to exhibit a Ki of less than 5 ~m, thereby confirming the utility of the compounds of the invention as effective thrombin inhibitors.
The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anti-coagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents.
The compounds are adm~inistered to a m~mm~l in a therapeutically effective amount. By "therapeutically CA 022~9~73 1999-01-06 WO98tO1428 - PCT~S97/11325 effective amount" it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.
By ~ ministered in combination" or "combination therapy"
it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention.
The term anti-platelet agents (or platelet inhibitory agents), as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA), and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include IIb/IIIa antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof.

,, ~

CA 022~9~73 1999-0l-06 WO98/01428 PCT~S97/11325 The term thrombin inhibitors (or anti-thrombin agents), as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds- Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof. The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No.
5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471,651 A2, the disclosures of which are hereby incorporated herein by reference.
The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics), as used herein, denotes agents that lyse blood clots (thrombi). Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby .

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/1132~
incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase.
Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.
The compounds of the present invention are also useful as standard or reference compounds, for example as a qua~ity standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, ~or use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness.
The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the ccmpounds of the present invention. If production of pNA is observed in the solutions containing test sample, but no compound of the present invention, then one would conclude factor Xa was present.

Dosaqe and Formulation The compounds of this invention can be adminis~ered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations)~

. . .

CA 022~9~73 1999-01-06 pills, powders, granules, el~xirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the -basis of the chosen route of administration and standard pharmaceutical practice.
The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient,and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.
By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day.
Intravenously~ the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion.
Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be ~mlnjstered in divided doses of two, three, or four times daily.
Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage ~min; stration will, of course, be continuous rather than intermittent throughout the dosage regimen.

. .. .. . ..

CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
For instance, for oral ~mi~i stration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in li~uid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
The compounds of the present invention can also be 30 ~nmi ni stered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic ac-id, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
Dosage forms ~pharmaceutical compositions) suitable for administration may contain from about l milligram to about lO0 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Li~uid dosage forms for oral ~mi ni stration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances- Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remin~ton's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:
Ca~sules A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with lO0 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
Soft Gelatin Ca~sules A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing lO0 milligrams of the active ingredient. The capsules are washed and dried.
Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit is lO0 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, ll milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
Iniectable A parenteral composition suitable for administration by injection is prepared by stirring l.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.
Sus~ension An aqueous suspension is prepared for oral administration so that each 5 mL contain lO0 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 ce~lulose, 5 mg of sodium benzoate, l.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.
Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about O.l to lO0 milligrams of the compound of Formula I and about l to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to lO milligrams per dosage unit, and the second anti-coagulant in an amount of about l to 5 milligrams per dosage unit.
Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about O.Ol to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about O.l to l milligrams of the compound of Formula I and about l to 3 milligrams of antiplatelet agents, per kilogram of patient body weight.
Where the compounds of Formula I are adminstered in combination with thrombolytic agent, typically a daily dosage may be about O.l to l milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I.
Where two or more of the foregoing second therapeutic agents are ~m;n; stered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination.
Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that CA 022~9~73 1999-01-06 WO98/01428 - PCT~S97/11325 although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric coated- By enteric coating one of the active ingredients, it is possible not only to m;nimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines- One of the active ingredients may also be coated with a material which effects a sustained-release throughout the gastrointestinal tract and also serves to m;n;m;ze physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.
These as well as other ways of mi ni m; zing contact between the components of combination products of the present invention, whether administered in a single dosage form or ~m; ni stered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

Claims (20)

WHAT IS CLAIMED AS NEW AND DESIRED TO BE SECURED BY LETTER
PATENT OF UNITED STATES IS:

1. A compound of formula I:

or stereoisomer or pharmaceutically acceptable salt form thereof wherein:

W and W3 are selected from CH and N;

W1 and W2 are selected from C, CH, and N;

provided that from 0-2 of W, W1, W2, and W3 are N;

one of D and Da is selected from H, C1-4 alkoxy, CN, C(=NR7)NR8R9, NHC(=NR7)NR8R9, NR8CH(=NR7), C(O)NR8R9, and (CH2)t NR8R9, and the other is absent;

provided that if one of D and Da is H, then at least one of W, W1, W2, and W3 is N;

one of J a and J b is substituted by -(CH2)n-Z-A-B;

J, J a, and J b combine to form an aromatic heterocyclic system containing from 1-2 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R1, provided that J b can only be C or N;

J, J a, and J b can, alternatively, combine to form a heterocyclic ring wherein J b is N and J and J a are CH2 substituted with 0-1 R1;

J, J a, and J b can, alternatively, combine to form a heterocyclic ring wherein J b is CH, J is NR1 and J a is CH2 substituted with 0-1 R1;

R1 is selected from H, C1-4 alkyl, (CH2)r OR3, (CH2)r NR3R3', (CH2)r C(=O)R2, (CH2)r(CH=CH)(CH2)r C(=O)R2, (CH2)r NR3C(=O)R2, (CH2)r SO2R4, (CH2)r NR3SO2R4, and (CH2)r-5-membered heterocyclic system having 1-4 heteroatoms selected from N, O, and S;

R2 is selected from H, OR3, C1-4 alkyl, NR3R3', CF3, and C3-10 carbocyclic residue substituted with 0-2 R6;

R3 and R3' are independently selected from H, C1-4 alkyl, and C3-10 carbocyclic residue substituted with 0-2 R6;

R4 is selected from C1-4 alkyl, NR3R3', and C3-10 carbocyclic residue substituted with 0-2 R6;

Z is selected from CH=CH, CH((CH2)m Q(CH2)mR5), CH((CH2)m Q(CH2)m R5)C(O)NR3, CH((CH2)m C(O)(CH2)m R5a), N((CH2)q Q(CH2)m R5), N(Q'(CH2)m R5), C(O)N((CH2)m Q'(CH2)m R5a), C(O)(CH2)r, C(O)O(CH2)r, OC(O)(CH2)r, C(O)(CH2)r NR3(CH2)r, NR3C(O)(CH2)r, OC(O)NR3(CH2)r, NR3C(O)O(CH2)r, NR3C(O)NR3(CH2)r, S(O)p(CH2)r, SO2CH2, SCH2C(O)NR3, SO2NR3(CH2)r, NR3SO2(CH2)r, and NR3SO2NR3(CH2)r;

Q is selected from a bond, O, NR3, C(O), C(O)NR3, NR3C(O), SO2, NR3SO2, and SO2NR3;

Q' is selected from a bond, C(O), C(O)NR3, SO2, and SO2NR3;

R5 is selected from H, C1-4 alkyl, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R6, provided that when Q is SO2 or NR3SO2, R5 is other than H
and when Q' is SO2, R5 is other than H;

R5a is selected from NHR5, OR5, and R5;

A is selected from:
benzyl substituted with 0-2 R6, phenethyl substituted with 0-2 R6, phenyl-CH= substituted with 0-2 R6, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

B is selected from:
X-Y, C3-6 alkyl, NR3R3', C(=NR3)NR3R3', NR3C(=NR3)NR3R3', benzyl substituted with 0-2 R6, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

A and B can, alternatively, combine to form a C9-10 carbocyclic residue substituted with 0-2 R6 or a 9-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

X is selected from C1-4 alkylene, -C(O)-, -C(O)CR3R3'-, -CR3R3'C(O), -S(O)p-, -S(o)p CR3R3'-, -CR3R3'S(o)p-, -S(O)2NR3-, -NR3S(O)2-, -C(O)NR3-, -NR3C(O)-, -NR3-, -NR3CR3R3'-, -CR3R3'NR3-, O, -CR3R3'O-, and -OCR3R3'-;

Y is selected from:
C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

R6 is selected from H, OH, (CH2)nOR3, halo, C1-4 alkyl, CN, NO2, (CH2)r NR3R3, (CH2)r C(O)R3, NR3C(O)R3', NR3C(O)NR3R3', CH(=NH)NH2, NHC(=NH)NH2, SO2NR3R3', CONHSO2R4, NR3SO2NR3R3', NR3SO2-C1-4 alkyl, and (C1-4 alkyl)-tetrazolyl;
R7 is selected from H, OH, C1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkoxy, C1-4 alkoxycarbonyl, C6-10 aryloxy, C6-10 aryloxycarbonyl, C6-10 arylmethylcarbonyl, C1-4 alkylcarbonyloxy C1-4 alkoxycarbonyl, C6-10 arylcarbonyloxy C1-4 alkoxycarbonyl, C1-6 alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C1-4 alkoxycarbonyl;

R8 is selected from H, C1-6 alkyl and (CH2)n-phenyl;

R9 is selected from H, C1-6 alkyl and (CH2)n-phenyl;

n is selected from 0, 1, 2, 3, and 4;

m is selected from 0, 1, and 2;

p is selected from 0, 1, and 2;

q is selected from 1 and 2; and, r is selected from 0, 1, 2, 3, and 4;

provided that:
(a) Z is other than CH2; and, (b) if Z is CH((CH2)m Q(CH2)m R5) or CH((CH2)m C(O)(CH2)m R5a), then B is other than X-Y, a C3-10 carbocyclic residue or a 5-10 membered heterocyclic system.

2. A compound according to Claim 1, wherein the compound is of formula II:

or a stereoisomer or pharmaceutically acceptable salt, wherein:

from 0-1 of W, W1, W2, and W3 are N;

R1 is selected from H, C1-4 alkyl, (CH2)r OR3, (CH2)r NR3R3', (CH2)r C(=O)R2, (CH2)r NR3C(=O)R2, (CH2)r SO2R4, (CH2)r NR3SO2R4, and (CH2)r-5-membered heterocyclic system having 1-4 heteroatoms selected from N, O, and S;

R2 is selected from H, OR3, C1-4 alkyl, NR3R3', and CF3;

R3 and R3' are independently selected from H, C1-4 alkyl, and phenyl;

R4 is selected from C1-4 alkyl, phenyl and NR3R3';

Z is selected from CH=CH, CH((CH2)m Q(CH2)m R5), CH((CH2)m Q(CH2)m R5)C(O)NR3, CH((CH2)m C(O)(CH2)m R5a), N((CH2)q Q(CH2)m R5), N(Q'(CH2)m R5), C(O)N((CH2)m Q'(CH2)m R5a), C(O), C(O)CH2, C(O)O, OC(O), C(O)(CH2)r NR3(CH2)r, NR3C(O), OC(O)NR3, NR3C(O)O, NR3C(O)NR3, S(O)p, SO2CH2, SO2NR3, NR3SO2, and NR3SO2NR3;

B is selected from:
X-Y, C3-6 alkyl, benzyl substituted with 0-2 R6, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

A and B can, alternatively, combine to form a C9-10 carbocyclic residue substituted with 0-2 R6 or a 9-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6; and, R6 is selected from H, OH, (CH2)n OR3, halo, C1-4 alkyl, CN, NO2, (CH2)r NR3R3', (CH2)rC(O)R3, NR3C(O)R3', NR3C(O)NR3R3', SO2NR3R3', CONHSO2R4, NR3SO2NR3R3', NR3SO2-C1-4 alkyl and (C1-4 alkyl)-tetrazolyl.

3. A compound according to Claim 2, wherein:

J, J a, and J b combine to form an aromatic heterocyclic system containing from 1-2 nitrogen atoms, substituted with 0-1 R1;

J, J a, and J b can, alternatively, combine to form a heterocyclic ring wherein J b is N and J and J a are CH2 substituted with 0-1 R1;

J, J a, and J b can, alternatively, combine to form a heterocyclic ring wherein J b is CH, J is NR1 and J a is CH2 substituted with 0-1 R1;

R1 is selected from H, C1-4 alkyl, (CH2)r OR3, (CH2)r NR3R3', (CH2)r C(=O)R2, (CH2)r NR3C(=O)R2, (CH2)r SO2R4, and (CH2)r NR3SO2R4;

Z is selected from CH((CH2)m Q(CH2)m R5), CH((CH2)m Q(CH2)m R5)C(O)NR3, CH((CH2)m C(O)(CH2)m R5a), N((CH2)q Q(CH2)m R5), N(Q'(CH2)m R5), C(O)N((CH2)m Q'(CH2)m R5a), C(O), C(O)CH2, C(O)(CH2)r NR3(CH2)r, NR3C(O), NR3C(O)NR3, S(O)2, SO2CH2, SO2NR3, NR3SO2, and NR3SO2NR3;

A is selected from:

benzyl substituted with 0-2 R6, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

B is selected from:
X-Y, C3-6 alkyl, benzyl substituted with 0-2 R6, C5-6 carbocyclic residue substituted with 0-2 R6, and 5-6 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

X is selected from -C(O)-, -C(O)CR3R3'-, -S(O)2-, -S(O)p CR3R3'-, -S(O)2NR3-, -C(O)NR3-, -NR3-, -NR3CR3R3'-, and O;

Y is selected from:
C5-6 carbocyclic residue substituted with 0-2 R6, and 5-6 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

R6 is selected from H, OH, (CH2)nOR3, halo, C1-4 alkyl, CN, NO2, (CH2)r NR3R3', (CH2)r C(O)R3, NR3C(O)R3', NR3C(O)NR3R3', SO2NR3R3', CONHSO2R4, NR3SO2NR3R3', NR3SO2-C1-4 alkyl and (C1-4 alkyl)-tetrazolyl;

n is selected from 0, 1, and 2; and, r is selected from 0, 1, and 2.

4. A compound according to Claim 3, wherein the compound is of formula II:

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

J and J b combine to form an aromatic heterocyclic system containing from 1-2 nitrogen atoms, substituted with 0-1 R1;

J and J b can, alternatively, form a heterocyclic ring wherein J b is N and J is CH2 substituted with 0-1 R1;

J and J b can, alternatively, form a heterocyclic ring wherein J b is CH and J is NR1;

Z is selected from C(O)N(Q'R5a), C(O), C(O)NR3, NR3C(O), and SO2NR3;

Q' is selected from C(O) and C(O)NR3;

R5 is selected from H and C1-4 alkyl;

R5a is selected from NHR5, OR5, and R5;

A is selected from:
benzyl substituted with 0-1 R6, phenyl substituted with 0-1 R6, piperidinyl substituted with 0-1 R6, piperazinyl substituted with 0-1 R6, and pyridyl substituted with 0-1 R6;

B is selected from:
X-Y, benzyl substituted with 0-1 R6, phenyl substituted with 0-2 R6, cyclohexyl substituted with 0-1 R6, and pyridyl substituted with 0-1 R6;

X is selected from: -C(O)-, -S(O)2-, SO2CH2, -S(O)2NR3-, -NR3- and -C(O)NR3-;

Y is selected from:
phenyl substituted with 0-2 R6, and pyridyl substituted with 0-1 R6;

R6 is selected from H, OH, (CH2)n OR3, halo, C1-4 alkyl, CN, NO2, (CH2)r NR3R3', (CH2)r C(O)R3, NR3C(O)R3', NR3C(O)NR3R3', SO2NR3R3', CONHSO2R4, NR3SO2NR3R3', NR3SO2-C1-4 alkyl and (C1-4 alkyl)-tetrazolyl;

n is selected from 0, 1, and 2.

5. A compound according to Claim 4, wherein the compound is of of formula IV:

or stereoisomer or pharmaceutically acceptable salt form thereof, wherein A, B, D, and Z are as defined above.

6. A compound according to Claim 1, wherein the compound is selected from:

3-((4-cyclohexyl)phenylaminomethylcarbonyl)methyl-5-amidinoindole 3-(4-p-toluenesulfonyl-piperazinecarbonyl)methyl-5-amidinoindole 3-(4-(2-aminosulfonylphenyl)pyridine-2-aminocarbonyl)methyl-5-amidinoindole;

3-(4-[2-tetrazole]phenyl)phenylaminocarbonyl)methyl-5-amidinoindole;

3-(4-biphenylaminocarbonyl)methyl-5-amidinoindole;

3-(4-(phenylmethylsulfonyl)piperazinecarbonyl)methyl-5-amidinoindole;

3-(4-cyclohexylphenylaminocarbonyl)methyl-5-amidinoindole;

3-(4-benzylpiperazinecarbonyl)methyl-5-amidinoindole;

3-(3-amidinobenzylamino(methylcarbonylmethoxy)carbonyl)methyl-5-amidinoindole;

3-(4-[2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-amidinoindole;

3-(1-benzylpiperidine-4-aminocarbonyl)methyl-5-amidinoindole;

3-(4-phenylpiperazinecarbonyl)methyl-5-amidinoindole;

3-(4-benzylpiperidinecarbonyl)methyl-5-amidinoindole;

3-{2-bromo-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyanoindole;

3-{2-methyl-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-methylamino indole;

3-{2-fluoro-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-amidnoindole;

3-{2-chloro-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyanoindole;

3-{2-iodo-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyanoindole;

3-{2-methyl-4-(2-aminosulfonyl)phenylphenylaminocarbonyl)methyl-5-amidinoindole;
3-{2-methyl-4-(2-(t-butylaminosulfonyl))phenylphenylaminocarbonyl)methyl-5-amidinoindole;

3-{4-(2-aminosulfonyl)phenyl)phenylaminocarbonylmethyl-.alpha.-(methylcarboxy methylether)-5-amidinoindole;

3-{4-(2-aminosulfonyl)phenyl)phenylaminocarbonylmethyl-.alpha.-(benzyl)-5-amidinoindole;

3-{4-(2-trifluoromethyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindole;

3-{4-(2-ethylaminosulfonyl)phenyl)phenylaminocarbonylmethyl-5-amidinoindole;

3-{4-(2-propylaminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindole;

2-methyl-3-{2-iodo-4-(2-aminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindole;

2-methyl-3-{4-(2-aminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindole;

3-{4-(2-aminosulfonyl)phenyl)phenyl}-N-methylaminocarbonylmethyl-5-amidinoindole;

2-methyl-3-{4-(2-t-butylaminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-methoxyindole; and, 3-{4-(2-N-methylaminosulfonyl)phenyl)phenyl}-N-methylaminocarbonylmethyl-5-amidinoindole;

or a stereoisomer or pharmaceutically acceptable salt form thereof.

7. A compound according to Claim 4, wherein the compound is of formula IVa:

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein A, B, D, and Z are as defined above.

8. A compound according to Claim 1, wherein the compound is selected from:

3-{4-(2-(n-butylaminosulfonyl)phenylphenylaminocarbonyl)methyl-5-cyanoindoline;

3-{4-(2-(n-propylaminosulfonyl)phenylphenylaminocarbonyl)methyl-5-amidinoindoline;

(-)-3-{4-(2-aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindoline;

3-{4-(2-aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindoline;

3-{4-(2-dimethylaminosulfonyl)phenyl)phenylaminocarbonylmethyl-5-amidinoindoline;

(+)-3-{4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindoline;

(-)-3-{4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-5-amidinoindoline;

3-{4-(2-aminosulfonyl)phenyl)pyrid-2-yl)aminocarbonylmethyl-5-aminocarboxyindoline;

3-{4-(2-t-butylaminosulfonyl)phenyl)phenyl}aminocarbonylmethyl-5-amidinoindoline; and, 3-{4-(2-t-butylaminosulfonyl)phenyl)pyrid-2-yl}aminocarbonylmethyl-5-amidinoindoline;

or a stereoisomer or pharmaceutically acceptable salt form thereof.

9. A compound according to Claim 4, wherein the compound is of formula IVb:

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein A, B, D, and Z are as defined above.

10. A compound according to Claim 1, wherein the compound is selected from:

3-{4-(2-aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-6-amidinoindazole;

3-{4-(2-aminosulfonyl)phenyl)phenyl aminocarbonylmethyl-6-amidinoindazole;

3-{4-(2-t-butyl aminosulfonyl)phenyl)pyrid-2-ylaminocarbonylmethyl-6-amidinoindazole; and, 3-{4-(2-t-butylaminosulfonyl)phenyl)phenyl aminocarbonylmethyl-6-amidinoindazole; and, or a stereoisomer or pharmaceutically acceptable salt form thereof.

11. A compound according to Claim 4, wherein the compound is of of formula IVc:
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein D, D a, Z, A, and B are as defined above.

12. A compound according to Claim 1, wherein the compound is selected from:
[4-(phenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;
[4-(phenyl)phenylcarbonyl]methyl-5-amidinobenzimidazole;
[4-(3-aminophenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;
[4-(3-aminophenyl)phenylcarbonyl]methyl-5-amidinobenzimidazole;
[4-(4-fluorophenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;
[4-(4-formylphenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;
[4-(2-aminosulfonylphenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;
[4-(2-tert-butylaminosulfonylphenyl)phenylcarbonyl]methyl-6-amidinobenzimidazole;
[4-[(2-tetrazolyl)phenyl]phenylcarbonyl}methyl-6-amidinobenzimidazole;
[4-(2-aminosulfonylphenyl)phenylaminocarbonyl]methyl-6-amidinobenzimidazole;
[4-(2-aminosulfonylphenyl)phenylaminocarbonyl]methyl-5-amidinobenzimidazole;

1-(4-benzylpiperidinecarbonyl)methyl-6-amidinobenzimidazole;
1-(4-benzylpiperidinecarbonyl)methyl-5-amidinobenzimidazole;
1-(4-benzylpiperidinecarbonyl)methyl-6-amidinobenzimidazole;
and, 2-[4-(2-tert-butylaminosulfonylphenyl)phenylcarbonyl3methyl-5-azabenzimidazole;
2S-[4-(2-tert-aminosulfonylphenyl)phenylaminocarbonyl]methyl-thio-1H-imidazo(4,5-C) pyridine; and, 2S-[4-(2-aminosulfonylphenyl)phenylaminocarbonyl]methyl-thio-1H-imidazo(4,5-C) pyridine;
or a stereoisomer or pharmaceutically acceptable salt form thereof.

13. A compound according to Claim 1, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is of formula V:
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein one of R and R a is -(CH2)n-Z-A-B and the other H;
W, W2, and W3 are selected from CH and N, provided that at most one of W, W2, and W3 can be N;

J is selected from N and C-R1;

R1 is selected from H, O, (CH2)r OR3, (CH2)rC(=O)R2, (CH=CH)C(=O)R2, (CH2)r NR3C(=O)R2, (CH2)r SO2R4, (CH2)r NR3SO2R4, and (CH2)r-5-membered heterocyclic system having 1-4 heteroatoms selected from N, O, and S;

R2 is selected from H, OR3, C1-4 alkyl, NR3R3 , CF3, and C3-10 carbocyclic residue substituted with 0-2 R6;

R3 and R3 are independently selected from H, C1-4 alkyl, and C3-10 carbocyclic residue substituted with 0-2 R6;

R4 is selected from OR3, C1-4 alkyl, NR3R3 , and C3-10 carbocyclic residue substituted with 0-2 R6;

Z is selected from CH=CH, CH(CH2)m Q(CH2)m R5, CH((CH2)m Q(CH2)m R5)C(O)NR3, CH(CH2)m C(O)(CH2)m R5a, N(CH2)q Q(CH2)m R5, NQ'(CH2)m R5, C(O)N((CH2)m Q'(CH2)m R5a), C(O), C(O)CH2, C(O)O, OC(O), C(O)NR3(CH2)r, NR3C(O), OC(O)NR3, NR3C(O)O, NR3C(O)NR3, S(O)p, SO2CH2, SO2NR3, NR3SO2, and NR3SO2NR3;

Q is selected from a bond, O, NR3, C(O), C(O)NR3, NR3C(O), SO2, NR3SO2, and SO2NR3;

Q' is selected from a bond, C(O), C(O) NR3, SO2, and SO2NR3;

R5 is selected from H, C1-4 alkyl, C3-8 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R6, provided that when Q is SO2 or NR3SO2, R5 is other than H
and when Q' is SO2, R5 is other than H;

R5a is selected from NHR5, OR5, and R5;

A is selected from:
benzyl substituted with 0-2 R6, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

B is selected from:
H, X-Y, NR3R3', C(=NR3)NR3R3', NR3C(=NR3)NR3R3', benzyl substituted with 0-2 R6, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

X is selected from C1-4 alkylene, -C(O)-, -C(O)CR3R3'-, -CR3R3'C(O), -S(O)p-, -S(O)p CR3R3'-, -CR3R3'S(O)p-, -S(O)2NR3-, -NR3S(O)2-, -C(O)NR3-, -NR3C(O)-, -NR3-, -NR3CR3R3'-, -CR3R3'NR3-, O, -CR3R3'O-, and -OCR3R3'-;

Y is selected from:
C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

R6 is selected from H, OH, (CH2)n OR3, halo, C1-4 alkyl, CN, NO2, (CH2)r NR3R3', (CH2)r C(O)R3, NR3C(O)R3', NR3C(O)NR3R3', CH(=NH)NH2, NHC(=NH)NH2, C(=O)R3, SO2NR3R3', NR3SO2NR3R3', and NR3SO2-C1-4 alkyl;

n is selected from 0, 1, 2, 3, and 4;
m is selected from 0, 1, and 2;
p is selected from 0, 1, and 2;
q is selected from 1 and 2; and, r is selected from 0, 1, 2, 3, and 4.

14. A compound according to Claim 13, wherein the compound is of formula VI:

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein one of R and Ra is -(CH2)n-Z-A-B and the other H;

W and W2 are selected from CH and N, provided that at most one of W and W2 can be N;

J is selected from N and C-R1;

R1 is selected from H, (CH2)r OR3, (CH2)r C(=O)R2, (CH2)r NR3C(=O)R2, (CH=CH)C(=O)R2, (CH2)r SO2R4, and (CH2)r NR3SO2R4;
R2 is selected from H, OR3, C1-4 alkyl, NR3R3 , and CF3;

R3 and R3 are independently selected from H, C1-4 alkyl, and phenyl;

R4 is selected from OR3, C1-4 alkyl, NR3R3 , and phenyl;

Z is selected from C(O), C(O)CH2, C(O)NR3, NR3C(O), S(O)2, SO2CH2, SO2NR3, NR3SO2, and NR3SO2NR3;

A is selected from:
C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

B is selected from:

X-Y, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with O-2 R6;

X is selected from -C(O)-, -C(O)CR3R3'-, -CR3R3'C(O), -S(O)p-, -S(O)p CR3R3'-, -CR3R3'S(O)p-, -S(O)2NR3-, -NR3S(O)2-, -C(O)NR3-, -NR3-, -NR3CR3R3'-, and -CR3R3'NR3-;
Y is selected from:
C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

R6 is selected from H, OH, (CH2)n OR3, halo, C1-4 alkyl, CN, NO2, (CH2)r NR3R3', (CH2)r C(O)R3, NR3C(O)R3', NR3C(O)NR3R3', C(=O)R3, SO2NR3R3', NR3SO2NR3R3', and NR3SO2-C1-4 alkyl;
n is selected from 0, 1, 2, 3, and 4;

p is selected from 0, 1, and 2; and, r is selected from 0, 1, 2, 3, and 4.

15. A compound according to Claim 14, wherein the compound is of formula VII:

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein, W and W2 are selected from CH and N, provided that at most one of W and W2 can be N;

R1 is selected from H, (CH2)rOR3, (CH2)r C(=O)R2, (CH2)r NR3C(=O)R2, (CH=CH)C(=O)R2, (CH2)r SO2R4, and (CH2)r NR3SO2R4;

R2 is selected from H, OR3, C1-4 alkyl, NR3R3', and CF3;
R3 and R3' are independently selected from H, C1-4 alkyl, and phenyl;
R4 is selected from OR3, C1-4 alkyl, NR3R3', and phenyl;
Z is selected from C(O), C(O)CH2, C(O)NR3, S(O)2, SO2CH2, SO2NR3, and NR3SO2NR3;
A is selected from:
C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;
B is selected from:
X-Y, C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

X is selected from -S(O)p-, -S(O)pCR3R3'-, -CR3R3'S(O)p-, -S(O)2NR3-, -NR3S(O)2-, and -C(O)NR3-;

Y is selected from:
C3-10 carbocyclic residue substituted with 0-2 R6, and 5-10 membered heterocyclic system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-2 R6;

R6 is selected from H, OH, (OH2)n OR3, halo, C1-4 alkyl, CN, NO2, (CH2)r NR3R3', (CH2)r C(O)R3, NR3C(O)R3', NR3C(O)NR3R3', C(=O)R3, SO2NR3R3', NR3SO2NR3R3', and NR3SO2-C1-4 alkyl;
n is selected from 0, 1, 2, 3, and 4;

p is selected from 0, 1, and 2; and, r is selected from 0, 1, 2, 3, and 4.

16. A compound according to Claim 13, wherein the compound is selected from:

1-(4-benzylpiperidinecarbonyl)methyl-5-amidinoindole;
1-(4-benzylpiperidinecarbonyl)ethyl-5-amidinoindole;
1-(4-(3-fluoro)benzylpiperidinecarbonyl)methyl-5-amidinoindole;
1-(1-(4-amidino)benzyl-N-(methylacetate)aminocarbonyl)methyl-5-amidinoindole;
methyl 1-(4-benzylpiperidinecarbonyl)methyl-5-amidinoindole-3-propanoate;
1-((4-benzylpiperidinecarbonyl)methyl-(3-ethanehydroxyl)-5-amidinoindole;
1-(4-benzylpiperidine-1-carbonyl)methyl-3-methylcarboxylic acid-5-amidinoindole;
1-(1-benzylpiperidine-4-aminocarbonyl)methyl-5-amidinoindole;

1-(4-benzoylpiperidinecarbonyl)methyl-5-amidinoindole;
1-(4-(3-fluoro)benzylpiperazinecarbonyl)methyl-5-amidinoindole;
1-(4-phenylbenzylaminocarbonyl)methyl-5-amidinoindole;
methyl 1-(4-benzylpiperidinecarbonyl)methyl-5-amidinoindole-3-propenoate; and, 1-(4-(2-fluoro)benzylpiperidinecarbonyl)methyl-5-amidinoindole;
or a stereoisomer or pharmaceutically acceptable salt form thereof.

17. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 2 or a pharmaceutically acceptable salt thereof.

19. A method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

20. A method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 2 or a pharmaceutically acceptable salt thereof.